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Abstract 
 
The Impact of Radiation on Glioblastoma Evolution 
Joseph Hiram McAbee 
 
Glioblastoma (GB) is the most common and malignant primary adult brain cancer with 
a median survival of 15 months despite treatment with surgical resection followed by chemo-
radiotherapy.  The clonal diversity and evolutionary dynamics inherent to GBs is considered a 
major obstacle to effective treatment response.  While studies have focused on temozolomide, 
a role for radiotherapy as an independent driver of GB evolution has not been investigated.  We 
addressed the impact of radiation on glioblastoma evolution and potential treatment 
implications by examining the influence of intratumoral heterogeneity (ITH) on intrinsic 
radiosensitivity, by determining the effects of radiation on glioma stem-like cell (GSC) initiated 
orthotopic xenografts, and by assessing radioresistance with a reirradiation protocol.   
To determine the impact of ITH on intrinsic radiosensitivity, we performed whole-
exome sequencing (WES) of multiple tumour fragments and corresponding patient-derived cell 
lines that underwent γH2AX foci analysis and limiting dilution assay analysis.  Cell lines from 
the same tumour seem to display similar levels of intrinsic radiosensitivity despite genomic 
differences, suggesting that radiotherapy regimens may be effective for the whole of the 
tumour.  To test the ability of radiation to drive GB evolution, we utilised GSC-initiated 
orthotopic xenograft models treated with or without fractionated radiation (3x5Gy) to examine 
differences in survival, morphology/histology, Viral integration site analysis (VISA), and 
WES.  Irradiated mice experienced a survival advantage and harboured less invasive tumours 
compared to control mice.   VISA revealed that control tumours harbour fewer clones than in 
vitro lines and that irradiated tumours harbour the fewest clones of all suggesting that radiation, 
particularly in the context of the brain microenvironment, drives GBM evolution.  WES results 
demonstrated that variants from irradiated tumours mapped to different COSMIC mutational 
signatures and displayed a considerable amount of subpopulation shifting compared to control 
tumours, consistent with radiation-induced evolution and subpopulation selection.  By adding 
a reirradiation protocol to this GSC-initiated orthotopic xenograft model, we sought to better 
understand the functional impact of radiotherapy on recurrent GB evolution and to establish an 
in vivo model for studying reirradiation.  After initial treatment, mice were rerandomised into 
6 
control (3x5Gy-Control) and radiation therapy groups (3x5Gy-3x5Gy) and retreated once the 
average BLI ratio began to increase.  A further survival advantage was found for mice 
undergoing reirradiation compared to mice receiving only one course of radiation.  This 
survival advantage was supported by clonogenic survival and reimplanta tion studies of cell 
lines derived from control and irradiated NSC11 tumours that did not demonstrate a difference 
in survival after radiation regardless of the previous tumour’s treatment regimen.  Whereas 
radiation-induced evolution may not influence radioresponse, it may lead to the identification 
of novel targets for sensitisation which may ultimately yield more effective treatment 
strategies. 
  Our results demonstrate that radiation, a treatment component for almost all 
glioblastoma patients, can have wide-ranging effects on the evolution of this dynamic tumour.  
In particular, the pressures imposed by radiation treatment seem to lead to the selection of a 
reduced number of clones.  This selection may have future implications for tumour evolution 
and the treatment of recurrent GB.  In addition, we have demonstrated for the first time the 
utility of a GSC-initiated orthotopic xenograft model for studying retreatment protocols and 
recurrent GB biology.  This reirradiation model may provide the opportunity to design and test 
more effective recurrent GB treatment strategies centered around recurrent biology. 
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Chapter 1. Introduction 
 
1.1 The Evolution of Cancer 
 
 The cancer burden is increasing.  In the United States, almost 40% of adults are 
expected to be diagnosed with cancer at some point during their lifetimes.  While the rate of 
deaths attributable to cancer fell by 26% from 1991 to 2015, the international incidence of 
cancer cases is expected to rise from 14.1 million in 2012 to an estimated 23.6 million by 2030 
(1).  Certainly, this elevation in cancer incidence can be attributed in some degree to a 
combination of improved methods of early cancer detection, increased post-reproductive 
average lifespan, and continued exposure to harmful carcinogens.  But the increased burden 
and the need for more effective treatments necessitate a better understanding of the various 
cancer types and the evolutionary processes which lead to their development, maintenance, 
progression, and resistance.  This thesis will examine the radiation-induced evolution of 
glioblastoma, the most malignant form of brain cancer.  We will first discuss some important 
aspects of cancer evolution, in general, before describing how glioblastoma specifically fits 
into an evolutionary framework.   
 
1.1.1 Determinants of Cancer 
 
In order for cancer cells to develop, survive, and proliferate, they must acquire several 
distinct capabilities which provide them a fitness advantage to generate a tumour and progress 
to malignancy.  Hanahan and Weinberg proposed a list of such cancer hallmarks (2).  As a 
cancer is a collection of aberrantly proliferating, mutated cells, two necessary and fundamental 
traits of neoplastic cells are their ability to sustain proliferative signaling and evade growth 
suppressors.  Neoplasms sustain chronic proliferation through many redundant mechanisms 
such as increased production of growth factors, amplification of receptor expression, or 
mutation-induced structural changes in receptors leading to ligand-independent constitutive 
activation (3).  In addition to enhancing proliferation, cancer cells must simultaneously be able 
to evade the normal cellular regulations against such uninhibited proliferation.  The 
retinoblastoma (Rb) and TP53 proteins and the cell cycle progression role which they command 
1. Introduction 
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are two extremely important examples of tumour suppressors.  Rb and TP53, or elements in 
their respective pathways, are often mutated in cancers and allow cancer cells to evade these 
critical gatekeepers regardless of high levels of extracellular or intracellular stress signals or 
genomic damage (4).  Further to the ability to evade growth suppressors, is the ability to resist 
cell death through apoptosis (5).  TP53 plays a major role in inducing apoptosis after extensive 
DNA damage but is one of the most commonly mutated tumour suppressors, resulting in the 
loss of apoptotic regulation.  Apoptosis can also be reduced in cancer cells through  a tumour-
promoting imbalance of anti-apoptotic (Bcl-2, Bcl-xL) and pro-apoptotic (Bax, Bim) factors.  
Other avenues of resisting cell death or capitalizing off of cell death of other cells involve 
autophagy which can cause cancer cells to shrink and become reversibly dormant (6) or 
necrosis which can recruit tumour-promoting immune cells to the tumour microenvironment 
through extracellular release of proinflammatory contents (7). 
Longevity of cancer cells is important for providing adequate time to attain and 
propagate cancer attributes.  While resisting cell death is an important contributory factor to 
this longevity, mechanisms by which cancer cells maintain replicative immortality are also 
important for tumour survival and progression.  Telomeres, which protect the ends of 
chromosomes with multiple tandem hexanucleotide repeats, are maintained in many cancers  
allowing neoplastic cells to undergo unlimited cycles of proliferation (8).  Increased expression 
of telomerase, which adds repeats to chromosome ends, enables cancer cells to avoid 
senescence and apoptosis to achieve a relatively immortalized state.   
Cancer cells which have evolved to the point of replicating and proliferating without 
regulation may be able to grow and progress into a full tumour.  Some of the extrinsic factors 
which can contribute to the natural evolution of a growing tumour are limitations on available 
space and nutrients.  Angiogenesis, a normal, transient component of wound healing, is co-
opted and continuously activated by cancer to produce new vessels for the provision of more 
nutrients and oxygen for tumour expansion as well as waste disposal (9).  Vascular endothelial 
growth factor (VEGF) is an angiogenesis inducer that is commonly upregulated in cancer by 
oncogenic signaling or hypoxic environments (10).  Angiogenesis represents a dynamic 
interaction between a tumour and its microenvironment.  In addition to angiogenesis, limited 
space and resources may also contribute to a cancer cell’s predilection for invasion and 
metastasis.  A cellular program typically involved in development, epithelial-mesenchymal 
transition (EMT), has been implicated in the invasion-metastasis cascade (11).  EMT-inducing 
transcription factors have been demonstrated in various cancer types and contribute to a variety 
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of functions including loss of adherens junctions, increased motility , and expression of matrix-
degrading enzymes which contribute to an invasive phenotype. 
Hanahan and Weinberg also describe two additional emerging hallmarks of cancer  
(immune evasion and metabolic reprogramming) and two characteristics of most cancers 
(tumour-promoting inflammation and genomic instability) which enable them to acquire many 
of the hallmarks discussed above (see Figure 1.1) (2).  Despite a usually intact host immune 
response, cancer cells which grow into tumours have successfully evaded destruction.   Because 
cancer cells are derived from a patient’s own cells and undergo periods of quiescence, a certain 
degree of self-tolerance can be built up (12).  More directly, cancer cells can downregulate its 
tumour-specific antigens and dysregulate antigen processing.  Cancer cells may also actively 
suppress the immune system through cytokine secretion (TGFβ and IL10) or PD-L1 expression 
which can reduce the level of active T cells and increase T regulatory cell function  (13).  
Immune cells not only fail to destroy cancer cells but can actually contribute to tumour survival 
as inflammation, which may originate as non-specific anti-tumour responses, may ultimately 
provide a source of growth factors, survival factors, and angiogenesis inducers that are 
necessary for cancer survival (14). 
   
Figure 1.1 Cancer Hallmarks.  
Established hallmarks, emerging 
hallmarks, and cancer 
characteristics as proposed by 
Hanahan and Weinberg (2). 
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 While angiogenesis manipulates the microenvironment to increase oxygen and nutrient 
availability, reprogramming of metabolic pathways is an intrinsic attempt to quickly obtain the 
energy required to undergo cell proliferation.  For instance, cancer cells have been shown to 
obtain a large portion of their energy through aerobic glycolysis (15).  While not as fruitful in 
ATP production as oxidative phosphorylation, aerobic glycolysis does provide a rapid source 
of ATP through breakdown of extracellular glucose which produces both energy and  
biosynthetic intermediates (16).  Such reprogramming can be directed by overexpression or 
overactivation of Myc, HIF-1, and PI3K pathways which are commonly altered in cancers to 
promote proliferation.  But clearly, very few of the hallmarks and characteristics listed above 
would be possible without underlying genomic alterations triggering cancer phenotypes.  
Therefore, genomic instability has emerged as an important characteristic of tumour cells  
(17,18).  As more mutations are gained the likelihood increases of acquiring advantageous 
mutations which confer necessary cancer hallmarks.  Increased mutation rates, dysfunctional 
DNA repair mechanisms, or epigenetic silencing can all contribute to genomic instability and 
intratumoral heterogeneity which ultimately leads to the production of cancer cells with enough 
advantageous mutations and acquired hallmarks to grow and populate a fully formed tumour. 
 
1.1.2 The Cancer Stem Cell Hypothesis 
 
Once a subset of cancer cells acquires the hallmarks mentioned above, the cancer cells 
must then proliferate.  This requirement for extensive self-renewal is one reason why “cancer 
stem cells” (CSC) represent potential units of selection for cancer evolution (19-21).  The 
cancer stem cell hypothesis originally developed through studies of leukaemia in which a 
cellular hierarchy emerged with CSCs at the apex (22).  Other cancers, including solid tumours, 
have since been described as developing through this process.  Essentially, CSCs are 
considered cancer cells which possess many of the same properties of adult somatic stem cells, 
i.e. replicative immortality and propagation of differentiated cells.  The ability of CSCs to 
produce a diverse pool of differentiated cells also grants them tumourigenic potential, another 
important feature of cells which are thought to promote development, progression, and 
resistance of cancer. 
An underlying prerequisite to produce a diverse cohort of progenitor and differentiated 
cells which encompass a heterogeneous tumour is that CSCs must themselves express a high 
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level of genotypic and phenotypic diversity.  The diversity inherent in CSCs makes them prime 
units of selection, because they harbour many mutations with different relative fitness levels.  
Based on the specific selective pressure driving evolution or the current need of the cancer, 
CSCs can redirect towards the resistant or most fit clone or subclone for a given situation.  The 
extensive self-renewal properties of CSCs allow them to then propagate whichever cell 
underwent positive selection.  Thus, sufficient genetic diversity of CSCs allows for 
evolutionary selection while extensive self-renewal allows for the selected trait to be passed on 
to cells that can populate a tumour (23,24).  CSCs have also been shown to be intrinsically 
resistant to therapies (25) which may be due to intrinsic diversity, stem cell niches, or periods 
of transient quiescence (26).  In fact, CSCs in glioblastoma are able to transition between 
proliferative and slow cycling states by Notch signalling and upregulation of histone 
demethylases (27).  Taken together, CSCs give rise to heterogeneous tumours capable of 
adaptation under evolutionary selective pressures (Figure 1.2).    
 
Figure 1.2 CSCs as Units of Evolution. A) Cancer stems cells propagate differentiated/fate-
restricted cancer cells to produce a heterogeneous tumour. B) Cancer cells with fitness 
advantages are better able to compete for limited space and resources. C) Therapeutic selection 
pressures such as surgery, radiotherapy, and chemotherapy are applied to the tumour. D) CSCs 
sometimes survive to repropagate a heterogeneous recurrent tumour because of resistance to or 
protection from therapy. E) Competitive release can eliminate or reduce larger, therapy-
sensitive populations providing the opportunity for smaller subpopulations to expand and 
populate a recurrent tumour. E) Intrinsic therapeutic resistance can cause a clonal population 
to continue to thrive during and after treatment.      
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1.1.3 Cancer as a Darwinian Process 
 
Cancer can be considered a complex, Darwinian, adaptive system (28,29) in part 
because cancer arises through a protracted evolutionary course in which various challenges and 
pressures contribute to the accumulation of adapted phenotypes and genotypes  (30).  As 
discussed, heterogeneity is a requirement for Darwinian selection as the intratumoral diversity 
within a given cancer type allows for natural selection to drive the cancer into a more well 
suited, more fit state (23).  Mutations with the potential to drive or enhance carcinogenesis 
(driver mutations) may arise through neutral evolution (large scale genomic/chromosomal 
instability that blindly increases rate of mutations), natural evolution (space and nutrient 
competition selects for clones better equipped to survive in harsh environments), or selective 
evolution (therapeutic pressures lead to the expansion of resistant clones) (31).  The interplay 
of acquired intrinsic mutations with extrinsic factors which test the fitness of those mutations 
contributes to the development of cancer.  The diversity of extrinsic factors demonstrate that 
cancer does not grow in a vacuum but is instead impacted by a dynamic milieu of diverse cell 
types, extracellular networks, and anti-cancer compounds.                 
The diversity between unique cancers originating in different tissue types demonstrate 
that local interactions with and restrictions by the tumour microenvironment can affect 
diversity over time.  The tissue ecosystem in which a tumour resides not only provides the 
location for natural selection to occur, but also provides its own set of challenges to determine 
fitness selection and impact clonal evolution (32).  The microenvironment provides many 
levels of mutual interactions with cancer cells ranging from immune cell infiltration with 
subsequent anti-tumour or even pro-tumour effects to providing protective/supportive niches 
for phenotypically inclined CSCs to promoting invasion/migration by the spatial heterogeneity 
of available resources (24,31).  Like cancer cells, the tumour microenvironment can also be 
impacted and altered by carcinogenic exposures and chemoradiotherapy.  In fact, the 
remodelled microenvironment post-therapy may provide new selection pressures or 
advantageous expansion opportunities for cancer cells that survived treatment either through 
intrinsic resistance or protective niches (33).  An alternative to the unidirectional hierarchy of 
the CSCs postulates that tumours arise from common ancestors of malignant cells that exist in 
a limited set of cellular expression states (NPC-like, OPC-like, Astrocyte-like, Mesenchymal-
like) with inherent plasticity which allows tumours to evolve and reversibly transition between 
states in response to various pressures (34).  Such complex interactions and evolutionary 
 1. Introduction 
 
  21 
possibilities make it obvious that we cannot solely rely on the underlying mutational 
architecture of primary cancers to provide insight into cancer biology.  We must also work to 
better understand the dynamic nature of cancer as an evolutionary, adaptive system. 
 
1.1.4 Selection Pressures Drive Evolution 
 
Maley and a panel of experts developed a consensus framework for classifying tumours 
and investigating the clinical implications of cancer evolution and ecology (35).  The 
components which make up their proposed ecological index are the available resources which 
sustain cancer cells and the potential hazards which harm them.  Certainly, cancer cells need 
oxygen, glucose, growth signals, and survival factors to develop and proliferate.  As stated 
previously, the microenvironment plays a significant role in this capacity and is a major source 
of selection pressures which drive evolution at all stages of cancer development and 
progression.  In addition to the microenvironment, one of the most potent sources of selective 
pressure with the ability to drive cancer evolution is anti-cancer therapy.     
Cancer therapeutics, such as chemotherapy or radiotherapy, impose artificial selection 
pressures which lead to high levels of cellular death, thus providing cells with resistance 
mutations or cells which evade treatment through other mechanisms to proliferate with less 
competition.  In addition to selecting cells which already possess intrinsic resistant properties, 
genotoxic drugs such as chemotherapies can induce novel mutations which can further enhance 
cancer cell fitness (24,36).  Even targeted therapies which incorporate knowledge of genetic 
alterations in cancer to attack a clonal driver mutation can be overcome as a subclone present 
at low frequency prior to treatment could potentially expand after therapy to generate a 
resistant, recurrent tumour (37-39).  Additionally, it has been postulated that another possibility 
for targeted therapy failure is because recurrences emerge from a persistent cellular reservoir 
of common ancestors which possess early truncal events no t in common protein-coding 
variants, but in larger genetic alterations such as whole copy-loss of chromosome 10, copy gain 
of chromosome 7, or TERT promoter mutations (40).  It is important, therefore, to examine 
cancer genomics both before and after treatment to obtain a more longitudinal picture of cancer 
evolution.  In order to design more effective therapies, we must consider the dynamic interplay 
between the genomic architecture of cancer, the tumour microenvironment, and therapy-driven 
evolution.  Glioblastoma is a rapidly evolving, heterogeneous brain cancer and elucidating the 
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impact of radiation on glioblastoma evolution could provide valuable insights for recurrent 
tumour biology and treatment. 
 
 
1.2 Glioblastoma 
 
Glioblastoma (GB), the most common and malignant form of adult brain cancer (41), 
develops de novo (primary) or from a lower grade tumour (secondary) (42).  It is of 
neuroepithelial origin and is thought to arise from neural stem cells, glial progenitor cells (such 
as OPCs), or astrocytes (43,44).  The incidence of GB is 3.21 per 100,000 in the United States 
and 4.64 per 100,000 in the United Kingdom (45,46).  The highest incidence rates of GB occur 
after the fifth decade of life and the cancer is 1.58 times more commonly diagnosed in men 
than women (45).  However, glioblastoma is diagnosed across all ages and is almost uniformly 
fatal, causing it to have one of the highest average years of life lost of any cancer (47). 
According to the World Health Organisation (WHO) classification of brain tumours, GB 
is considered a grade 4 neoplasm due to its malignant histological/cytological features, invasive 
propensity, rapid disease evolution, and poor outcomes (48).  Typically, glioblastoma has been 
presumptively diagnosed as a heterogeneously, peripherally enhancing lesion on T1-weighted 
MRI with gadolinium contrast and definitively diagnosed after surgical resection and 
histopathological analysis.  In particular, evidence of nuclear atypia, increased mitotic activity, 
palisading necrosis and/or microvascular proliferation provide support for a diagnosis of 
glioblastoma (48).  The most recent iteration of the WHO classification scheme also considers 
some molecular markers to more accurately subtype gliomas.  In particular, the 2016 
classification scheme divides GB into IDH-wildtype (90%), IDH-mutant (10%; secondary 
GB), and GB NOS (IDH evaluation not available) (49).  ATRX loss and TP53 mutation are 
commonly identified in IDH mutant diffuse astrocytomas, whereas 1p/19q codeletion defines 
oligodendrogliomas, a different diffuse glioma entity not typically associated with GB (49).  
While the current WHO classification system is an improvement because it utilises some 
molecular evidence in its algorithm, the molecular and phenotypic landscape of GB is much 
more diverse and complicated than the few mutations mentioned in the classification scheme.   
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1.2.1 Intrinsic Mutational Landscape 
 
Glioblastoma was one of the first solid tumours investigated by The Cancer Genome 
Atlas (TCGA).  In 2008, the TCGA published its initial findings after examining the 
methylation, gene expression and copy number profiles of over 200 human GB samples (50).  
Almost half of the tumours were also subjected to genomic variant analysis.  Integrating 
multiple types of analysis for such a large cohort allowed for the delineation of three core GB 
pathogenesis pathways: receptor tyrosine kinases (RTK/RAS/PI3K), retinoblastoma (Rb), and 
tumour suppressor p53 (TP53). Of the tumours sampled approximately 75% contained 
mutations in all three of the core pathways, suggesting potential targets for therapeutic 
intervention (50) and highlighting the need for multi-target combination therapies.   
One of the most commonly mutated RTKs is epidermal growth factor receptor (EGFR).  
EGFR, which is encoded on chromosome 7p12, has been shown to be overexpressed or 
amplified in over 40% of GB (51,52) or structurally altered in others.  The most common 
mutant structural variant (EGFRvIII) is caused by a deletion of exons 2 to 7 which results in 
truncation of the extracellular domain of the receptor and ultimately causes ligand-independent 
constitutive activation of EGFR (53).  Constitutive activation of the RTK leads to activation of 
the PI3K downstream signaling pathway which has been implicated in proliferation through 
alteration of mRNA for enhanced association with polysomes for active transcription (54).  
While the implications of EGFR amplification and variants on clinical outcomes have not been 
completely determined, they have been proposed as potential indicators of poor prognosis.  The 
prevalence of EGFR variants has made the receptor an attractive option for drug targeting 
(55,56).     
While EGFR is a very prevalent gain of function mutation in GB, PTEN (tyrosine 
phosphatase/tensin homolog protein), a negative regulator of the PI3K/Akt pathway, is 
considered to be one of the most common loss of function genetic alterations (57).  PTEN 
deletion occurs most commonly through loss of heterozygosity (LOH) of chromosome 10q.  In 
LOH an entire gene and its surrounding chromosomal region is lost, and if the gene in question 
is a tumour suppressor then the remaining copy is left vulnerable to future mutations and 
subsequent malignant transformation (58).  In the case of PTEN, loss of this tumour suppressor 
prevents negative regulation of PI3K which can lead to uncontrolled activation and 
proliferation, particularly in the context of additional mutations which constitutively activate 
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the pathway (59,60), as described above.  PTEN has been associated with poor prognosis (61), 
is found more frequently in primary GB (62), and may represent an important early genetic 
step leading to the glioblastoma phenotype.    
TP53 has been found to be mutated in up to 30% of primary GB, although mutations 
are more commonly detected in low grade astrocytomas and secondary GB (57).  However, it 
is estimated that at least one component of the TP53 pathway is mutated in over 80% of all 
GBs (52).  TP53 mutations are common to many cancer types as the normal tumour suppressor 
function of TP53 must be overcome for cancer cells to survive and proliferate (63).  The TP53 
pathway, when functioning normally, regulates cell cycle progression, response to DNA 
damage, and apoptosis.  When the p53 transcription factor is activated, it promotes cell cycle 
arrest or apoptosis through activation of target genes.  P53 activation also leads to the activation 
of MDM2 (an E3 ubiquitin ligase) which serves as an autoregulatory feedback loop to inhibit 
and degrade p53.  MDM2 is itself inhibited by the tumour suppressor protein p14ARF (64).  
Therefore, mutation of TP53, amplification of MDM2, or deletion of p14ARF can ultimately 
lead to the inactivation of the p53 pathway and the survival of cancer cells  (65).  While the 
prognostic significance of TP53 mutations is unclear, it has been shown that TP53 
overexpression may be associated with improved progression free survival (PFS) for patients 
who received long courses of adjuvant temozolomide (66). 
Another tumour suppressor protein involved in the regulation of cellular proliferation 
and survival, retinoblastoma, is found to be deleted in a small number of GBs (50).  
Retinoblastoma normally binds E2F to prevent it from activating cell cycle progression target 
genes (67).  The phosphorylation of Rb by cyclin-D1-CDK 4/6 complexes causes it to release 
E2F to allow G1-S progression (68).  CDK4/6 can be overexpressed in GB leading to 
uncontrolled progression.  A more common alteration in this pathway is the upstream regulator 
of CDK4/6, CDKN2A (2B less commonly).  CDKN2A (or p16INK4a) is a tumour suppressor 
protein that is encoded at the same locus as p14ARF and normally works to inhibit CDK4 from 
phosphorylating Rb (69,70).  As with the TP53 and RTK pathways, any of the mediators 
mentioned above could be mutated to cause uninhibited cell cycle progression and enhanced 
survival of cancer cells bearing the Rb pathway mutation (71,72).    
As seen by the WHO classification, isocitrate dehydrogenase (IDH) is an important 
molecular marker for delineating the evolutionary history of a GB.  IDH, an enzyme involved 
in the citric acid cycle, is often mutated in low grade gliomas and secondary GBs (73) and in a 
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small subset of primary GBs (74).  IDH mutations are conserved through cycles of malignant 
progression, suggesting that they are an early event in glioma development (75).  IDH1 is the 
most commonly mutated enzyme and exists in the cytoplasm, while IDH2 exists in the 
mitochondria (76,77).  Wild type IDH oxidatively decarboxylates isocitrate to α-ketoglutarate 
and carbon dioxide, but its altered enzymatic action in IDH-mutant gliomas yields reduced 
levels of α-ketoglutarate and increased levels of 2-hydroxyglutarate (2-HG).  The elevated 
levels of 2-HG inhibit enzymes involved in histone and DNA demethylation leading to changes 
in epigenetic alterations and gene expression that impact various tumour-related pathways such 
as invasion, survival, and hypoxia signalling (78-80).  It has been suggested that the epigenetic 
alterations induced by IDH1 mutations may be sufficient for the glioma hypermethylation 
phenotype.  IDH1 mutations are often associated with younger patients, longer survival, and 
lower grade gliomas (74) and can be detected most often by R132H antibody specific 
immunohistochemistry  (the most common amino acid change) (81).  Other clinical 
implications of IDH mutations include higher rates of TMZ response (82), association with 
larger extent of surgical resection (83), and a novel method of non-invasive biomarker imaging 
of 2-HG on magnetic resonance spectroscopy (84).  The inclusion of IDH mutation status in 
the WHO classification scheme reflects its relative importance in both prognosis and 
development of glioblastoma. 
In addition to IDH mutation status, MGMT methylation status is also now routinely 
tested in GB patients due to its potential to predict prognosis and response to alkylating 
chemotherapy.  The MGMT gene encodes for O6-methylguanine DNA methyltransferase, an 
enzyme involved in DNA repair.  MGMT normally counteracts the alkylation caused by 
temozolomide by removing alkyl groups from guanine to its own cysteine residue so that the 
cell can survive and continue to replicate (85,86).  When the MGMT promoter is methylated, 
the gene is effectively silenced, MGMT cannot repair the alkylation caused by TMZ, and cell 
death is initiated.  Therefore, MGMT promoter methylation is associated with increased patient 
survival and improved response to TMZ (87,88).  Interestingly, MGMT promoter methylation 
has also been shown to be predictive of improved response to radiotherapy (89).  Inversely, if 
a GB expresses high levels of MGMT, then it can provide an avenue for TMZ resistance.   
However, MGMT is only a single component in the DNA repair response to chemotherapy.  If 
MGMT is unable to remove alkyl groups, then normally the DNA mismatch repair system will 
recognize O6-methylguanine mismatches and trigger apoptosis after unsuccessful repair and 
induction of cytotoxic double-strand breaks.  Unfortunately, mutations can also occur in MMR 
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genes (MSH2, MSH6, MLH1, MLH3, PMS1, PMS2).  Mutations in MSH6, in particular, have 
been associated with GB (90,91) as MSH6 deficient cells cannot properly trigger cell cycle 
arrest in response to DNA damage caused by TMZ.  If MGMT promoter methylation is coupled 
with MSH6 mutation/loss, then a GB becomes resistant to both the alkylation by TMZ and the 
killing which should be induced by that alkylation.  The loss of normal MMR function in this 
context leads to an increased tolerance to mutagenic activity and thus a hypermutation 
phenotype observed in recurrent tumours (92).  Our group has recently shown the impact of 
treatment pressures on DNA repair genes and hypermutation, as a patient who underwent three 
surgical resections with intervening treatments including alkylating chemotherapy 
demonstrated hypermutation after the final resection suggesting that acquired mutations in 
DNA repair genes may have allowed such extensive numbers of mutations to occur unhindered.     
TERT (telomerase reverse transcriptase) and ATRX (alpha-thalassemia X-linked 
mental retardation protein) mutations are an important aspect of GB’s ability to  maintain 
replicative immortality despite ongoing divisions through telomere maintenance.   As 
mentioned previously, for stem cells and cancer cells, elevated levels of telomerase leads to 
continual elongation of the telomeres and thus continual division (93).  Point mutations (G>A 
transitions) in the TERT promoter leads to increased TERT expression and telomerase activity 
and increased cancer cell DNA viability (94,95).  Alternatively, ATRX interacts with DAXX 
to form a complex that deposits H3.3 histone variants at telomeres to maintain their length (96).  
ATRX mutation/loss has been associated with IDH1 mutations and alternative lengthening of 
telomeres phenotype (ALT) through dysregulation of macroH2A1 telomere deposition, 
decreased binding of polymerase tankyrase 1 to macroH2A1, and lack of telomere sister 
cohesion resolution (97).  ALT leads to longer telomeres compared to samples with TERT 
promoter mutations (98,99).  TERT and ATRX mutations seem to be mutually exclusive in 
gliomas, possibly reflecting the similar survival advantage conferred by both mutation types 
(94). 
While the above variants represent some of the most common mutations in GB, there 
is considerably more variation in GB.  Therefore, in an attempt to stratify GBs based on 
recurring patterns within this heterogeneous group of tumours, various classification schemes 
have been proposed (100-103).  One of the most commonly utilised classification schemes was 
proposed by Verhaak et al. and placed GB into Proneural, Neural, Classical, and Mesenchymal 
subtypes based on TCGA gene expression data (102).  GBs in the Proneural subtype commonly 
exhibit mutations in IDH1, PDGFRA, and TP53.  Patients in this subgroup tend to be younger 
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and tend to experience longer overall survival (OS), as would be expected for IDH-mutant 
GBs.  The neural subtype is not characterized by particular mutations but by the expression of 
neuronal markers.  Classical subtype GBs harbour frequent EGFR amplification, chromosome 
7 amplification, and chromosome 10 loss.  Classical GBs lack TP53 mutations and tend to have 
the best response to aggressive treatment.  Lastly, the Mesenchymal subtype typically includes 
NF1 and PTEN deletions/mutations.  The survival advantage after treatment is also significant 
for the mesenchymal subtype although patients in this subgroup have the worst prognosis  
overall.    
Eckel-Passow proposed a simpler scheme by classifying GBs based on the presence of 
3 molecular markers: IDH mutations, TERT promoter mutations, and 1p/19q codeletions (low 
grade gliomas) (104).  GBs with TERT only mutations were the most common and patients 
were the oldest mean age at diagnosis, while IDH-only mutated GBs were associated with the 
youngest age at diagnosis.  The molecular subgroups were not associated with overall survival 
in GB although TERT-only GBs had the shortest survival.  With more recent TCGA findings, 
a new glioblastoma classification scheme has been proposed that includes not only biomarker 
expression but also DNA methylation profiles, gene expression patterns, and telomere 
length/maintenance description (98).  While the classical and mesenchymal subtypes were 
mostly retained in this scheme (“classic-like” and “mesenchymal-like”), the proneural and 
neural subtypes were replaced with further subgroups.  In particular, IDH-mutant gliomas 
(without 1p/19q co-deletion) were subdivided into G-CIMP-low and G-CIMP-high subgroups 
based on their relative levels of DNA methylation.  G-CIMP (glioma-CpG island methylator 
phenotype) was demonstrated by gliomas with high levels of methylation at many loci (105).  
G-CIMP tumours are found in younger patients with better prognosis and are typically 
associated with IDH mutations (106).  As discussed previously, IDH mutations and the 
competitive inhibition of α-ketoglutarate enzymes, such as ten-eleven translocation 
methylcytosine dioxygenase (TET) DNA demethylases, may represent the molecular 
mechanism for such hypermethylation (107).  While patients with G-CIMP tumours of any 
type generally have a better prognosis than IDH-wildtype tumours, G-CIMP-high tumours had 
better prognosis when compared to G-CIMP-low tumours.  The neural subtype was basically 
replaced with a small subset of IDH-wildtype GB which corresponded to the LGm6 
methylation cluster assignment (LGm6-GBM).  While these and other classification schemes 
are thought to provide information for patient stratification, prognosis, and treatment response 
(108,109), the importance of subtyping is ultimately unclear due to the observed intratumoral 
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heterogeneity (ITH) of GB which can lead to the presence of multiple subtypes within the same 
tumour (Figure 1.3). 
 
Figure 1.3 Glioblastoma intratumoral heterogeneity . An illustrated simple example of GB 
ITH in which spatially distinct tumour fragments may harbour different subtypes.  Common 
mutations for each subtype are listed as an example of potential observable diversity, but ITH 
may also be observed in DNA methylation patterns, gene expression, and more.  Separate 
clones may possess many similar mutations to other clones (linear evolution) or only a few 
similarities in probable early event mutations that are shared from ancestral precursors 
(divergent evolution).   
 
1.2.2 Intratumoral Heterogeneity 
 
While knowledge of common mutations, core pathways, and molecular subtypes is 
necessary and important, many of the above studies characterized genomic mutation patterns 
of GB based on single surgical biopsies and thus may not have captured the full genomic 
architecture of each tumour.  In fact, it has been shown that a single tumour can harbour 
spatially distinct tumour fragments which correspond to different GB subtypes, making the 
utility of any classification scheme difficult.  Sottoriva et al. utilised comparisons of copy 
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number alterations (CNA) and reconstructed tumour fragment phylogenies to examine the 
relative heterogeneity between spatially and temporally distinct tumour fragments within the 
same tumour (110).  The prevalence of a given copy number event allows for inferring 
evolutionary trends.  Common CNAs found in all fragments were considered to be early events 
in the evolutionary process whereas shared CNAs (found in more than one fragment) and 
unique CNAs (found in only one fragment) were considered middle and late events, 
respectively.  For GB, CNAs in EGFR and CDKN2A were found to be early events whereas 
CNAs in PTEN and PDGFRA were considered to be late events.  Tumour phylogenies were 
reconstructed through molecular clock analysis.  Molecular clock analysis utilises a measure 
of mitotic distance between cells within a fragment, namely the number of cell divisions, to 
identify subclones.  The genomic locus IRX2 has been shown to accumulate methylation errors 
linearly with age (111).  By examining the relative amount of methylation on the IRX2 locus 
for a given cell population (a mitotic clone corresponds to a unique methylation tag), the 
composition and hierarchical relationships of mitotic clones within tumour fragments can be 
determined.  As such, even within single tumour fragments, multiple mitotic clones with 
differing cell lineages were delineated.  Another study which sequenced multiple tumour 
fragments found evidence of similar extensive ITH as only 51% of mutations were clonal and 
two of the treatment-naïve tumours even contained small fragments with hypermutator 
phenotype (112).  Possible therapeutic targets were inconsistently identified within different 
fragments from a given tumour, demonstrating that a multi-sampling surgical and sequencing 
technique provides a more complete picture of a given GB’s genomic makeup  (112).   
In addition to differences in genomic patterns, ITH has also been shown at the level of 
transcription.  Patel et al showed by single-cell RNA-Seq of 430 cells from five GBs that 
diverse programs of transcription were variably expressed between cells from a single tumour.  
The cells within a given tumour corresponded to multiple GB subtypes further highlighting 
ITH and the potential limitations of utilising subtypes for treatment decisions.  Another study 
based on RNA-Seq analysis found differences in molecular composition and GB subtypes 
between cells from the contrast-enhancing tumour core and cells from the non-enhancing 
tumour margin (mostly neural subtype).  While the expression patterns of the marginal samples 
were contaminated with “normal” brain cells, the microenvironment could ultimately influence 
expression patterns of residual neoplastic cells within the parenchyma and contribute to 
observed differences in cell type-specific alteration patterns.   
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Differences in DNA methylation patterns (113,114) and drug sensitivity (115) have 
provided an even more comprehensive understanding of contributions to and implications of 
GB ITH.  Such extensive ITH is thought to be a major factor behind the inevitable tumour 
progression, treatment resistance, and recurrence observed in GB (116-119), as multiple 
subclones with differential treatment sensitivity can exist within the same tumour.  For 
example, single tumours were found to harbour amplifications in three different receptor 
tyrosine kinases (120), representing potential intrinsic resistance routes to treatments targeting 
a single specific RTK.  EGFR, MET, and PDGFRA driver genes, which all contribute to protein 
production, were amplified in different cells coexisting within the same tumour.  Similar results 
in which two or more RTKs were amplified within a single tumour were found in 34 TCGA 
cases (121).  Furthermore, in vitro inhibition of the PI3K pathway for cell lines derived from 
gliomas expressing RTK coamplification required inhibition of both EGFR and PDGFR.  The 
addition of therapeutic selection pressures to the context of ITH can lead to the contraction or 
expansion of various subclones and the potential for a recurrent tumour to be populated with 
resistant cell populations.  The importance of this evolutionary process and its implications for 
effective treatment development necessitates further analysis of ITH and GB evolution in order 
to elucidate genomic patterns, early and late evolutionary events, and key, actionable branch 
points in a tumour’s evolutionary history. 
  
1.2.3 Treatment and Survival 
 
Glioblastoma is a rapidly progressing and evolving disease.  As such, patients who 
remain untreated experience an overall survival time of less than 6 months.  After maximal 
safe surgical resection, the current standard of care for newly diagnosed glioblastoma, the 
Stupp Protocol, consists of fractionated radiotherapy (30 fractions of 2Gy) and concomitant 
and adjuvant temozolomide (TMZ) (122).  Despite such radical treatment, the median survival 
is still only about 15 months.  Glioblastoma has 5-year and 10-year post-diagnosis survival 
estimates of less than 6% and 3%, respectively, some of the lowest rates among all forms of 
cancer (41).        
Surgical resection is important for both diagnostic purposes and to relieve tumour 
burden and mass effect on the brain.  In addition to providing relief from symptoms and 
improving postoperative function (123), patients who underwent resection had increased 
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survival (124).  Furthermore, those patients who received a more extensive resection enjoyed 
a greater survival advantage (125,126).  In fact, partial resection or biopsy is associated with 
greater risk of postoperative complications such as hemorrhage, herniation, and oedema (127).  
While the preoperative performance status and location of tumour relative to eloquent brain 
areas must be considered to properly weigh the risk-benefit ratio, in general, the greater the 
resection, the better the outcome.  This survival advantage is applicable to all glioblastoma 
patients, regardless of age (128,129).  This may be due in part to the many surgical advances 
which have improved the safety of GB surgical resection.  Intraoperative electrocortical 
stimulation, awake craniotomy, and neuronavigation provide surgeons with tools necessary to 
better avoid language and motor-associated areas.  Intraoperative MRI and f luorescence-
guided surgical resection have been developed to improve extent of resection.  While both do 
improve resection, iMRI has not been clearly shown to improve survival for GB patients (130), 
while fluorescence-guided surgical resection has been associated with an increase in PFS 
(131,132).  Fluorescence-guided surgical sampling involves the use of 5-ALA (5-
Aminolevulinic acid; Gliolan) which is taken by the patient preoperatively to cause 
fluorescence of GB tissue when exposed to 405-nm wavelength blue light.  Fluorescence is due 
to uptake of drug through the blood-brain-barrier (BBB) and into glioma cells where it is 
converted into protoporphyrin IX (fluorescent metabolite).  The exact mechanism that leads to 
fluorescence has not been confirmed, but some hypotheses include low levels of ferrochelatase, 
high levels of metabolism, or disturbances in mitochondrial electron transport changes leading 
to accumulation of reactive oxygen species and ultimately reduction in heme synthesis (133-
135).  Regardless of the mechanism of action of 5-ALA, fluorescence-guided surgical sampling 
has also been important for studies on ITH as it aids in the collection of better-quality, spatially 
distinct tissue for downstream experimentation (110,136). 
Another important benefit of surgical resection is the improved response to adjuvant 
therapy experienced by patients who undergo resection, particularly gross total resection.  This 
benefit is evident for multiple modalities of therapy including radiotherapy after 5-ALA 
resection, temozolomide, standard chemoradiotherapy, and BCNU wafers (137).  As seen with 
BCNU wafers, surgery also provides the opportunity to add therapies directly to the tumour 
cavity to treat GB locally and immediately after surgery, which will be discussed in more detail 
in Section 1.2.4.    The cytoreductive results of maximal, safe surgical resection thus provide 
many benefits to the GB patient and should be included in first line GB treatment regimens 
whenever possible. 
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After recovery from surgery, typically 3-4 weeks, patients undergo conformal external-
beam radiotherapy (discussed in Section 1.2.5) with concomitant daily temozolomide 
(75mg/m2/d).  After 6 weeks of combined treatment, patients will continue adjuvant 
temozolomide (150-200 mg/m2/d) for 1 week per month for six monthly cycles.  Except for 
occasional nausea/vomiting and myelosuppression, which is monitored by serial blood counts, 
TMZ is usually well tolerated.  Many patients who experience myelosuppression are able to 
continue taking TMZ at a reduced dose.  While many chemotherapies have been studied for 
survival benefit with GB (138), TMZ has emerged as the current standard chemotherapeutic 
agent due to demonstrated improvement in median survival when coupled with RT compared 
to RT alone (122).  This benefit was confirmed in both the 2-year and 5-year survival follow-
up (139), thus solidifying the use of TMZ for first line GB treatment with radiotherapy.    
Many clinical trials have tested various alternative strategies for treating GB.  In an 
effort to treat the disease by inhibiting a fundamental aspect of its biology, a monoclonal 
antibody (Bevacizumab) was developed to inhibit VEGF-A (140).  Because GB is a highly 
vascular and quickly expanding tumour, angiogenesis inhibitors represent an attractive strategy 
to combat this biological feature and deprive the tumour of a potential mechanism of obtaining 
needed resources.  The safety of bevacizumab was first established for recurrent GB.  After 
successful phase II trials which demonstrated clinical activity, increased 6-month PFS 
compared to other recurrent treatment modalities, and decreased steroid doses required to 
control oedema, the FDA approved it for recurrent GB in 2009 (141-143).  After its testing 
with recurrent GB, bevacizumab was then added to the Stupp protocol for newly diagnosed 
GB.  Unfortunately, the results were even less clear than for recurrent GB, as the results from 
two randomised, double-blind, placebo-controlled phase III trials demonstrated only minor 
improvements in PFS and no change in median OS when comparing bevacizumab to placebo 
controls (144,145).  Because bevacizumab can disrupt contrast-enhancement, pseudoresponses 
are common in which a tumour may appear to be stable radiologically even if the tumour is 
really growing.  Such a phenomenon could explain why PFS was extended but not OS.  
Therefore, it seems that bevacizumab may not provide much clinical benefit for newly 
diagnosed GB.  The lack of clinical utility coupled with an increased number of observed 
complications and severe adverse events in the bevacizumab group has limited its use.     
Immunotherapies are becoming another popular method to inhibit a fundamental 
characteristic of GB; in this case immune evasion (146,147).  The brain, due to the restrictions 
of the blood brain barrier, is not as easily accessible for immune cells as other parts of the body.  
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However, microglia within the brain are capable of immune responses (148) and bone marrow-
derived macrophages can get recruited to brain tumours, particularly when the BBB becomes 
leaky or disrupted during tumour progression or treatment (149).  Also, tumour-associated 
macrophages (TAMs) have been found in high grade gliomas and have been attributed to 
immunosuppressive phenotypes via STAT3 signaling (150).  While there have been many 
efforts to more effectively harness intrinsic antitumour responses and to reduce the tumour’s 
ability to evade the immune system, to date, immunotherapies against GB have not been 
extremely successful.  A recent phase III trial (CheckMate-143) of nivolumab, a PD-1 
checkpoint inhibitor, sought to inhibit the ability of GB to trigger immune suppression.  PD-1 
is expressed on activated T cells that secrete IFN-γ, but PD-1 receptor expression also leads to 
increased PD-L1 expression and resulting interaction on surrounding cells which triggers an 
inhibitory feedback loop to suppress T cell proliferation and enhance T regulatory cell 
development (151).  The CheckMate-143 trial was stopped after interim analysis as nivolumab 
did not improve median OS over bevacizumab for recurrent GB patients (152).  A phase II 
study of pembrolizumab, another PD-1 inhibitor, treated recurrent GB patients with 
pembrolizumab with or without bevacizumab and compared findings to historical controls of 
recurrent GBs treated with bevacizumab alone.  The study found that pembrolizumab alone did 
not significantly contribute to an increase in median OS, further suggesting that checkpoint 
inhibitors may have limited activity as monotherapies (153).  Many trials are ongoing which 
pair checkpoint inhibitors with various other forms of therapy in an effort to enhance clinical 
and immune responses.   
There have also been several attempts at producing effective vaccines against GB.  
Rindopepimut, a peptide vaccine against EGFRvIII, showed promise in early clinical trials and 
in combination with bevacizumab.  However, a phase III trial of the vaccine was halted at 
interim analysis due to a lack of OS benefit (154,155).  Dendritic cell (DC) vaccines pulse a 
patient’s own monocyte-differentiated dendritic cells with tumour antigens or resection lysates 
for delivery back into the patient to generate tumour-specific effector cells and immune 
response.  A phase II trial for tumour lysate-pulsed DC vaccines demonstrated enhanced 
cytokine response in “vaccine responders” who had longer times to tumour progression and 
survival compared to nonresponders.  Compared to patients who received chemotherapy only, 
both responders and nonresponders experienced longer survival when chemotherapy was 
added after vaccination, although higher fold responders experienced increased time to tumour 
progression after the addition of chemotherapy (156).  While several phase I and II trials 
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demonstrate the safety and potential utility of DC vaccines, randomized control trials are 
necessary to establish clinical efficacy (157).  In addition, subsets of responders and 
nonresponders need to be studied and compared in more detail to better understand the diverse 
mechanisms of immune evasion.  Other strategies include viral vaccines, oncolytic viral 
therapy, and CAR-T cell therapy.  Viral vaccines provide the opportunity for gene therapy 
centered around directly killing the cell or activating the immune system, and an early phase I 
trial established the safety and tolerability of adenovirus transduction of herpes simplex virus 
thymidine kinase with subsequent ganciclovir treatment (158,159).  Oncolytic viral therapies 
lead to viral replication in tumour cells and subsequent lytic cell destruction .  A phase I dose-
finding and toxicity study of convection-enhanced, intratumoral delivery of poliovirus 
demonstrated a 21% overall survival rate at 24 and 36 months compared to 14 and 4%, 
respectively for historical controls (160).  CAR-T cell therapy relies on the modification of T 
cells to target tumours based on selected antigens and then cause lytic killing of the identified 
tumour cells (161,162).  However, CAR-T cell therapy is associated with high risk toxicities 
such as Cytokine-release syndrome and CAR-T-cell-related encephalopathy syndrome, and 
therefore requires intensive monitoring and patient workups.  While many of these new 
treatment modalities are interesting, again, randomized control trials will ultimately be required 
to establish clinical efficacy.  Several of these studies have produced a small subset of long-
term survivors, similar to the standard of care Stupp protocol which provides a 2 and 5 -year 
overall survival rate of around 10% and 5%, respectively.  For younger or IDH mutant patients, 
the percentage of long-term survivors is higher.  While a small subset of long-term survivors 
may not point towards significant clinical benefits, the underlying biology and characteristics 
of these long-term survivors need to be better understood so that future patients could 
potentially be stratified and treated based on their predicted response.  This is especially 
important due to the potential significant toxicities associated with some of these modalities.  
As the difficulties with translating immunotherapies into clinical benefit makes clear, a better 
understanding of both primary and recurrent GB biology, the immune response, and the 
microenvironment is needed in order to improve combinatorial therapeutics for GB.  These 
approaches must also take into account possible methods of GB resistance and evasion.     
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1.2.4 Local Delivery Strategies 
 
One strategy for improving therapy is through bypassing the blood brain barrier.  After 
resection, chemotherapeutics or other targeted modalities can be delivered directly to the 
tumour cavity for local treatment of residual disease.  Local delivery also provides treatment 
in a therapeutic window of opportunity: the weeks during recovery from surgery in which 
patients currently receive no form of anti-neoplastic therapy.  Many chemotherapeutic drugs 
have shown efficacy against GB cells in vitro or in vivo, but when translated to the clinic they 
do not display the same efficacy.  It is hypothesised that one factor contributing to this lack of 
clinical efficacy may be the BBB preventing certain chemotherapies and other systemic drugs 
from entering the brain at high enough concentrations to produce an observable clinical effect.  
Thus, there are potentially many drugs and combinations of drugs which could be repurposed 
for GB if the BBB could be successfully and efficaciously circumvented (163).   
Gliadel is a technology that bypasses the BBB by implanting carmustine-loaded, rigid 
polymer wafers into the cavity after GB resection.  Like Bevacizumab, Gliadel is also one of 
the few therapies to have been FDA-approved for treatment of newly diagnosed and recurrent 
malignant gliomas in recent years.  The wafers allow drug diffusion at higher than systemic 
concentrations over a period of several weeks to the tissue surrounding the cavity which 
contains residual cells.  However, the utility of Gliadel has been controversial.  While initial 
studies in recurrent GB demonstrated an advantage in median OS and 6 -month survival for 
Gliadel versus placebo controls (164), trial results in newly diagnosed GB are less clear.  A 
large phase III trial of 240 patients demonstrated an increased OS (13.9 months versus 11.6 
months) for Gliadel with radiotherapy compared with placebo and radiotherapy (165).  
However, subgroup analysis revealed the GB subgroup did not experience a statistically 
significant survival advantage and that incidence of CSF leak and intracran ial hypertension 
were elevated with Gliadel.  A more recent trial which examined Gliadel implant after 5 -ALA 
guided resection (14.2 months) showed no survival benefit over 5-ALA resection alone (14.3 
months) and demonstrated an increased incidence of wound infection in the wafer group (166).  
Even though a single institutional study found no difference in perioperative morbidity after 
Gliadel wafer treatment (167), the potential for side effects shown in other studies coupled with 
the little to no increase in survival benefit, has limited the clinical adoption of this local delivery 
strategy (168).  A potential cause of its limited clinical performance is the stiffness of the 
polymer which seems to make it difficult to achieve optimal tissue apposition and controlled 
1. Introduction 
36 
drug diffusion.  The Melville Laboratory for Polymer synthesis has developed a hyaluronic 
acid-based hydrogel delivery system for the treatment of GB that avoids the pitfalls mentioned 
for Gliadel (169,170).  These hydrogels represent a new avenue for local delivery of 
chemotherapeutics, radiosensitisers, and other drugs, and will be discussed in more detail in 
Appendix A. 
 
1.2.5 The Role of Radiation for Glioblastoma 
 
Because most GBs recur within 2 centimetres of the original tumour site (171-173), 
radiation of the tumour bed and the immediately surrounding tissue has been a major part of 
GB therapy for many years.  Fractionated radiotherapy (3D conformal RT) up to 60Gy is the 
gold standard for treating newly diagnosed GB after resection as it has been shown to provide 
significant survival benefit alone (174,175) and an additive survival benefit when in 
combination with TMZ (139,176).  RTOG guidelines for target volume delineation involve 
treating the FLAIR signal hyperintensity with a cone-down boost to the T1 MRI Contrast-
enhancing region with a 2-cm expansion around the tumour region (177).  In a phase III trial 
comparing standard TMZ with dose-dense TMZ for newly diagnosed GB, either RTOG or 
EORTC (more conservative target volume delineation that does not include oedema) guidelines 
were allowed for radiotherapy planning.  Cox modeling demonstrated that the choice of 
radiation technique was not a significant predictor of overall survival in this trial (178,179), 
suggesting comparable outcomes between the guidelines.  While randomized stud ies are 
needed to definitively compare efficacy between the two,  use of the EORTC guidelines is 
associated with smaller irradiated normal brain volumes without an increase in recurrences at 
the margin (180).  Importantly, intensity-modulated RT allows radiation oncologists to provide 
the prescribed RT dose while limiting radiation exposure to important neuroanatomical 
structures (brainstem, optic nerves, optic chiasm) (181-183).  While hyperfractionation 
(184,185) and accelerated fractionation (186) protocols have undergone clinical testing, these 
regimens have shown no survival benefit or only similar benefit to standard fractionation, 
respectively, thus limiting their use in the context of GB.  Interestingly, abbreviated (short 
course) RT protocols have shown clinical benefit by increasing survival and reducing risk for 
treatment of newly diagnosed GB in the elderly and patients with a poor performance status 
(187,188).   
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Other radiotherapy modalities have been examined for their potential to improve 
survival by providing boosts of radiation in addition to standard fractionation.  Interstitial 
brachytherapy with iodine-125 failed to demonstrate a statistically significant increase in 
survival when compared with standard RT (189,190).  Stereotactic radiosurgery (SRS) uses 
either a cobalt source (Gamma Knife) or a linear photon accelerator (LINAC) to achieve large 
doses of RT in the tumour volume while sparing the surrounding tissue.  When SRS was 
coupled with fractionated radiotherapy for newly diagnosed GB, no survival ben efit was 
attained.  This lack of clinical improvement was consistent regardless of whether SRS occurred 
concurrently with fractionated RT (+/- chemotherapy) (191,192) or after fractionated RT (193).  
Thus far, SRS has been shown to have the most clinical utility for small, recurrent GB (194).  
Despite standard of care treatment and many other experimental therapies, GB 
inevitably recurs which raises the issue of trying to identify the best recurrent treatment 
strategy.  While there is not a consensus for best recurrent therapy regimen, and indeed such 
regimens may need to be individualized based on tumour volume, tumour location, patient 
performance status, and other factors, several institutions are testing reirradiation protocols to 
control tumour growth (clinicaltrails.gov).  Early reports signal that fractionated reirradiation 
protocols may be a safe and effective tool for increasing PFS and OS for recurrent GB, but 
randomised controlled trials are needed to establish a clear clinical benefit (195-197).  In 
addition to the utility of SRS for small, recurrent lesions, pulse-reduced dose rate RT may also 
be a beneficial way to provide reirradiation therapy while potentially reducing the risks of 
radiation retreatment (198).      
An attractive method for improving a tumour’s response to radiation both in the primary 
and recurrent setting, is the use of radiosensitisers (199).  Historically, hypoxic cell sensitisers 
and halogenated pyrimidines were utilised to selectively isolate and sensitize hypoxic and 
rapidly proliferating tumours cells to RT, but these methods proved ineffective.  More recently, 
targeted approaches which seek to exploit intracellular signaling pathways, particularly DNA 
repair mechanisms, have been developed.  A few methods of improving radiosensitivity of 
GSCs (thought to be more radioresistant than other tumour cells) include, inhibition of HDAC 
(200), inhibition of mTORC1/mTORC2 (201), inhibition of ATM kinase (202), PARP 
inhibition (203,204), and inhibition of a combination of cell cycle checkpoint and DNA repair 
targets (205,206).  A targeted, multimodal approach is also being explored through the use of 
cisplatin-infused gold nanoparticles in conjunction with RT (207).  While there are many 
potential radiosensitisers available (208), selecting appropriate radiosensitisers based on a 
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more thorough understanding of radiation-induced GB evolution and underlying GB biology 
will no doubt lead to better sensitisation and response to radiotherapy. 
 
 
1.3 Glioblastoma Evolution 
 
The intratumoral heterogeneity of glioblastoma yields brain tumours with such a variety 
of genotypic and phenotypic cell populations that a given tumour may harbour subclones that 
are resistant to standard of care or experimental treatments even prior to undergoing such 
treatments.  Yet the process of GB evolution becomes even more difficult and dynamic as we 
know that GB can also evolve not only in response to therapeutic challenge, but also in response 
to other selective pressures.  The investigation of GB evolution after exposure to various 
selection pressures is important for understanding underlying GB biology and resistance 
mechanisms which have implications for developing more effective, better targeted 
therapeutics for recurrent disease.             
 
1.3.1 Primary versus Recurrent Tumours 
 
A common approach to examining cancer evolution is to compare genomic 
architectures between primary and recurrent tumours.  By examining changes in genetic 
alterations, scientists can speculate on the relative effects of time, microenvironment, and 
treatment.  Several studies have provided relatively large cohort analyses of whole -exome 
(WES) and whole-genome (WGS) sequencing of primary and recurrent patient-matched 
samples.  Kim et al. found through TCGA genomic analysis and WES of matched tumours that 
TP53 mutations were strongly associated with an increase in subclonal mutations, including an 
increase in prevalence of G-CIMP methylation phenotype (209).  Thus, the detected TP53 
mutations could suggest a susceptibility to apoptosis suppression or increased DNA damage 
tolerance after treatment.  Furthermore, WGS of 10 matched patient samples demonstrated two 
patterns of evolution: linear and divergent.  Linear evolution, or clonal evolution, occurs when 
dominant clones present in primary tumours directly lead to regrowth of recurrent tumours 
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such that there are many shared mutations in addition to newly accumulated variants.  
Divergent evolution, or ancestral origin evolution, occurs when the recurrent tumour regrows 
from an “ancestral” clone that split early from the primary tumour’s more dominant clones.  
When the dominant clones are removed by treatment, the ancestral clone which has 
accumulated many new mutations over time repopulates the tumour such that the primary and 
recurrent mutation patterns are quite different.  Genomic analyses including WES, RNA-Seq, 
and array-comparative genomic hybridisation of 38 GB patients reveal that tumours that 
recurred distally were more likely to exhibit a branched (divergent) evolutionary pattern, with 
divergence in GB driver genes between paired tumours (210).  This study also demonstrated 
that TMZ-induced hypermutation was rarely associated with IDH-wildtype primary tumours, 
suggesting that a GB’s evolutionary history is affected by the complex interplay of baseline 
mutational architecture, early behaviour of heterogenous tumour cells, interaction with the 
microenvironment, and therapeutic selection pressures.   
Similar results were found by Lee et al. through interrogation of  multisector and 
longitudinal samples from 52 GB patients.  Tumour fragments that were spatially proximal 
demonstrated more similarities in mutation and expression signatures, while distal foci and 
recurrences separated by longer periods of time were thought to have been seeded by distinct 
early  clones reflecting a divergent pattern (115).  The genomic similarity amongst spatially 
local fragments also corresponded to similar drug responses as cell lines derived from local 
samples exhibited similar responses to screened compounds while distant and longitudinal 
samples exhibited more diverse responses.  These results from relatively large matched cohorts 
suggest that spatial and temporal proximity may have a correlation with genomic similarity, 
especially relative to distally and longitudinally separated recurrences.  However, as previously 
discussed, fragments from the same tumour and even cells within the same fragment can 
display a large amount of ITH.  Indeed, slightly conflicting results were found through the 
analysis of genetic alterations and COSMIC mutational signatures (211,212) of 10 presumably 
local recurrences (213).  In this study, differences in genetic alterations were found between all 
paired samples, even in one case in which no intervention occurred between surgeries for the 
two recurrences, suggesting that both treatment and time (including interactions with the 
microenvironment) can lead to changes in genetic alteration patterns in locally recurrent 
tumours.  It was also noted that even among the genetic similarities between paired tumours, 
the percent reads for given mutations varied widely, suggesting subclonal/clonal expansion and 
contraction.   
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Studies of paired primary and recurrent tumours demonstrate both the extensive ITH of 
GB and the evolutionary dynamics at work during disease progression.  Therefore, longitudinal 
analysis of GB evolution must become a common feature of GB research, clinical evaluation, 
and treatment decisions.  This priority is evidenced by the ongoing work of the Glioma 
Longitudinal Analysis Consortium (GLASS) which seeks to better understand the cellular and 
molecular changes involved in GB evolution in an effort to improve treatments and outcomes 
(214).  While such longitudinal studies provide better insight into GB evolution and represent 
an improvement in GB genomic investigation from initial TCGA studies (based mostly on 
single biopsies of primary tumours), they still represent single snapshots in time of primary and 
recurrent tumours.  Recent advances in liquid biopsies for GB provide the potential to 
incorporate more frequent disease interrogation for improved, up-to-date monitoring of patient 
response to targeted treatments (215-218).  Therefore, liquid biopsies may provide an avenue 
for treatment improvements based on a better understanding of GB evolution and the selective 
pressures which drive that evolution for individual patients.  Liquid biopsies provide an easier 
method for more frequent, longitudinal monitoring of tumour burden, treatment response, and 
clonal evolution.  It provides the opportunity to examine whether treatments have led to 
resistance or even whether new susceptibilities may have arisen after a given treatment 
regimen.  Liquid biopsies would prevent the risks associated with multiple surgical biopsies 
and could potentially capture more holistic genomic and transcriptomic profiles of the tumour 
than a focal biopsy.  Furthermore, the ease and relative safety of longitudinal tumour response 
monitoring will allow for easier testing of targeted therapeutics in clinical trials.  While more 
studies will need to be completed to optimize liquid biopsy protocols to make them more 
reproducible across studies, to pinpoint potentially useful biomarkers to correlate with response 
and prognosis, and to detect important evolutionary branch points to suggest initiation of 
matched target therapies, it seems clear that liquid biopsies could prove to be a very valuable 
tool for expanding personalized medicine options for GB patients.           
 
1.3.2 Microenvironment as a Source of Selective Pressure 
 
There are many potential sources of selective pressure that may contribute to GB 
evolution.  The tumour microenvironment (TME) represents a complex source of non-tumour 
cells which interact with glioma cells and can influence glioma growth and evolution.  Immune 
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cells, particularly microglia and macrophages (TAMs), are recruited to tumour sites and have 
been shown to influence GB growth and invasion (219).  Reduction in the number of microglia 
has been shown to reduce in vivo glioma growth (220,221), which could be a function of the 
loss of supportive factors released from microglia such as EGF, STI1, IL-6, and TGF-β which 
stimulate proliferation, migration, and invasion (222-225).  TAMs have also been implicated 
in glioma growth through their involvement in promoting angiogenesis via RAGE (receptor 
for advanced glycation end product) and VEGF signalling (226).  An increased amount of TAM 
infiltration has been correlated with the mesenchymal transcriptional subtype and the transition 
from proneural to mesenchymal subtype has been correlated with activation of the NF-κB 
pathway (227).  Such enrichment of immune cells in mesenchymal subtype GBs was 
corroborated through in silico cell sorting (CIBERSORT) experiments of TCGA data (228), 
further supporting the close interaction and mutual influence of GB expression and supportive 
TAMs in the microenvironment. 
In addition to immune cells, GB is also influenced by resident astrocytes in the TME.  
In vitro experiments proved that astrocytes can enhance invasion and reduce radiosensitivity 
of GSCs (229,230).  Activation of the JAK/STAT pathway of reactive astrocytes can lead to 
release of anti-inflammatory cytokines which promote unhindered GB growth through 
immunosuppression (231).  Endothelial cells and other stromal cells may also play a role in the 
microenvironmental regulation of GB.  Tumour cell niches have been described in the TME as 
locations in which cancer stem cells can directly contact, interact and communicate with non-
neoplastic cells to promote tumour growth and survival.  The perivascular niche, vascular-
invasive niche, and hypoxic niche have been described and associated with angiogenesis, 
migration, and necrosis, respectively (232).  The complex interactions of GB cells with the 
TME are important to assess, not only because of their direct impact on evolution, but also 
because the TME provides the in-situ context in which residual GB cells undergo treatment.      
 
1.3.3 Therapy-induced Evolution 
 
Therapeutic selection pressures are potentially some of the strongest drivers of 
evolution.  A landmark study by Johnson et al. demonstrated chemotherapy-induced evolution 
as 6 out of 10 low-grade glioma that underwent alkylating chemotherapy with TMZ were found 
to be hypermutated when they recurred as high-grade glioma.  The recurrent tumours displayed 
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acquisition of driver mutations in core GB pathways as a result of the hypermutator phenotype 
and its associated susceptibility to acquiring new mutations.  Not only are low-grade glioma at 
risk of hypermutation after alkylating chemotherapy, but GB itself is susceptible to such 
evolution.  It is estimated that around 50% of low-grade glioma that undergo malignant 
transformation and up to 20% of recurrent GBs express the hypermutator phenotype (233,234).  
Recurrent GBs have been shown to express the hypermutator phenotype in the context of 
MGMT promoter methylation and MSH2/6 mutation which increase susceptibility to DNA 
damage by TMZ and decrease a cell’s ability to properly respond to such damage, respectively  
(Figure 1.4) (90,91).  Such studies imply that chemotherapy drives evolution leading to the 
emergence of resistant clones.  Consistent with studies of clinical specimens, temozolomide 
treatment of mice bearing brain tumour xenografts initiated from GB primary cultures also 
suggested the expansion of drug resistant clones (235). 
 
Figure 1.4 TMZ-induced evolution. Temozolomide alkylates tumour cell DNA.  MGMT 
can remove alkyl groups from DNA and allow tumour cells to evade cell death.  If MGMT 
promoter methylation is present, then MGMT does not function properly.  In this case, the 
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DNA Mismatch repair complex MSH6-MSH2 can detect incorrect base pairing caused by 
replication after alkylation damage.  Ultimately, DSBs are induced and cells undergo 
apoptosis after futile cycles of replication.  However, if loss of function mutations in MMR 
genes are coupled with nonfunctional MGMT, then alkylation and C>T and G>A transitions 
will accumulate.  This leads to survival of cancer cells with unchecked mutation 
accumulation resulting in the hypermutator phenotype.  
 
While TMZ-induced hypermutator phenotype GBs can acquire a high number of new 
mutations following treatment, therapy can also lead to reduction of clonal diversity and 
selection of pre-existent clones.  Targeted deep sequencing of 21 patients revealed that clonal 
diversity (variant burden) was reduced in non-hypermutated recurrent tumours, suggesting the 
selection of variants after treatment (236).  Similar results were found by examining the 
branched evolutionary patterns of 114 patients after recurrence (237).  Evolutionary rate 
models predicted that many recurrences emerged through the growth of clones that were 
present many years before diagnosis.  These early clones had convergently gained “clonal 
replacement” mutations in key driver genes.  Such results further support the removal of clonal 
populations prevalent in primary disease after treatment and subsequent selection and 
proliferation of early branching subclones to repopulate recurrent disease. 
Treatment-induced evolution has implications not just for the therapeutic modalities 
which potentially induced the evolution but can also impact sensitivities to other targets.  
Longitudinal analysis of  GB samples demonstrated a discordance between primary and 
recurrent tumours in 90% of the druggable targets tested after standard chemoradiotherapy 
(238), further supporting the concept that molecular analysis at initial diagnosis is not enough 
to capture the ITH of GB, particularly after treatment driven evolution.  Indeed, while a study 
of the impact of standard of care treatment on 186 pairs of primary-recurrent GB found that 
approximately 80% of cancer gene mutations were stable at recurrence, many variants did 
demonstrate a change in status in subsets of patients (239).  EGFR, a commonly targeted RTK, 
was one of the least stable mutations.  In particular, 37% of patients with EGFRvIII in the 
primary tumour lost expression at recurrence, similar to a previous study (240), which implies 
that certain recurrent tumours need to be re-resected/re-biopsied in order to confirm mutation 
status of relevant variants with implications for precision medicine clinical trial inclusion.   
Several of the above studies have investigated the role of chemotherapy in GB evolution.  
However, despite the inclusion of radiotherapy in virtually all GB treatment regimens, little 
consideration has been given to the contribution of radiotherapy alone to GB evolution.  In 
1. Introduction 
44 
order to assess the potential of radiation to drive evolution, a clinically and biologically relevant 
model is needed. 
 
 
1.4 A Model for Studying Radiation-induced Evolution 
 
Because glioblastoma is an evolutionary dynamic, genotypically diverse, and 
phenotypically heterogenous tumour, it presents a difficult challenge for researchers.  Accurate 
models of this disease must be able to not only capture the underlying heterogeneity of the 
cancer, but also be able to recapitulate many of its histological, phenotypic, and clinical 
features.  In the context of evolution, a cancer model is arguably most useful when it 
demonstrates a measured degree of treatment response (non-curative) followed by eventual 
progression and recurrence.  Such a GB model would not only mimic the clinical course of the 
disease but would provide the opportunity to compare primary and recurrent tumours and the 
evolutionary processes that connect them.  Glioblastoma stem-like cells (GSC) provide such a 
model.       
 
1.4.1 Glioblastoma Stem-like Cells 
 
Glioblastoma-stem like cells isolated from human GB surgical samples either through 
derivation and propagation in serum free, EGF/FGF-containing media (241) or through 
isolation of CD133+ cells (242) were found to exhibit many of the same properties as adult 
somatic stem cells (243).  Specifically, GSCs are undifferentiated cells with the ability to 
generate a heterogeneous population of fate-restricted cells, GSCs have the ability to self -
renew, and perhaps most importantly, GSCs (sometimes called tumour-initiating cells) have 
the ability to initiate tumours (244).  GSCs have also been implicated in treatment response, 
both chemoresistance and radioresistance (245,246), which may have implications for GB 
evolution and recurrence and also suggests their potential application for initial radiotherapy 
and drug response screening (247).   
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CD133 is thought to be one of several potential stem cell markers which can enrich for 
a clonogenic subpopulation of GSCs (244).  Definitive markers of GB and GSCs are 
controversial because marker expression is known to fluctuate and some studies have 
demonstrated that cell populations lacking marker expression (CD133 or NG2) can sometimes 
still initiate proliferative tumours (248,249).  Such results could indicate that self -renewal and 
tumour initiation capabilities may not be restricted to specific GSC populations.  However, 
while CD133 sorting may not fully capture the genotypic and phenotypic heterogeneity of 
GSCs (136,250,251), it does provide a more uniform population of clonogenic cells with which 
to perform in vivo studies.   
 
1.4.2 GSC-initiated in vivo Models of Glioblastoma  
 
One of the shared, defining features of GSCs is the ability to produce tumours upon 
orthotopic implantation.  Importantly, GSC-initiated orthotopic xenografts have been shown to 
replicate the genotype, phenotype and in vivo growth patterns of GB (252).  While some GSCs 
are diffusely invasive and may serve as better models for glioma infiltration, others form 
discrete nodular and vascular masses and may serve as better models of tumour-associated 
angiogenesis (253).  With respect to GB evolution, we have previously shown that after the 
initial implant of 100% CD133+ GSCs, xenografts at the time of morbidity are comprised of a 
variety of cell subpopulations including those expressing GFAP or βIII tubulin  (254).  This is 
consistent with tumour cells that have differentiated, at least partially, along astrocytic and 
neuronal pathways, respectively.  In addition, there continued to be a small subpopulation 
(approximately 10%) of tumour cells expressing CD133, suggesting the enduring presence of 
GSCs. 
GSCs isolated from paired surgical samples provide evidence for both linear and 
branched evolutionary patterns.  GSCs were found to both accumulate mutations as a result of 
TMZ or to undergo positive selection in which a primary subclone (TP53 at low frequency 
prior to treatment) was positively selected and expanded to populate the recurrent tumour 
(255).  Furthermore, GSCs isolated from a patient’s tumour prior to and after EGFR-targeted 
therapy led to xenografts which recapitulated the disease genotype and phenotype (256).  In 
particular, EGFR amplification seen in the initial tumour/xenografts was lost in the recurrent 
tumour/xenograft.  In addition to demonstrating similar cell populations, the GSCs from the 
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initial tumour were found to be more proliferative in vivo and more sensitive to EGFR 
inhibition in vitro.  A potential next step would be to treat the initial tumour-derived xenograft 
with EGFR inhibitor to determine if a recurrent tumour would regrow in vivo which mirrors 
the clinical outcomes and genotype/phenotype seen in the recurrent tumour-derived xenografts.  
In this regard, GSC-initiated orthotopic xenografts have already demonstrated efficacy as 
models of therapy-driven evolution.  In a study by Chen et al., a Nestin-RTK-GFP transgene 
was utilised to label a subset of endogenous, quiescent GSCs.  This labelled subset was found 
to regrow the tumour in a hierarchical fashion after treatment with TMZ initially caused arrest 
of proliferation (257).  Chronic ganciclovir treatment, used to target GFP+ cells, led to tumour 
growth arrest, suggesting that the labelled glioma stem cell-like population was involved with 
treatment resistance, tumour cell proliferation and growth of recurrent tumours (257).   
 
1.4.3 The Brain Tumour Microenvironment and Response to Radiation 
 
Another reason that GSC-initiated xenografts closely replicate GB in situ is the 
interaction of GSCs with the brain tumour microenvironment.  Many adult neural stem cells 
reside in neurogenic parts of the brain, including the subventricular zone of the lateral ventricles 
and the subgranular zone within the hippocampal dentate gyrus (258).  Glioma stem-like cells 
have also been found to reside in such niches leading to the question of whether GSCs invade 
into or out of these areas during early tumourigenesis (259,260).  In addition, integrin α6 has 
been identified as a possible GSC marker and its role as a receptor for the extracellular matrix 
protein laminin highlights the importance of microenvironmental interactions for GSC function 
and development (261).  GSCs are not only influenced by the microenvironment but can also 
shape the microenvironment in return.  This influence has been particularly evident regarding 
tumour vasculature.  For example, GSCs have been shown to secrete high levels of VEGF 
which may induce angiogenesis (262).  Further evidence suggests that GSCs may even 
transdifferentiate into vascular endothelial cells (263,264) as CD31+ endothelial cells were 
found to harbour GB-specific mutations (265).  While such findings are controversial and 
warrant corroboration, they do present an interesting example of GSC-induced changes in the 
microenvironment.        
To study the possible responses to radiotherapy in terms of evolution and therapeutic 
consequences, the GSC-derived xenograft model must also display ITH with respect to cellular 
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phenotype and radioresponse.  Such ITH was demonstrated through  analysis of ɣH2AX and 
53BP1 foci induction and dispersal in GSC xenografts.  Even though CD133+ stems cells and 
CD133- differentiated cells have similar radiosensitivity in vitro, when irradiated as orthotopic 
xenografts CD133+ cells were less radiosensitive than CD133 - tumour cells (266).  In vivo 
GSCs were less susceptible to foci induction, showed an increase in expression of genes related 
to reactive oxygen species, and experienced an increase in relative cell percentage after 
radiation (266).  The microenvironment has also been shown to play a significant role in this 
radioresponse as tumour cells grown as orthotopic xenografts were able to more quickly 
disperse ɣH2AX foci following radiation therapy compared to cells grown in vitro (254).  GSC-
initiated xenografts exhibit the intratumour heterogeneity, microenvironmental interactions, 
and evolutionary dynamics necessary to simulate that of a GB in situ, thus providing a useful 
model for the study of radiation-induced GB evolution. 
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Chapter 2. Aims and Hypotheses 
 
2.1 Aims 
 
The extensive intratumoral heterogeneity of glioblastoma renders it susceptible to 
evolution when exposed to selective pressures.  Such pressures as imposed by the tumour 
microenvironment and therapeutic regimens can lead to the expansion or contraction of various 
subclones depending on the relative fitness of each subclone as determined by its sensitivity to 
a given challenge.  For example, a certain drug could remove all sensitive clones and thus 
provide the opportunity for resistant clones to expand quickly to grow a recurrent tumour due 
to competitive release.  In this way, selective pressures drive evolution and contribute to tumour 
recurrence, progression, and treatment failure.  While the role of chemotherapy in treatment-
induced evolution has been studied, the impact of radiotherapy alone on glioblastoma evolution 
has not been determined.   
As outlined in this thesis, I will endeavor to describe the effect of ITH on intrinsic 
radiosensitivity to determine whether spatially distinct regions of the same tumour may have 
different sensitivities.  Then I will discuss whether radiation alone can drive the evolution of 
GSC-initiated orthotopic xenografts and whether it leads to the emergence of resistant 
subclones.  In this context, the GSC-initiated xenograft model will also be proposed as a 
potential model system for studying recurrent GB and reirradiation protocols.   Finally, I will 
report on biocompatibility and efficacy studies for a new hydrogel delivery system, which 
could provide immediate and local delivery of targeted combinatorial therapeutics, including 
radiosensitisers.  Ultimately, by better characterizing the impact of radiation on glioblastoma 
evolution and by studying recurrent GB and retreatment strategies, we can harness insights 
related to recurrent glioblastoma biology and radiation biology for the production of more 
effective systemic and local therapies to improve outcomes for glioblastoma patients.  With 
this thesis, I would like to answer the following questions: (1) Does ITH translate into 
differences in intrinsic radiosensitivities between patient-derived cell lines derived from 
distinct tumour fragments?  (2) Does radiation alone drive glioblastoma evolution?  (3) If 
radiation drives glioblastoma evolution, does it lead to the emergence of radioresistant clones?  
(4) Can the GSC-initiated xenograft model be used to study recurrent GB treatment strategies?  
(5) Are hyaluronic acid-based hydrogels biocompatible and effective at local drug delivery?  
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2.2 Hypotheses 
 
(1) Does ITH translate into differences in intrinsic radiosensitivities between patient-derived 
cell lines derived from distinct tumour fragments?   
 
Hypothesis:  I hypothesised that patient-derived cell lines derived from spatially distinct 
tumour fragments would display intratumoral heterogeneity.  Furthermore, I hypothesised that 
the heterogeneity between cell lines would extend to radioresponse such that different cell lines 
from the same tumour would display different intrinsic radiosensitivities.   
 
After deriving cell lines from multiple spatially distinct tumour fragments from several 
patients, we examined differences in radioresponse through standard radiation biology 
techniques.  Similarities or differences in radioresponse and extent of ITH were further 
interrogated through genomic analysis of these patient-derived cell lines and their 
corresponding tumour samples.  If there are major differences in radioresponse and genetic 
alterations between cell lines derived from distinct regions of the same tumour, then it would 
suggest that multiple therapeutic targets are needed for holistic treatment of GB. 
 
(2) Does radiation alone drive glioblastoma evolution? 
   
Hypothesis:  I hypothesised that, similar to other therapeutic modalities, radiation is capable of 
providing selective pressure sufficient to drive glioblastoma evolution.   
 
GSC-initiated orthotopic xenograft models treated with fractionated radiotherapy were 
utilised to examine the survival, phenotypic, and genomic consequences of radiation.   Due to 
the variability in tumour growth patterns and inconsistency in growth rates of the patient-
derived cell lines utilised for Aim 1, those lines were deemed inappropriate for examining the 
effects of a therapeutic challenge.  Therefore, GSC lines which have previously been shown to 
provide reproducible in vivo tumours with consistent radioresponse were selected for the study 
of radiation-induced evolution.  Morphologic and histological analysis characterised potential 
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changes in recurrent GB biology.  Viral integration site analysis (VISA) examined the impact 
of radiation on clonal diversity, while WES highlighted any changes in mutation patterns of 
GSC-initiated tumours before and after treatment with radiation.  These measures were 
employed to provide evidence for radiation-driven GB evolution. 
 
(3) If radiation drives glioblastoma evolution, does it lead to the emergence of radioresistant 
clones?   
 
Hypothesis:  As mentioned above, I predicted that radiation drives glioblastoma evolution.  
Furthermore, I hypothesised that such radiation-induced evolution would lead to the emergence 
of resistant clones which would contribute to the regrowth of a radioresistant recurrent tumour. 
 
GSC-initiated orthotopic xenograft models were again applied to study the functional 
implications of possible radiation-induced evolution.  Tumour cells were isolated from morbid 
control and irradiated tumours and were put back into culture.  These xenograft-derived cell 
lines were subsequently tested for evidence of differential radioresponse through clonogenic 
survival assays and a reimplantation survival study.  Such studies may provide valuable 
information on the potential functional implications of radiation-induced GB evolution.   
 
(4) Can the GSC-initiated xenograft model be used to study recurrent GB treatment strategies?   
 
Hypothesis:  I predicted that through regular in vivo tumour growth monitoring, GSC-initiated 
xenografts could serve as models of recurrent tumour growth and could be successfully 
reirradiated to provide a clinically relevant model of recurrence and retreatment.   
 
GSC-initiated xenografts underwent a first course of fractionated radiation.  After 
treatment, the irradiated mice were followed by serial imaging to monitor for tumour regrowth.  
Once regrowth was noted, the same fractionated radiation protocol was reapplied.  Survival 
analysis was performed to determine the in vivo radioresponse of recurrent tumours after 
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reirradiation.  Such studies may not only demonstrate whether such models would be useful 
for studying recurrent treatment regimens, but may also serve as a more clinically relevant 
approach for determining functional implications of radiation-induced evolution.     
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Chapter 3. Materials and Methods 
 
 The following represent general methodologies employed throughout the work 
included in this thesis.  Study-specific methods are described in Chapters 4-6 and Appendix A.  
  
3.1 Human glioblastoma sample collection 
 
 Human glioblastoma tissue was collected from patients that underwent 5-ALA 
fluorescence-guided surgical resection at Addenbrooke’s Hospital at the University of 
Cambridge.  Fluorescent tumour tissue was collected for diagnosis, storage as fresh frozen 
tissue by the Addenbrooke’s tissue bank, and  derivation of patient-derived cell lines.  Matched 
whole blood samples were also collected.  Informed consent for tissue and corresponding 
clinical data to be used for research purposes was obtained from all patients prior to surgery.  
Tissue collection protocols were compliant with the UK Human Tissue Act 2004 and approved 
by the Local Regional Ethics Committee (LREC ref. 04/Q0108/60). 
 
 
3.2 Cell culture of glioblastoma cells 
 
3.2.1 Derivation and propagation of patient-derived cell lines 
 
Primary tumour samples were placed in specimen tubes and immediately placed on ice 
for transport to the human tissue fume hood.  Under the fume hood, tumour fragments were 
minced with scalpels separately, transferred to a 50mL Falcon tube, and incubated at 37.5oC 
and 5% CO2 for 45-90 minutes with 2-5 mL of Accutase (Gibco), depending on the size of the 
tumour sample, to degrade extracellular material.  After incubation, HBSS (without Calcium 
and Magnesium, Gibco) was added to the suspension for dilution.  The single cell suspension 
was then filtered through a 40 µm cell strainer to remove debris, endothelial/vascular cells, and 
extracellular material.  The resulting single cell suspension was spun down at 1200 g for 5 
minutes.  The supernatant was carefully discarded and 1-3.5 mL red blood cell lysis buffer was 
added to resuspend the pellet depending on the size and suspected level of blood content of the 
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pellet.  After 10 minutes of incubation at room temperature, cells were spun down again at 
1200 g for 5 minutes.  The supernatant was carefully discarded and then 10 mL of HBSS was 
added to resuspend and wash the pellet.  Washing occurred 1-3 more times depending on the 
size of the pellet.  After a final wash and spin, the supernatant was discarded and the pellet was 
resuspended in serum free medium (SFM; Neurobasal A (Invitrogen, UK) with 20 mM L-
glutamine, 1% PSF solution, 20 ng/ml hEGF (Sigma, UK), 20 ng/ml hFGF (R&D systems, 
UK), 2% B27 (Invitrogen, UK) and 1% N2 (Invitrogen, UK)).  Cells were counted with a 
hemocytometer and then plated with SFM at a density of approximately 100,000 cells per mL 
in 25 or 75 cm2 cell culture flasks and placed in a 37.5oC, 5% CO2 incubator. 
After 7-10 days, cells began to form floating neurospheres.  Once there were enough 
neurospheres of sufficient size to be viable, neurospheres were removed from flasks, spun 
down at 1200 g for 5 minutes, washed with HBSS, resuspended in SFM, and added to cell 
culture flasks that had been pre-coated with extracellular matrix (ECM; Sigma).  Neurospheres 
then plated down forming an adherent monolayer of glioma cells that were maintained and 
utilised for future experiments.  To passage adherent monolayer cultures, media was removed 
from flask and 2-4 mL of Accutase was added for 10 minutes in 37.5o C incubator.  Around 4 
mL of SFM was added to floating cells and suspension transferred to 15 ml Falcon tube.  If 
needed, Accutase step was repeated to remove remaining cells from flask.  Cells were then 
spun at 1200 g for 5 minutes, resuspended in HBSS and spun again.  The supernatant was 
discarded and SFM was added.  Cells could then be counted, re-plated, frozen down, or utilised 
as needed.    
 
3.2.2 Freezing and thawing patient-derived cell lines 
 
Depending on the growth rate of individual, patient-derived cell lines, lines were 
passaged every one to two weeks.  Typically, with each passage, cells were counted using a 
hemocytometer and 500,000-1 million cells in SFM were added to freezing media (SFM with 
10% DMSO) to a total volume of 1 mL.  Lines were then frozen down in isopropanol freezing 
containers at -80oC before being transferred to liquid nitrogen for permanent storage.   
Individual patient-derived cell lines were thawed and re-established when necessary.  
Cells were removed from -80oC freezer or liquid nitrogen storage and placed on dry ice.  15 
mL Falcon tubes with 10 mL of SFM were prepared.  Then, cryovials were thawed by holding 
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in gloved hands.  Once thawed, cells were quickly transferred to SFM and spun down.  
Supernatant was discarded and cells were washed with SFM or HBSS 1-3 more times, 
depending on the size of the initial pellet.  Finally, 10 mL of SFM was added to pellet and 
solution was placed in a 75 cm2 culture flask and placed in a 37.5oC, 5% CO2 incubator.  A few 
days later, cells were transferred to ECM-coated flasks.           
 
3.2.3 Glioblastoma stem-like cells and other glioblastoma lines 
 
GSC lines NSC11, NSC20, and NSC23 were isolated from three human GB surgical 
specimens and were kindly provided by Dr. Frederick Lang (MD Anderson Cancer Center).  
They were maintained as neurospheres in stem cell medium composed of DMEM/F-12 
(Invitrogen), B27 supplement (Invitrogen), and human recombinant bFGF and EGF (50ng/ml 
each, R&D Systems) at 37oC, 5% CO2, and 5% O2, as previously reported (267,268).  FACS 
was utilised to sort for CD133+ cells from each culture.  To prepare cells, TrypLe Express 
(Sigma) was utilised to generate single cell suspensions from neurospheres.  After 30 seconds 
of exposure, defined trypsin inhibitor (Sigma) was added and neurospheres were disaggregated.  
After washing, single cell suspensions were labelled with anti-CD133 antibody (PE-
conjugated, Miltenyi) and FACS sorted under sterile conditions.  CD133+ GSCs were 
expanded and utilised for all experiments.   The U251 human GB cell line was obtained from 
the Division of Cancer Treatment and Diagnosis Tumour Repository (DCTD), National Cancer 
Institute (NCI), grown in Dulbecco's Modified Eagle Medium (DMEM) supplemented with 
10% FBS (Invitrogen), and maintained as adherent cultures at 37oC, 5% CO2.   
GSC lines and U251 cells were cultured less than 2 months after resuscitation.  Cell 
lines tested negative for mycoplasma contamination by PCR analysis (Idexx BioAnalytics).  
All lines were transduced with lentivirus (LVpFUGQ-UbC-ffLuc2-eGFP2, provided by Viral 
Technology Laboratory, NCI Frederick) as single cells at a MOI of 1 to express both GFP and 
luciferase.  GFP expression was monitored in vitro and, in some cases, cells were sorted for 
GFP positivity by FACS prior to in vivo implantation.  For use in an in vitro experiment, GSC 
neurospheres were disaggregated into single cells, as described above, and seeded onto poly-
L-ornithine (PO, Invitrogen)/laminin (Sigma-Aldrich) coated tissue culture dishes in stem cell 
media.  Under these conditions, single-cell GSCs attach and grow as an adherent monolayer 
maintaining their CD133 expression and stem-like characteristics (269). Radiation was 
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delivered to in vitro cultures using a 320 kV Xray machine (Precision X-Ray Inc.) at a dose 
rate of 2.3Gy/min. 
 
 
3.3 In vivo protocols 
 
3.3.1 Orthotopic implantation of glioblastoma cell lines 
 
 CD133+ GSCs (1.0 x 105) or U251 (2.5 x 105) transduced to express luciferase and 
GFP were orthotopically implanted into the right striatum of 6-week-old athymic female nude 
mice (Ncr nu/nu; NCI Animal Production Program).  A single cell suspension of the cells to be 
implanted were collected and then counted on a Coulter counter.  Cells were then spun down 
and resuspended in sterile PBS such that the required number of cells could be implanted in 
5µL per mouse.  Mice were anaesthetized using isoflurane gas and transferred to a stereotactic 
surgical frame with continued isoflurane exposure and heat pads.  Mice were secured with ear 
clamps.  Meloxicam was provided subcutaneously prior to surgery initiation and Marcaine was 
provided topically after surgical incisions for post-operative pain relief.  Scalps were scrubbed 
with iodine and 70% surgical grade ethanol three times prior to making a 1 cm sagittal incision 
to the right of midline with a sterile scalpel.  The bregma was identified and a burr hole created 
with a 22-gauge needle 1 mm anterior and 2 mm lateral to the bregma.  Once a hole was made 
in the skull, a Hamilton syringe pre-loaded with glioma cells was lowered to a depth of 3.5mm 
inferior to the skull surface and then raised 0.5mm.  After a delay of two minutes, glioma cells 
were slowly injected over 4 minutes.  Once all cells were injected, two minutes were waited 
prior to slowly removing Hamilton syringe.  Mouse was removed from stereotactic frame and 
incision was closed with veterinary glue.  Each mouse was monitored in a heated plastic 
chamber until fully recovered.     
 
3.3.2 Bioluminescent imaging for monitoring tumour growth 
 
On day 6 (U251) or day 21 (NSC11, NSC20, NSC23) after implantation, mice were 
randomised according to bioluminescent imaging (BLI) signal into two groups: control and 
radiation (RT).  BLI was performed by injecting mice intraperitoneally with D-luciferin 
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(0.01ml/g body weight; 15mg/ml sterile PBS; GoldBiotechnology).  After a period of 
approximately 15 minutes, mice were briefly anaesthetized with isoflurane and imaged with a 
Xenogen IVIS 200 imaging system (Caliper Life Sciences).  BLI was performed weekly after 
irradiation until the first mouse of a given treatment group died.  Subsequent BLI total 
fluorescence values were compared to the initial, pre-treatment total fluorescence value of a 
given mouse’s tumour to provide BLI ratios.  Tumour growth rate curves were generated in 
SigmaPlot by charting changes in BLI ratios for each treatment group as a function of time 
after irradiation. 
 
3.3.3 Irradiation for treating in vivo tumours 
 
After confirmation of tumour growth, mice randomised to receive irradiation were 
anaesthetized with an intraperitoneal injection of a ketamine/xylazine cocktail and placed in a 
well-ventilated Plexi glass jig with lead shielding of critical normal structures (e.g. torso, neck, 
ears).  For GSC tumours, 5Gy was delivered for 3 consecutive days.  For U251 tumours, 3Gy 
was delivered on 3 consecutive days.  Radiation was delivered using an X-Rad 320 X-irradiator 
(Precision X-Rays, Inc.) at a dose rate of 2.9 Gy/minute.  Immediately after receiving 
irradiation, mice were intraperitoneally injected with AntiSedan to reverse the effects of 
ketamine.  Mice were placed on a warmer and monitored until fully recovered.       
 
3.3.4 Subcutaneous injection of glioblastoma cells 
 
To generate leg tumours 1.0 x 106 U251 cells per 100µl sterile PBS were 
subcutaneously (SC) injected into the right hind legs of 6-week-old athymic female nude mice 
while awake.  Tumour size was monitored biweekly with digital calipers.  Once the average 
tumour size of a cohort reached 150-200 mm3, mice were randomised into control and radiation 
(3x3Gy) groups.  Fractionated radiation was delivered locally with awake animals restrained 
in a custom designed lead jig which shielded all structures except for the tumour-bearing leg.  
Radiation (3Gy) was provided over three consecutive days utilising the same X-Rad 320 X-
irradiator mentioned above.  SC tumours were monitored biweekly with digital caliper 
measurements.  Once an individual tumour reached a volume of  1500 mm3 or 2 cm in any 
dimension, mice were humanely euthanised and SC tumours were collected for analysis.   
3. Materials and Methods 
58 
3.3.5 Survival analysis 
 
All mice were observed daily to monitor for onset of neurologic symptoms.  Once mice 
reached morbidity, they were humanely euthanised utilising an approved schedule 1 method.  
Overall survival for each mouse was recorded and GraphPad Prism 7 (GraphPad Software) was 
used to generate Kaplan–Meier survival curves.  The number of mice utilised for each study, 
based on previous work using established glioma cell lines, were estimated by a On e-Way 
ANOVA analysis to allow 80% power to detect a 25% increase in growth delay/survival when 
the differences between the mean tumour volumes/survival times is 1.25 standard deviations 
different than controls.  All in vivo experiments were performed as approved by the NIH Guide 
for Care and Use of Animals and conducted in accordance with the Institutional Animal Care 
and Use Committee.  Additionally, all in vivo experiments performed in the UK were 
performed according to Home Office UK guidelines. 
 
 
3.4 DNA and RNA extraction 
 
3.4.1 Xenograft tumour collection 
 
 After humanely euthanising mice by cervical dislocation, cardiac perfusion was 
performed with chilled PBS.  Briefly, the rib cage was removed, the right atrium was cut, a 
butterfly needle was inserted and clamped in the left ventricle, and the inferior vena cava was 
clamped shut.  PBS was injected into the left ventricle into the blood stream to perfuse the brain 
to remove blood.  If the brain was needed for histology, then 10% Formalin was perfused after 
the PBS.  After cardiac perfusion, the scalp was cut and the skull opened to expose the brain.  
The entire brain was carefully removed and transferred to a PBS-filled petri dish for tumour 
removal or a container containing 10% Formalin for further fixation prior to histology 
preparation.  GFP+ tumour tissue was visualised and dissected under a fluorescent stereoscope 
(Leica).  Tumour tissue was transferred to a cryovial and snap frozen in liquid nitrogen prior 
to storing in a -80oC freezer.  When the fresh frozen tumour tissue was needed for DNA 
extraction, it was thawed on ice and then homogenised in the cryovial with a plastic pestle.  A 
small amount of tissue was transferred to RLT buffer for initiation of the extraction p rocess.  
Remaining tissue was returned to the -80oC freezer for possible future experiments.   
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3.4.2 Homogenisation of patient tumour samples 
 
 Human glioblastoma fresh frozen tumour samples were requested and collected from 
the Addenbrooke’s tissue bank.  Small amounts of tissue (approximately 30mg) were 
transferred into Lysing Matrix D tubes containing ceramic spheres.  600µL of RLT buffer 
containing 10% β-mercaptoethanol was added and tubes run for two 15 second cycles on a 
FastPrep-24 homogeniser (MP Biomedicals).  Once tissue was homogenised, samples were 
transferred into separate tubes and centrifuged for 3 minutes at top speed to remove tissue 
debris.  Lysate was transferred to an AllPrep DNA spin column for further extraction.   
 
3.4.3 DNA isolation 
 
 DNA isolation was performed with AllPrep DNA/RNA Mini kits (Qiagen) when both 
DNA and RNA were needed from a given sample.  When only DNA was needed or when DNA 
was extracted from blood samples, DNeasy Blood and Tissue kits (Qiagen) with a similar 
protocol were utilised.  To isolate DNA, tumour tissue or cell lysate was transferred to an 
AllPrep DNA spin column and centrifuged for 30 seconds at 8000g.  The flow-through was 
utilised for RNA isolation as discussed below.  The spin column itself was transferred to a new 
collection tube and 500µl Buffer AW1 was added prior to centrifuging for 15s at 8000g.  Flow-
through was discarded and 500µl Buffer AW2 was added and centrifuged for 2 minutes at full 
speed.  The spin column was then placed in a new 1.5mL collection tube and 100µl EB Buffer 
was added directly to the membrane.  The spin column was incubated at room temperature for 
1 minute and then centrifuged for 1 min at 8000g for DNA elution.  DNA was quantified with 
Nanodrop and stored in a freezer prior to use for downstream applications.  
 
 
3.5 Histology and Immunohistochemistry 
 
3.5.1 Histology preparation and H&E 
 
Mice were euthanised and perfused with chilled PBS then formalin via cardiac 
puncture, as described.  Brains were then removed and placed in 10% buffered formalin for at 
least 24 hours.  After fixation, brains were transferred to cryowells and covered with 3% 
agarose gel.  Once gel hardened, brains were removed from cryowell, attached to a plastic disc, 
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and transferred to a tissue chopper table (McIlwain).  Brains were cut into 1 mm thick sagittal 
or coronal slices.  Right hemisphere sagittal slices (medial slices containing right olfactory bulb 
and more lateral slices) and anterior coronal slices were then embedded in paraffin.  Tissue 
slices were further cut into 6 µm thick slices and attached to positively charged histology slides.  
At least one slide per brain underwent hematoxylin and eosin staining.  Unstained slides were 
also prepared for each brain for subsequent immunohistochemical staining.    
 
3.5.2 DAB staining 
 
FFPE right hemisphere sections of control and irradiated tumour-bearing brains were 
deparaffinized with Xylene and rehydrated in a descending concentration ethanol series.  Heat-
induced epitope retrieval was achieved using Citrate Buffer (pH=6) in a steamer for 1 hour. 
Slides were washed in TBS and once in 3% H2O2/TBS.  Tissue was blocked at room 
temperature with Immpress 2.5% Horse Serum Blocking Buffer (Vector Labs).  Human SOX2 
primary antibody (Cell signaling, 1:250) was applied and incubated overnight at 4oC. Immpress 
HRP secondary (anti-rabbit, Vector Labs) was applied and incubated at room temperature for 
30 minutes. Slides were washed in TBS and DI water. Four drops of ImmPACT DAB reagent 
were added to 4 ml of ImmPACT diluent (Vector Labs) and applied until visible colour change 
occurred (no more than 5 minutes). Slides were washed in tap water, counterstained with 
hematoxylin for 30 seconds, dehydrated with ascending alcohol series, dried, cleared in xylene, 
mounted with permount, dried overnight, and visualised with an AxioScan automated imager 
(Zeiss). 
 
 
3.6 Whole exome sequencing 
 
3.6.1 Library preparation and sequencing 
 
Genomic DNA was subjected to WES, which was performed by the Center for Cancer 
Research Genomics Technology Laboratory.  Extracted DNA underwent library prep 
according to the Agilent SureSelect XT (All Exon V5 +UTR) protocol and sequenced on an 
Illumina HiSeq4000 device using paired-end sequencing to an average sequencing depth of > 
180x.   
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3.6.2 Variant calling 
 
Mouse reads were removed as previously described (270).  Alignment and tumour-only 
variant calling was performed with the Center for Cancer Research Collaborative 
Bioinformatics Resource (CCBR) pipeline (https://github.com/CCBR/Pipeliner).  Read data 
was trimmed for the presence of adaptors and low quality using Trimmomatic v0.33 and the 
following parameter settings: Leading:10; Trailing:10; Sliding window:4:20; Minlen:20 (271).  
Reads were mapped to the hs37d5 reference genome using BWA-mem v0.7.17 with default 
parameter settings (272).  Following alignment, BAM files were processed using SAMtools 
and PCR duplicates were marked using Picard v2.1.1 (273).  Indel realignment and base 
recalibration were performed using the Genome Analysis Toolkit v.3.8 (GATK, Broad 
Institute, Cambridge, MA), following the GATK Best Practices (274,275).  MultiQC v1.4 was 
used to aggregate QC metrics from FastQC, FastQ Screen, Picard, BamTools and Trimmomatic 
(276,277).  Variant calling was performed using MuTect2 (278).  Germline variants were 
excluded using a panel of normals (279).  Only protein-altering variants were retained (280).   
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Chapter 4. Intratumoral Heterogeneity and 
Radiosensitivity 
 
 
 Glioblastoma is an extremely heterogeneous tumour type.  Not only has heterogeneity 
been shown between individual tumours (50,98,102), but heterogeneity within individual 
tumours has been demonstrated, adding to the genomic and phenotypic complexity.  As 
described previously, intratumoral heterogeneity has been established through multi-sampling 
surgical techniques, single cell RNA-seq analysis, and interrogation of DNA methylation 
patterns (112,113,281).  Indeed, spatially distinct tumour fragments from a single tumour can 
harbour different genomic alteration and gene expression patterns, even corresponding to 
different GB subtypes (110).  Because ITH is considered a requirement for cancer to undergo 
evolution, the functional implication of GB ITH is that selection due to external pressures may 
be a major cause of GB treatment resistance and recurrence (116,118,119). 
 Therapeutic selection pressures have the potential of causing the contraction or even 
elimination of treatment sensitive clones.  After this contraction, treatment-resistant clones, or 
clones that were protected from the treatment due to a protective niche or temporary quiescent 
state, are then free to expand and repopulate a recurrent tumour.  Such competitive release 
could lead to a more aggressive tumour with genotypic and phenotypic profiles different from 
the primary tumour.  For example, coamplification of different types of receptor tyrosine 
kinases within different cells from the same tumour has been demonstrated in multiple studies 
(120,121).  Such ITH could have potential implications for targeted treatments centered around 
RTK inhibition, such as EGFR inhibitors, as coamplification could provide a clear path to 
resistance.  Thus, potentially effective treatments may only produce a response in a subset of 
glioma cells as targets may be inconsistently expressed within heterogeneous tumours (112).  
Some studies suggest that distal samples (and more longitudinally separated samples) may 
exhibit larger differences in treatment response compared to proximal samples (115).  
However, other studies demonstrate that locally recurrent tumours can display many genetic 
alterations and even variations in shared mutation prevalence, suggesting subclonal expansion 
and contraction (213).  Because radiotherapy is a standard component of GB treatment, the 
ability of radiation to produce a consistent therapeutic response across spatially distinct regions 
of the tumour should be explored.   
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 In this study, we sought to investigate the potential impact of ITH on intrinsic 
radiosensitivity by examining differences in in vitro radiosensitivity between cell lines derived 
from spatially distinct tumour fragments.  Multiple cell lines from spatially distinct fragments 
from three different tumours were derived following 5-ALA fluorescence guided surgical 
sampling (136).  Whole-exome sequencing of matched cell lines and tumour specimens 
demonstrated that the cell lines were good models of their tumour of origin, while still 
displaying heterogeneity between cell lines from the same tumour.  DNA double-strand break 
foci analysis and limiting dilution assays demonstrate that while there were minor differences 
between some of the lines, there do not seem to be consistent differences in radiosensitivity 
between cell lines derived from spatially distinct tumour fragments.  These results suggest that 
glioblastoma ITH does not lead to differential radiosensitivity of spatially (and genetically) 
distinct tumour regions.  If this is true, then the heterogeneous tumour may have a relatively 
homogeneous response to irradiation.   
   
 
4.1 Methods for studying radiosensitivity of patient-derived cell 
lines 
 
Methods for deriving and maintaining patient-derived cell lines, extracting DNA, and 
performing whole exome sequencing can be found in Chapter 3.  Methods described below 
were specifically utilised for the study of radiosensitivity of patient-derived cell lines. 
 
4.1.1 γH2AX foci analysis 
 
 Poly-L-ornithine (PO) was added to each chamber of 2-chambered slides and slides 
were incubated overnight in 37oC incubator.  PO was removed and washed twice with sterile 
PBS and then Laminin (Sigma-Aldrich) in PBS (1:500) was added to each chamber and 
incubated for at least 4 hours to overnight at 37oC.  A single cell glioma cell suspension was 
created by adding Accutase (Gibco) to culture flasks or neurospheres.  After incubation of up 
to 10 minutes, PBS was added, cells were disaggregated by pipetting, and cell suspension was 
filtered through a sterile 40µm cell strainer.  Cells were spun down at 1000 rpm for 5 minutes, 
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resuspended in 5 mL sterile PBS, and counted with a Coulter counter.  Cells were spun down 
for a final time and then plated at a density of around 50,000 cells per chamber in SFM.  Cells 
were incubated on chamber slides at 37oC/5% CO2/5% O2 until cells reached 70% confluency.  
Slides were then irradiated at 2 Gy with a 320 kV Xray machine (Precision X-Ray Inc.) at a 
dose rate of 2.3Gy/min.  After irradiation, slides were fixed at 1, 6, and 24 hours post-irradiation 
with 10% formalin for 10 minutes at room temperature.  Cells were then washed three times 
with PBS and stored in PBS at 4oC for up to ten day prior to staining.  For staining, cell 
membranes were permeabilised with 0.2% Triton/PBS for 10 minutes at room temperature and 
then rinsed with PBS-T.  Blocking buffer (PBS-T, 5% Goat serum, 1% BSA) was added for 1 
hour at room temperature with gentle rocking.  Primary antibody to anti-phospho-histone 
H2AX Ser 129 (1:1000, Millipore) was then added in blocking buffer and incubated overnight 
at 4oC with gentle rocking.  Next, cells were washed three times with PBS-T for 5 minutes per 
wash at room temperature.  Secondary antibody (Alexa Fluor 488 or 555 goat anti-mouse IgG, 
1:1000, Invitrogen) in blocking buffer was added and incubated for 2 hours at room 
temperature in the dark with gentle shaking.  Cells were again washed three times with PBS-T 
and chambers were removed from slide.  One drop of ProLong Gold/Diamond Antifade with 
DAPI was added to each chamber area and a glass coverslip was added.  Weight was applied 
to remove bubbles and slides were allowed to dry overnight.  Slides were stored at 4 oC prior to 
imaging on a fluorescent microscope at 40x magnification.  ImageJ was utilised to analyse TIF 
files and manually count the number of foci per nuclei.  Twenty-five nuclei per condition and 
time point were counted. 
 
4.1.2 Limiting dilution assay 
 
 For limiting dilution assays a single cell suspension was obtained as described above.  
Once cells were counted, serial dilutions were performed to obtain a suspension with 100 -1000 
cells per 100µl.  Every well of a 96-well plate was first filled with 100µl SFM without bubbles.  
Then 100µl of the cell dilution made above was added to all wells in row A for a final volume 
of 200µl.  With a multichannel pipette, solutions in row A were thoroughly mixed before 
removing 100µl from row A to transfer to row B.  Next, row B wells were thoroughly mixed 
and 100µl of solutions were transferred to row C.  This pattern was continued through row H.  
An example range would be: Row A (100 cells), B (50), C (25), D (12), E (6), F (3), G (1), H 
(0).  A light microscope was used to visually verify that wells A-G contained single cell 
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solutions.  Plates were then incubated at 37oC, 5% CO2, 5% O2.  Twenty-four hours later, 
individual plates were irradiated with a range of radiation doses (1-3Gy) using a 320 kV Xray 
machine (Precision X-Ray Inc.) at a dose rate of 2.3Gy/min and then returned to the incubator.  
At 14 to 21 days post-irradiation, plates were removed from incubator and examined under a 
light microscope.  The number of positive wells were determined and recorded.  Wells were 
positive if they contained one or more spheres of approximately 30 cells.  Number of spheres 
per well was also recorded.  Finally, ELDA: Extreme Limiting Dilution Analysis online 
software was utilised to calculate the cancer cell initiating frequency and significance 
(http://bioinf.wehi.edu.au/software/elda/) (282).   
 
4.1.3 Whole exome sequencing analysis: Correlation and superFreq 
 
 After sequencing, filtering, and variant calling, variant allele frequencies (VAF) were 
utilised to calculate Pearson’s correlation coefficients for all combinations of samples.  Next, 
the superFreq software was utilised to identify single nucleotide variants (SNV) and copy 
number alterations (CNA) and to predict and compare the number of clones in the samples 
(283)(https://github.com/ChristofferFlensburg/superFreq/).  In brief, once SNVs and CNs are 
called in superFreq, genes with similar differential coverage and VAFs in a sample are 
clustered.  SNV frequencies are converted to clonalities which are based in part on CN clonality 
estimates.  SNV and CN clonalities are then tracked across samples from the same individual 
and mutations with similar clonalities are clustered into clones.  Clones are then sorted based 
on the size of the predicted clone/subpopulation.  Finally, SNVs are annotated with VEP and 
compared to COSMIC data (COSMIC will be further discussed in Chapter 5).  All WES 
analysis done in collaboration with bioinformaticians within the Radiation Oncology Branch, 
National Cancer Institute, National Institutes of Health (Kristin Valdez and Dr. Uma 
Shankavaram). 
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4.2 Results 
 
4.2.1 Glioblastoma surgical samples and patient-derived cell lines 
 
 After presentation and preoperative imaging suggestive of glioblastoma, patients 
underwent 5-ALA fluorescence-guided surgical resection at Addenbrooke’s Hospital.  Surgical 
specimens were both frozen for tissue bank storage and processed, as described in Chapter 3, 
to derive and establish GB cell lines.  Tissue and patient-derived cell lines from three patients 
were chosen for inclusion in this study due to matching tissue availability and the successful 
derivation of multiple self-renewing cell lines from each tumour.  While the inclusion of patient 
tumour samples able to generate multiple cell lines could potentially have selected for more 
proliferative, aggressive phenotypes, or at least tumours with phenotypes/genotypes more 
amenable to in vitro propagation, the need for multiple cell lines from the same tumour for in 
vitro radiosensitivity testing made this potential bias unavoidable.  The clinical course of each 
patient and histopathological features of each neoplasm (Fig. 4.1D) are described below. 
J3:  A 54-year-old male presented with a two-month history of symptoms ranging from 
loss of confidence at work, short term memory loss, worsening of bipolar symptoms, and severe 
headaches to left-sided motor impairment and swallowing/speech difficulty.  MRI showed a 
large right frontal heterogeneously enhancing glioma (7cm) with oedema and mass effect (Fig. 
4.1A).  Surgical resection was complicated as the tumour was very necrotic and vascularised.  
After tumour and clots were removed, haemostasis was difficult to achieve due to residual 
disease, resulting in the need to reoperate later in the day to remove an intracavitary 
haematoma.  While histopathological analysis revealed a minor oligodendroglial component, 
1p19q codeletion was not detected, thus providing a diagnosis of a WHO Grade 4 GB.  The 
tumour was IDH1 mutation negative, MGMT promoter methylation negative, and had a MIB-
1 of 40%.  The patient was deemed too unwell to tolerate further treatments and palliative 
treatment was recommended.  Unfortunately, he passed away 14 days later. 
J7:  A 73-year-old female who presented after a grand mal seizure had been 
experiencing a few weeks of headaches and 1 week of difficulty with memory prior to the 
seizure.  Preoperative MRI showed a left frontal lobe tumour (4.2cm) with heterogeneous 
contrast enhancement involving cortex and white matter in  the middle frontal gyrus with 
extension into the inferior frontal gyrus (Fig. 4.1B).  Patient underwent 5-ALA fluorescence-
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guided subtotal surgical resection with no postoperative complications.  Histopathological 
analysis revealed a WHO Grade 4 GB.  The tumour was IDH1 mutation negative, MGMT 
promoter methylation positive (46%), and had a MIB-1 of 15%.  Patient received the Stupp 
protocol and completed radiotherapy and concomitant chemotherapy.  Patient did not receive 
final adjuvant cycle of TMZ due to admission for siezures and sepsis.  At last EMR review, 
patient had apparently stable disease, had survived for over a year since surgery, and was on 
conservative management and best supportive care.  
J14:  A 56-year-old male presented with a 12-day history of expressive dysphasia and 
word-finding difficulties and headaches.  MRI showed a heterogeneously enhancing tumour 
(3.6cm) in the middle and posterior left temporal lobe with vasogenic oedema, left uncal 
herniation and minor midline shift consistent with GB (Fig. 4.1C).  Patient underwent an awake 
craniotomy with 5-ALA fluorescence guided gross total surgical resection.  Postoperative 
wound exploration, debridement, and resuturing was done due to CSF leakage from anterior 
part of wound.  Histopathological analysis revealed a WHO Grade 4 GB.  The tumour was 
IDH1 mutation negative, MGMT promoter methylation positive (26%), and had a MIB-1 of 
15%.  Patient received radiotherapy and adjuvant and concomitant TMZ at an outside hospital 
in Ipswich.  At last EMR review, the Cambridge MDT had discussed the patient’s follow-up 
MRI images taken during adjuvant TMZ treatment and found them to be inconsistent with 
recurrence.  The recommendation was for the patient to continue standard adjuvant treatment 
protocol under the local oncology team.   
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Figure 4.1 Glioblastoma samples. Preoperative T1-weighted magnetic resonance images of 
A) J3, B) J7, and C) J14 glioblastomas.  D) Histopathology findings for each tumour.   
 
 
4.2.2 Patient-derived cell lines as models of glioblastoma tumour fragments 
 
 Whole exome sequencing was performed on DNA extracted from spatially distinct 
glioblastoma surgical specimens, corresponding patient-derived cell lines, and matched whole 
blood controls to assess the ability of cell lines to serve as models of ITH between surgical 
samples.  First, Pearson’s correlation coefficients were calculated based on variant allele 
frequencies (VAF) for all samples.  Comparison of correlation coefficients demonstrates that 
surgical specimens and cell lines from the same patients are much more highly correlated with 
each other than with samples from different patients (Fig. 4.2), suggesting that the derived cell 
lines are good models of their tumours of origin.  Patient-specific analysis for J3 reveals that 
J3T1 and J3T4 cell lines are more similar to each other than to their respective tumour 
fragments (Fig. 4.3A).  This similarity is evident by relatively few VAFs that are significantly 
different between the samples (indicated by red x’s) compared to an abundance of shared non 
dbSNPs (likely somatic SNPs; blue dots on the diagonal).  The relative similarity of the cell 
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lines could be the result of discrepancies in tumour tissue handling or biological changes 
imposed by the in vitro culturing environment (discussed further in Sections 7.2 and 7.3).   The 
similarity between cell lines was also reflected in the copy number (CN) profiles of the samples 
(Fig. 4.3B).  It should be noted that in the Super-Freq generated copy number profile, the J3T4 
tumour sample seems to harbour a vastly different profile to the other samples,  which was 
unexpected based on Pearson’s correlation coefficients comparisons.  Therefore, a different 
copy number caller (Sequenza) was utilised in an attempt to corroborate the difference.  As 
shown in Figure 4.3C, the J3T1 and J3T4 tumour sample copy number profiles generated by 
Sequenza are very similar, suggesting that the differences seen in the initial profile may simply 
be a technical artefact.   
The relationships between samples were further supported by superFreq analysis.  
Figure 4.4A displays an SNV heatmap generated by superFreq that compares the SNV 
frequencies for significantly changing somatic SNVs across all samples.  SuperFreq also 
utilises SNV and CN data to group mutations into clones for comparing differences between 
matched samples.  Figure 4.4B demonstrates that while several clones are preserved across all 
samples, there are observed differences between samples, particularly for the J3T1 tumour.  
The distribution of clones for J3 further supports that the cell lines are most similar to each 
other and are more similar to J3T4 tumour than J3T1 tumour.  However, coefficients were still 
above 0.7 when comparing cell lines to their corresponding tumour fragments and all J3 
samples were found to share mutations in specific GB driver genes (TP53 c.584T>C, PTEN 
c.181C>G, MECOM c.301G>A), again suggesting that the cell lines are good models of their 
tumour of origin.  Even though the cell lines may not represent exact models of their 
corresponding tumour fragments, since J3T1 and J3T4 cell lines are not perfectly correlated 
(0.81) it is expected that some degree of heterogeneity is still present between the lines and 
would allow for further examination of ITH impact. 
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Figure 4.2 Pearson’s correlation coefficients. Coefficient calculations are based on variant 
allele frequencies (VAF) of all J3, J7, and J14 samples sequenced.  Germline variants were 
removed from this analysis. 
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Figure 4.3 Comparison of J3 samples. A) VAF scatter plot comparing J3T1 patient-derived 
cell line and J3T4 patient-derived cell line.  Red Xs indicate VAFs that are significantly 
different between two samples.  Blue dots represent non dbSNPs (likely somatic SNPs). B) 
Copy number profiles for each J3 sample generated by SuperFreq (next page).  C) Sequenza-
generated copy number profiles for J3T1 and J3T4 to interrogate technical error observed in 
SuperFreq copy number calling for J3T4 tumour sample (next page). 
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Figure 4.4 J3 superFreq analysis. 
A) Heatmap comparing presence 
and frequencies of SNVs that 
change significantly between J3 
samples.  Genes are assigned 
unique colours if they are 
repeatedly mutated (more than one 
SNV is detected for that gene).  B) 
River plot representing the 
phylogenetic relationship of clones 
and their respective clonalities 
across J3 samples.  Each clone is 
represented by a unique coloured 
shape and is composed of a group 
of mutations with similar 
clonalities (SNVs and CNAs).     
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Comparison of correlation coefficients for J7 samples suggest that, similar to J3, cell 
lines are more similar to each other than to their respective tumour fragments (Fig. 4.5A).  As 
for J3, J7T1 and J7T3 cell lines were both more similar to one tumour fragment (J7T1) than 
the other.  Copy number profiles were similar for all samples (Fig. 4.5B).  The relationships 
between samples were further supported and represented by superFreq-generated SNV 
frequency heatmaps (Fig. 4.6A).  While figure 4.6B indicates a more complicated distribution 
of clones for J7 than J3, it still displays a few highly conserved clones that are shared at high 
clonality between the two J7 cell lines and contribute to their similar makeup.  When comparing 
cell lines to their corresponding tumour fragments, correlation coefficients were around 0.6.  
All J7 samples shared variants in a few GB driver genes (PIK3CB c.2884T>A, PERM1 
c.4681C>T), while J7T1 tumour and J7T1 cell line shared a PTEN c.353A>T variant.  The 
Pearson’s correlation coefficient between cell lines was 0.76, again suggesting that the J7 cell 
lines represent a good model of the tumour of origin and that the cell lines maintain 
heterogeneity between lines. 
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Figure 4.5 Comparison of J7 samples. A) VAF scatter plot comparing J7T1 patient-derived 
cell line and J7T3 patient-derived cell line.  Red Xs indicate VAFs that are significantly 
different between two samples.  Blue dots represent non dbSNPs (likely somatic SNPs). B) 
Copy number profiles for each J7 sample (next page). 
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Figure 4.6 J7 superFreq analysis. 
A) Heatmap comparing presence 
and frequencies of SNVs that 
change significantly between J7 
samples.  Genes are assigned 
unique colours if they are 
repeatedly mutated (more than one 
SNV is detected for that gene).  B) 
River plot representing the 
phylogenetic relationship of clones 
and their respective clonalities 
across J7 samples.  Each clone is 
represented by a unique coloured 
shape and is composed of a group 
of mutations with similar clonalities 
(SNVs and CNAs). 
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In contrast to J3 and J7, J14 analysis demonstrates that J14T6 cell line is most similar 
to the corresponding J14T6 tumour fragment (Fig 4.7A).  In addition, J14T3 cell line is most 
similar to its corresponding J14T3 tumour fragment, although it correlates almost equally well 
with all samples.  CN profiles for J14 samples are displayed in figure 4.7B and demonstrate 
very similar profiles for J14T6 cell line, J14T6 tumour, and J14T3 tumour.  The relationships 
between samples are further supported when comparing SNV frequency and clonal distribution 
(Figs. 4.8A and B, respectively).  Figure 4.8B demonstrates three shared clones between J14T6 
cells and tumour and two shared clones between J14T3 cells and tumour which support the 
similarities between these samples.  Therefore, the patient-derived cell lines from the J14 
tumour seem to be good models not only for the overall tumour of origin, but also for their 
respective tumour fragments.  Taken together, these data suggest that while patient-derived cell 
lines may not be exact models for spatially-distinct tumour fragments in all cases, they do seem 
to be good models of their tumours of origin.  Furthermore, the heterogeneity found to exist 
between cell lines, even when they resemble each other more closely than their respective 
tumour fragments, suggest that they can serve as potential models for studying the impact of 
ITH on radiosensitivity.    
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Figure 4.7 Comparison of J14 samples. A) VAF scatter plot comparing J14T6 tumour 
fragment and J14T6 patient-derived cell line. Red Xs indicate VAFs that are significantly 
different between two samples.  Blue dots represent non dbSNPs (likely somatic SNPs).  B) 
Copy number profiles for each J14 sample (next page). 
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Figure 4.8 J14 superFreq analysis. 
A) Heatmap comparing presence 
and frequencies of SNVs that 
change significantly between J14 
samples.  Genes are assigned unique 
colours if they are repeatedly 
mutated (more than one SNV is 
detected for that gene).  B) River 
plot representing the phylogenetic 
relationship of clones and their 
respective clonalities across J14 
samples.  Each clone is represented 
by a unique coloured shape and is 
composed of a group of mutations 
with similar clonalities (SNVs and 
CNAs). 
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4.2.3 γH2AX foci analysis 
 
 As an initial assessment of DNA repair competence, a component of intrinsic 
radiosensitivity, we analysed γH2AX foci.  H2AX foci correspond to radiation-induced DNA 
double strand breaks (DSBs) and their dispersal correlates with DSB repair (284,285).  Because 
DSBs are the critical lesion in radiation-induced cell death, H2AX foci can serve as a surrogate 
measure of radiosensitivity (286,287).  Figure 4.9A demonstrates the average number of 
γH2AX foci counted for J3T1 and J3T4 cell lines at various time points after 2Gy of radiation 
(RT).  Foci counts were compared to matched cells that received no treatment.  J3T1 and J3T4 
seem to be similar in DNA repair ability, particularly regarding their rates of dispersal (6 hr 
and 24 hr time points).  There were no significant differences when comparing foci counts 
between the two J3 lines.  Likewise, J14T3 and J14T6 display very similar repair competency 
based on similar foci counts between cell lines at each time point assessed (Fig. 4.9C).  Again, 
no significant differences were found between the J14 lines.  Only the two J7 lines exhibited 
differences in γH2AX foci counts (Fig. 4.9B).  In particular, J7T1 harboured significantly more 
foci at the 1-hour post RT time point compared to J7T3 (p=0.017).  In contrast, J7T3 harboured 
significantly more foci at the 24-hour post RT time point compared to J7T1 (p=0.017).  The 
differences may suggest that J7T1 is initially more sensitive to increased DSB induction at 1 
hr, but ultimately is better able to repair its DSBs (increased DSB dispersal at 24 hr).  However, 
since there is discrepancy in the γH2AX foci trends between the two cell lines at early and late 
time points, the data may also suggest that overall, like J3 and J14, there are no clear differences 
between the J7 cell lines.  While DNA repair for most cells is complete at 24 hours, as assessed 
by mean γH2AX foci, it may not be complete for cells with possible DNA repair pathway 
deficiencies or cells with lingering DSBs.  If DSBs are not repaired properly, then the cell is 
likely to die and lose its clonogenicity.  Therefore, a longer-term cellular assay which examines 
clonogenicity, such as a limiting dilution assay, is needed to better assess in vitro 
radiosensitivity.  
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Figure 4.9 γH2AX foci analysis. Mean of γH2AX foci (with SE) for A) J3T1 and J3T4, B) 
J7T1 and J7T3, and C) J14T3 and J14T6.  Foci were measured at various time points after 2Gy 
irradiation and also for untreated control samples. * p < 0.05   
 
4.2.4 Limiting dilution assays 
 
 Limiting dilution assays (LDA) offer an alternative method for assessing in vitro 
radiosensitivity.  Specifically, LDA determines the effects of radiation on clonogenicity, or the 
ability for cells to survive and continuously divide and grow into neurospheres.  This longer 
term cellular assay reflects the two principal mechanisms of radiation-induced cell death: 
apoptosis and mitotic catastrophe (288).  Clonogenic survival assays, the gold standard for in 
vitro radiosensitivity testing, also measure the consequences of radiation on clonogenic 
potential of cells.  However, we found that several of our patient-derived cell lines were not 
amenable to clonogenic assays, thus necessitating the use of LDA.  After adding serial dilutions 
of each cell line to 96-well plates, individual plates were irradiated (0-3Gy) and allowed to 
divide.  After 2-3 weeks, the wells were scored as positive or negative, based on the presence 
of a neurosphere, and survival curves were constructed with ELDA: Extreme Limiting Dilution 
Assay online software (282).  Figure 4.10A, B, and C display the stem cell frequency estimate 
curves generated with ELDA for the second replicates of  J3T1 and J3T4, J7T1 and J7T3, and 
J14T3 and J14T6, respectively, as a function of cell number and radiation dose.  Black, red, 
green, and blue lines correspond to 0, 1, 2, and 3Gy, respectively.  The more parallel an 
individual line is with the y-axis, the higher the stem cell frequency for that condition and the 
lower the number of seeded cells needed to produce a positive, neurosphere-containing well.  
For each cell line, as more radiation was added, the stem cell frequency declined and wells 
with fewer seeded cells became less likely to be positive.  J3T1 and J3T4 seem to have similar 
levels of stem cell frequency and thus clonogenicity after irradiation, as do J7T1 and J7T3.  
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These similarities in radiosensitivity are more easily visualised when the stem cell frequency 
estimates are converted to survival fractions by dividing the inverse of the ELDA-generated 
stem cell frequency estimate by the inverse of the stem cell frequency estimate of the control 
group (Fig. 4.10D).  In contrast to J3 and J7, the survival curves for J14T3 and J14T6 suggests 
that there may be a difference in clonogenicity between the two J14 lines (Fig. 4.10D).  J14T3 
seems to have better survival and a corresponding increase in clonogenicity at each dose, but 
especially at 1Gy and 2Gy as the differences in surviving fractions at these doses are 
statistically significant (p<0.05).      
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Figure 4.10 Limiting dilution assays. Stem cell frequency estimates (with confidence 
intervals) for A) J3T1 and J3T4, B) J7T1 and J7T3, and C) J14T3 and J14T6.  Black, red, 
green, and blue lines correspond to 0, 1, 2, and 3Gy, respectively.  D) Survival fraction as a 
function of radiation dose calculated from stem cell frequency estimates for J3, J7, and J14 cell 
lines. * p<0.05 by 2-way ANOVA.   
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J7 cell lines exhibited some differences by γH2AX foci analysis and J14 cell lines 
exhibited differences by LDA assay.  Minor differences were also noted when comparing 
COSMIC mutational signatures and SNV profiles for these lines (Fig. 4.11).  In addition to 
shared signatures, mutations in J7T1 cells mapped to signature 17 (unspecified aetiology), 
whereas mutations in J7T3 cells mapped to signature 6 (defective DNA mismatch repair) (Fig. 
4.11A).  Similarly, several genetic variants were detected in J7T1 samples (both cells and 
tumour) independent of J7T3 samples, and vice versa (Fig. 4.11B).  While J14T3 and J14T6 
cells had essentially the same COSMIC mutational signature profiles (Fig. 4.11C), they did 
possess variants that were unevenly distributed between sample types (Fig. 4.11D).  The 
differences noted in COSMIC signatures and variant profiles provide further evidence for ITH 
between cell lines, which could contribute to the observed differences in radiosensitivity.  
When combining analysis of all tumours and lines, γH2AX DNA repair competence data was 
remarkably similar between lines (Fig. 4.12A).  Beyond the previously noted differences in 
foci counts between J7T1 and J7T3, the only other statistically significant difference was 
between J3T1 and J7T1 at 1 hour after irradiation (p<0.05, 2-way ANOVA, multiple 
comparisons).  In regards to LDA, all cell lines regardless of tumour of origin had a statistically 
significant difference in survival fraction after 1Gy compared to J14T6 (Fig. 4.12B; p<0.05, 2-
way ANOVA, multiple comparisons).  Additionally, J7T3 and J14T3 had a statistically 
significant difference in survival fraction after 2Gy.  However, when taken together, 
differences in radioresponse between cell lines from the same tumour are not conserved across 
methods (Fig. 4.12A-B), suggesting that all cell lines from the same tumour tested may 
ultimately have relatively similar intrinsic radiosensitivities.  Because of the overall complexity 
of radiosensitivity, there are many factors which could be contributing to the differences 
observed within and between individual assays such as LDA and γH2AX foci analysis, making 
it possible that these complex factors could cancel each other out.  While these results may 
suggest that ITH does not translate to differences in radiosensitivity between different regions 
of the same tumour, future studies will need to interrogate other components of radiosensitivity, 
such as cell death and cell cycling, in order to develop a more holistic picture of the impact of 
ITH on radiosensitivity.  
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Figure 4.11 COSMIC mutational signatures and SNV profiles.  The relative contribution 
of mutations in A) J3 samples or C) J14 samples to pre-defined COSMIC signature profiles.  
Signatures were defined as positive when they had a cumulative normalized contribution over 
signature-specific cutoffs. B) Non-synonymous mutations differentially detected in J7T1 
samples (cells and tumour) or J7T3 samples (cells and tumour). D) Non-synonymous mutations 
differentially detected in J14T3 samples or J14T6 samples. 
 
 
Figure 4.12 Intrinsic radiosensitivity.  Combined radioresponse outcomes for all lines based 
on A) γH2AX foci analysis and B) limiting dilution assays.   
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4.3 Discussion 
 
 The goal of this study was to test the hypothesis that there are differences in intrinsic 
radiosensitivity between cells isolated from spatially distinct regions of human glioblastoma.  
Because ITH is thought to be a critical factor leading to GB resistance and recurrence, we 
utilised multiple cell lines derived from spatially distinct tumour samples as a model of GB 
ITH.  Cell lines were derived from tumour fragments that were resected by 5-ALA 
fluorescence-guided surgery, a technique that has already been shown to capture ITH in both 
tissue samples (110) and patient-derived cell lines (136,247,250).  In addition, patient-derived 
cell lines have been utilised for many types of cancer as effective models of the tumour of 
origin (289,290).  While in vitro culturing can lead to phenotypic and genotypic changes of the 
cell lines over time (291-293), reflecting differences from the parent tumour, they have still 
proven an efficient model for studying cancer.  Our WES results suggest that our patient-
derived GB cell lines are good models of their parent tumours.  In some cases (J14), the lines 
are also good models of the specific tumour fragment from which they were derived.  Other 
cases demonstrated that the cell lines were more similar to each other in genetic alteration 
patterns than to their respective fragments.  However, differences were observed between all 
samples from a given patient suggesting that ITH was preserved in the patient-derived cell 
lines.  Therefore, our GB patient-derived cell lines represent viable models for studying the 
influence of ITH on radiosensitivity. 
 Patient-derived cell lines have been utilised extensively for studying cancer response to 
therapies, particularly chemotherapeutics and other drugs (289).  Many large databases have 
been generated that combine cancer cell line genetic patterns and pharmacologic profiles to 
study response and resistance mechanisms (294,295).  While many studies have centered 
around intertumour heterogeneity, there have also been studies that examine intratumour 
heterogeneity and its potential implications in cell lines (136,296).  For glioblastoma, 
glioblastoma stem-like cells (GSCs) have been suggested as a potential source of ITH both in 
tumours and in cell lines (250,251).  Such models of ITH are invaluable for efficiently studying 
potential heterogeneous responses to therapy.  While the impact of ITH on differential drug 
sensitivity to some anti-GB agents have been performed (235,247,297-299), to our knowledge 
the influence of ITH on intrinsic radiosensitivity has not been previously addressed.  Our results 
seem to indicate that only minor differences or even no differences in radiosensitivity may exist 
between cell lines derived from spatially distinct tumour samples.  While differences were 
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observed in genetic alterations and clonal composition between samples, these differences, 
while reflecting ITH, may not contribute to significant differences in radiosensitivity.     
 If glioblastoma ITH does not have a significant impact on radiosensitivity, then it would 
suggest that spatially distinct tumour regions may have relatively uniform radioresponse.  If 
this finding is applicable to the clinical setting, then the optimisation of radiotherapy, including 
treatment with radiosensitisers, would be expected to improve treatment outcomes for GB 
patients.  It should be noted that this study was performed on treatment-naïve patient derived 
cell lines so the results may only be relevant in the primary disease setting.  Therefore, the 
study of how radiation drives the evolution of GB may provide important insights on treatment 
resistance and recurrent GB biology.  Ultimately, because ITH may not yield differential 
radiosensitivities, insights on treatment-induced evolution may lead to advances in treatment 
that improve radioresponse for the tumour as a whole.    
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Chapter 5. Radiation drives the evolution of 
orthotopic xenografts initiated from glioblastoma 
stem-like cells 
 
 
Despite aggressive, multimodal treatment, glioblastoma inevitably recurs.  Whereas the 
mechanisms mediating this consistent therapeutic resistance have not been defined, the clonal 
diversity and evolutionary dynamics inherent to GB is considered a major obstacle in the 
development of effective treatment (110,115,209,210,281).  As previously mentioned, 
comparison of genomic data generated from glioma tissue obtained at initial surgery and at 
recurrence revealed an altered mutational profile, an effect that was attributed to temozolomide 
treatment (300).  The implication of such studies is that the temozolomide driven evolution 
results in the emergence of resistant clones.  Consistent with studies of clinical specimens, 
temozolomide treatment of mice bearing brain tumour xenografts initiated from GB primary 
cultures suggested the expansion of drug resistant clones (235).  Given that GBs regrow after 
initial treatment, understanding the consequences of treatment-driven evolution may not only 
generate insight into the fundamental biology of recurrent GBs but also suggest novel 
therapeutic strategies. 
While studies to date have focused on temozolomide (90,91,300), a role for 
radiotherapy as an independent driver of GB evolution has not been investigated.    We have 
demonstrated that genetic diversity of cell lines derived from spatially distinct tumour 
fragments does not predict differences in in vitro radiosensitivity.  However, in vitro 
radiosensitivity studies of treatment-naïve tumour-derived cell lines cannot address the ability 
of radiation to drive evolution.  An in vivo model which provides microenvironmental context, 
mimics clinical radioresponse, and can be sampled after receiving either radiation or mock 
treatment is needed.  Towards this end, orthotopic xenografts initiated from CD133+ GB stem-
like cells (GSCs) would appear to provide a model system for testing the potential of radiation 
to influence GB evolution.  As described, GSCs represent a clonogenic subpopulation 
considered to be critical in the development, maintenance and treatment response of GBs 
(241,242,245).  Moreover, orthotopic xenografts grown from GSCs replicate the genotype, 
phenotype and in vivo growth pattern of GB (252).  With respect to GB evolution, we have 
previously shown that CD133+ GSCs implanted into nude mice produce heterogeneous 
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tumours of differentiated cells while retaining a subpopulation of GSCs at morbidity  (254).  
This GSC-initiated xenograft model has been utilised to demonstrate a role for the 
microenvironment in radioresponse (254) and the relative radioresistance of CD133+ GSCs 
(266).  Thus, the GSC xenograft model exhibits the intratumour heterogeneity and evolutionary 
dynamics that may simulate that of a GB in situ. 
To investigate the potential of radiotherapy to influence GB evolution, the study 
described here defines the consequences of a fractionated radiation protocol on the growth 
pattern, clonal diversity and genomic architecture of GSC-initiated orthotopic xenografts.  The 
data presented show that tumours that regrow after irradiation were less invasive and had 
different mutational signatures as compared to untreated tumours.  In addition, based on viral 
integration site analysis (VISA), radiation exposure resulted in a reduction in intra tumour 
heterogeneity (clonal diversity), an effect that was dependent on the brain microenvironment.  
These results indicate that radiation drives the evolution of the GSC-initiated orthotopic 
xenografts. 
 
 
5.1 Methods for studying radiation-induced GB evolution 
 
Methods for maintaining GSC (NSC11 and NSC20) and U251 human GB cell line cultures, 
initiating and irradiating brain tumour xenografts, and immunohistochemistry can be found in 
Chapter 3.  Methods described below were specifically utilised for the study of radiation-
induced GB evolution. 
 
5.1.1 Viral Integration Site Analysis (VISA)  
 
VISA was performed by Center for Cancer Research Genomics Technology Laboratory 
as described (301,302).  Briefly, genomic DNA was sheared to an average size of 400bp and 
subjected to linker-mediated, nested PCR using a combination of long terminal repeat 
(lentivirus) and linker-specific primers.  Illumina sequencing adaptors were added at the same 
time.  The library was sequenced on Illumina MiSeq using 2x150bp PE reads.  Integration site 
junctions were mapped to hg19 human reference genome.  Insertion sites are expressed as a 
percentage of the total reads.  To compare samples within an experiment, integration sites 
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detected in at least 2 of the samples were subjected to unsupervised hierarchical cluster analysis 
using R to visualise relative changes in clonal diversity. 
 
5.1.2 Whole exome sequencing analysis: COSMIC and EXPANDS 
 
Genomic DNA was subjected to WES and variant calling was performed with the 
CCBR pipeline as described in Chapter 3.  COSMIC mutational signature analysis was 
performed with the YAPSA R package (v1.8.0) as described (212,303).  The mutational 
catalogue was corrected to account for differences in triplet motifs between WGS and WES 
capture regions.  Signature-specific cut-offs used can be found with the following R code: 
library(YAPSA), data(cut-offs), cutoffCosmicValid_rel_df[6,] (304).  Tumour subpopulations 
were further defined using EXPANDS algorithm and R package (v2.1.2) with default 
parameters (305).  EXPANDS determines cell-frequency probabilities by using copy number 
variation (CNV) and single nucleotide variant (SNV) allele frequencies to estimate the fraction 
of cells harbouring a SNV (SNVs and CNVs are filtered to remove variants on the X and Y 
chromosomes).  SNVs are clustered and filtered based on cell-frequency probability 
distributions (305).  For COSMIC and EXPANDS analyses variants were included when they 
were protein altering, present in at least 2 out of 3 replicates, and had vaf > 5%.   All WES 
analysis done in collaboration with bioinformaticians within the Radiation  Oncology Branch, 
National Cancer Institute, National Institutes of Health (Kristin Valdez and Dr. Uma 
Shankavaram).  
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5.2 Results 
 
5.2.1 In vivo models of radioresponse 
 
As a model system for investigating the impact of radiotherapy on GB evolution, 
orthotopic xenografts initiated from CD133+ GSC lines were used.  While selection of cell 
populations prior to implant could potentially influence overall tumour heterogeneity or 
treatment response, it was necessary to start with a more homogeneous population with known 
in vivo growth dynamics and reproducible treatment responses.  Since CD133+ GSCs have 
been shown to produce heterogeneous tumours and contribute to radioresistance, as previously 
discussed, this subpopulation of GSCs represent a good model for studying the impact of 
radiation on GB evolution.  CD133+ GSCs were transduced with a lentivirus containing a 
bimodal expression vector fused with the bioluminescent protein ffLuc2 and fluorescent 
protein eGFP2 under UbC promoter control (LVpFUGQ-UbC-ffLuc2-eGFP2) (266).  After in 
vitro expansion and confirmation of successful transduction by fluorescent microscopy and 
flow cytometry, cells were implanted into the right striatum of nude mice.  At 21 days post-
implant, upon reaching a size consistently detectable by BLI, tumour-bearing mice were 
randomised into treatment groups, control (mock) and 3x5Gy.  As shown in figures 5.1A and 
B, this fractionated irradiation protocol resulted in significant survival increases for NSC11 or 
NSC20 tumour-bearing mice.  This survival advantage was consistent with the delay in growth 
rate reflected by BLI as a function of time after irradiation (figures 5.1C-F).  Given that 3x5Gy 
initiated at day 21 post-implant significantly delays tumour growth yet does not achieve 
curative effects, a situation not unlike that typically observed in clinic, this treatment protocol 
was used to test the hypothesis that radiation drives the evolution of GSC-initiated brain tumour 
xenografts. 
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Figure 5.1 Radioresponse of GSC-initiated xenografts.  On day 21 post-implant mice were 
randomised and treatment initiated the following day as described in text (3x5Gy).  Kaplan–
Meier survival curves were generated for A) NSC11 and B) NSC20 tumour-bearing mice (n=10 
mice per group).  Tumour growth defined by BLI ratio as a function of time after irradiation 
for C) NSC11 and D) NSC20.  Representative images of NSC11 tumour-bearing mice two 
weeks after treatment for irradiated (E) and untreated (F) mice. 
 
 
 
E) 2 weeks post-RT 
3x5Gy 
F) Control 
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5.2.2 Radiation-induced changes in morphology and histology 
 
 As an initial assessment of the potential for radiation to influence GB evolution, the 
growth patterns of control and irradiated GSC xenografts were compared at morbidity.  GSCs 
engineered to express GFP can be visualised in tumour-bearing brains using a 
stereomicroscope.  Representative images (Fig. 5.2A) of control mice demonstrate GFP signal 
from NSC11 or NSC20 cells extends anteriorly and posteriorly throughout most of the right 
hemisphere, well beyond the right striatum implantation site, reflecting a highly invasive 
tumour.  However, in irradiated mice, GFP fluorescence was more restricted and limited 
primarily to the anterior portion of the hemisphere.  To determine whether these observations 
extended to the histological level, right hemisphere sagittal sections from control and irradiated 
NSC11 and NSC20 bearing brains were evaluated for human SOX2 staining, which is highly 
expressed in both lines.  As shown in Figure 5.2C, GSCs in control mice were diffusely 
distributed with poorly defined margins and grey and white matter infiltration.  In mice that 
received fractionated radiation, tumours were less invasive with more clearly demarcated 
borders and tumour core hypercellularity as compared to controls.  While indicative of a 
reduced invasive propensity, in broader terms these results suggest that the fundamental 
biology of GSC-initiated tumours that regrow after irradiation diverges from that of untreated 
tumours.  As a possible explanation, we hypothesised that morphological/histological 
modifications detected in recurrent xenografts reflected the radiation-induced selection of 
tumour cell subpopulations, i.e., radiation-driven evolution. 
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Figure 5.2 Morphology and histology of NSC11 and NSC20 tumours.  A) Representative 
GFP fluorescence images of control and irradiated (3x5Gy) tumour-bearing brains at 
morbidity.        B) Corresponding bright field images.  Photos were taken on a stereoscope at 
2.5x magnification.  C) Right hemisphere sagittal sections at plane of injection site stained for 
SOX2 (magnification 20x). 
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5.2.3 Viral Integration Site Analysis 
 
To directly address the question as to whether radiation modifies the clonal diversity 
(i.e., intratumoral heterogeneity) of GSC-initiated xenografts, viral integration site analysis 
(VISA) was used (301).  Facilitating the application of VISA, these in vivo studies have 
centered on the use of GSCs transduced with the lentivirus LVpFUGQ-UbC-ffLuc2-eGFP2, 
which, as discussed above, allows for in vivo tumour growth monitoring and ex vivo 
visualisation.  In addition to these attributes, the stable integration of the lentivirus into  the 
genome at essentially random sites provides a unique tag for each cell in the transduced 
population, which is inherited by subsequent daughter cells.  Because the integration site is 
largely within a transcriptional unit, sequencing of PCR amplified genomic DNA surrounding 
the lentiviral sequence allows for assigning each site to a single location/gene or nearest gene.  
Identifying the gene thus merely provides a method for easily cataloguing the integration site.  
The percent reads for a given gene/site corresponds to the size of the clone within the 
transduced population. 
 For this experiment CD133+ NSC11 cells were transduced with the described 
lentivirus; the culture was expanded and used for orthotopic implantation or collected for in 
vitro (IV) VISA.  At 21 days post-implant, as for the survival studies, mice were randomised 
according to BLI into 2 groups: control (ic) and irradiated (icRT, 3x5Gy).  At morbidity, mice 
were euthanised, GFP-expressing brain tissue grossly dissected, and DNA was extracted for 
VISA.  The % reads detected at a given integration site (clonal frequency) were visualised for 
the individual xenografts and in vitro cultures in the heat map shown in figure 5.3A.  As 
compared to NSC11 cells grown in vitro, there was a reduction in the number of clones detected 
(unique integration sites) in each of the 4 untreated xenografts (ic), suggesting a selection for 
clones that preferentially grow under in vivo orthotopic conditions.  Moreover, as compared to 
the untreated tumours (ic) there was a further reduction in the total number of individual clones 
detected in the 4 xenografts that had been irradiated (icRT). 
VISA and unsupervised hierarchical cluster analysis of clonal frequency were also 
performed on NSC20 samples (Fig. 5.3B).  Although there was variability between xenografts 
in the control (ic) and irradiated (icRT) groups, as compared to NSC20 in vitro cultures, there 
was a reduction in clonal diversity in each of the orthotopic xenografts, with a further reduction 
evident in the irradiated tumours, similar to NSC11.  The VISA results were also expressed in 
figures 5.3C-D as the average number of unique integration sites detected in each experimental 
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group.  As shown, the largest number of integration sites was detected under in vitro conditions, 
which was reduced in orthotopic xenografts and further reduced after irradiation of xenografts.  
These results suggest that only a subset of the NSC11 and NSC20 cells proliferating in vitro 
will form a tumour after orthotopic implantation.  Moreover, of those clones that grow 
orthotopically, after irradiation there is an additional reduction in clonal diversity, which is 
consistent with radiation-driven tumour evolution. 
 
 
 
 
Figure 5.3 Viral Integration Site Analysis of NSC11 and NSC20. VISA comparing GSCs 
in vitro to those grown as intracerebral xenografts that had received mock treatment (ic) or 
3x5Gy (icRT).  Treatment protocol is as described in text.  Unsupervised hierarchical cluster 
analysis of integration sites detected in A) NSC11 and B) NSC20.  The absence of colour 
indicates the clone was not detected in a given sample (≤0.001% of total reads).  The number 
of unique integration sites (mean ± standard error) detected by VISA in C) NSC11 and D) 
NSC20 samples.  Because there was overlap of sites within each group, sites shared between 
samples of a given group were counted only once.  * p < 0.05 
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To investigate the role of the microenvironment in the radiation-induced reduction in 
clonal diversity, VISA was performed on NSC11 cells irradiated in vitro.  Twenty-four hours 
after plating, cultures received either mock (control), 4Gy (single dose), or 3x2Gy.  Cells were 
harvested for VISA when they reached 70-80% confluency, which corresponded to 7, 19 and 
21 days for control, 4Gy and 3x2Gy, respectively.  Clonogenic survival analysis showed that 
the surviving fraction of NSC11 cells exposed to 4 Gy and 3 x 2 Gy was 0.008 ± 0.004 and 
0.039 ± 0.031 (mean ± SEM, n = 3), respectively.  As shown in Figure 5.4A, cultures did not 
cluster according to treatment group.  Moreover, there was no significant difference in the 
average number of integration sites among the 3 groups (Fig. 5.4B).  These results suggest that, 
in contrast to the orthotopic model, in vitro irradiation had no detectable effect on clonal 
diversity.  These data suggest that the radiation-induced reduction in clonal diversity is 
dependent on the in vivo microenvironment. 
To determine whether radiation-driven evolution was limited to xenografts initiated 
from GSCs and to further interrogate the role of the brain microenvironment, VISA was applied 
to the established glioma cell line U251.  In this experiment, lentivirus transduced U251 cells 
were grown as intracerebral (ic) xenografts and as subcutaneous (SC) leg tumours.  At 6 days 
after ic (when tumours were detectable by BLI) and 18 days after sc implantation (150-200 
mm3), U251 tumours received 3Gy for 3 consecutive days (3x3Gy), a regimen previously 
demonstrated to give a reproducible survival benefit for U251 xenografts .  Irradiated and 
control ic tumours were collected at morbidity and sc tumours when the volume exceeded 
1500mm3.  Unsupervised hierarchical cluster analysis of the clonal frequency of the tumour 
samples as compared to U251 grown in vitro is shown in figure 5.4C with the average number 
of integration sites in each group shown in 5.4D.  Whereas there was no consistent difference 
between control ic and sc tumours, the number of integration sites were reduced in each 
compared to U251 in vitro, although not to the degree as observed for the GSC ic tumours.  In 
response to irradiation, the number of integration sites in sc tumours is reduced suggesting a 
decrease in clonal diversity.  However, in ic U251 tumours irradiation induced a greater 
reduction in integration sites, suggesting that the radiation-mediated reduction in clonal 
diversity is not limited to xenografts initiated from GSCs.  Moreover, these results suggest that 
the brain microenvironment plays a critical role in radiation-driven evolution of GB xenografts. 
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Figure 5.4 Viral Integration Site Analysis of NSC11 in vitro and U251 . U251 cells were 
grown in vitro (IV) and as subcutaneous (SC) and intracerebral (ic) xenografts.  A) 
Unsupervised hierarchical cluster analysis of integration sites detected in NSC11 cells that 
were untreated (control) or irradiated with a single dose of 4Gy or 3 daily doses of 2Gy (3x2Gy) 
B) Unsupervised hierarchical cluster analysis of U251 cells.  U251 xenografts (sc and ic) 
received 3x3Gy as described in text.  IV samples were initiated from the same pool of cells 
used for sc and ic implantation and collected when 70-80% confluent.  C)   Number of unique 
integration sites (n=3, mean ± standard error) detected in NSC11 in vitro.  D) Number of unique 
integration sites (n=3, mean ± standard error) detected in U251 cells.  * p < 0.05 
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5.2.4 Whole exome sequencing 
 
Because investigations of tumour evolution typically apply WES to describe genetic 
ITH, this approach was used to evaluate the potential for radiation-driven evolution of GSC-
initiated orthotopic xenografts.  Genomic DNA extracted from morbid tumour samples were 
utilised for WES, similar to VISA experiments.  Over 5500 SNVs + indels were detected in 
NSC11 tumours of which the majority were shared between control and irradiated tumours 
(Fig. 5.5A).  Variants unique to control or irradiated tumours (private mutations) were 
consistently detected among the 3 samples in each group (Fig. 5.5B).  The shared and private 
mutations in control and irradiated tumours were classified according to the mutational 
signatures generated from patient characteristics within large cancer cohorts using COSMIC 
mutational signature profiling (211,212,306).  As shown in Figure 5.5C, the shared mutations 
distributed to mutational signatures 1 (Deamination of 5-methylcytosine), 5 (unspecified 
aetiology), 11 (TMZ treatment), 20 (Concurrent POLD1 mutation and mismatch repair 
deficiency) and 26 (Defective DNA mismatch repair).  Mutations unique to control tumours 
associated with similar signature profiles.  However, private mutations found in irradiated 
tumours did not include signatures 1, 5, and 20, but mapped to signatures 3 (Defective HR 
DNA repair: BRCA1/2 mutation), 6 (Defective DNA mismatch repair), and 15 (Defective 
DNA mismatch repair), which were not associated with the unirradiated tumours.  These results 
suggest the emergence of different subpopulations in irradiated samples as compared to control 
NSC11 tumours. 
These analyses were also performed on WES data generated from control and irradiated 
NSC20 tumours (Figure 5.6).  In NSC20 tumours over 6000 SNVs + indels were detected with 
most of the variants shared between control and irradiated tumours with a similar number of 
private mutations detected only in control or irradiated NSC20 tumours (figures 5.6A-B).  
Using the shared mutations between control and irradiated NSC20 tumours the mutational 
signatures identified were similar to those in NSC11 tumours (signature #s 1,5,11,20,26) (Fig. 
5.6C).  In contrast, the signatures defined using the private mutations found in irradiated 
NSC20 tumours corresponded to increases in signatures 5 (unspecified aetiology) and 19 
(unspecified aetiology) and decrease in signature 11 (TMZ treatment).  Whereas these 
signatures were substantially different from those identified for irradiated NSC11 tumours, as 
for NSC11, these analyses suggest that irradiation modified the subpopulations comprising 
NSC20 tumours, consistent with radiation-driven evolution. 
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Figure 5.5 The influence of radiation on mutations detected in NSC11 xenografts .  On day 
21 post-implant, brain tumours (n=3) were exposed to 3x5Gy (RT) or mock irradiated (control) 
and collected for WES at morbidity.  A)  Venn diagram comparing the number of mutations 
between treatment groups.  B)  The relative percentage of shared or private variants for each 
tumour (control and treated).  C)  The relative contribution of shared and private mutations in 
control and irradiated tumours to pre-defined COSMIC signature profiles (211,212).  
Signatures were defined as positive when they had a cumulative normalised contribution over 
signature-specific cutoffs.  In A and C, variants were included if they were protein-altering, 
were present in at least 2 out of 3 replicates, and had vaf > 5%.   
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Figure 5.6 The influence of radiation on mutations detected in NSC20 xenografts.  
Treatment as in Figure 5.5.  A)  Venn diagram comparing the number of mutations between 
treatment groups.  B)  The relative percentage of shared or private variants for each tumour 
(control and treated).  C)  The relative contribution of shared and private mutations for control 
and irradiated tumours to pre-defined COSMIC signature profiles.  Signatures were defined as 
positive when they had a cumulative normalised contribution over signature-specific cutoffs. 
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To investigate the effects of radiation on xenograft subpopulation heterogeneity in more 
detail, the bioinformatics tool EXPANDS was applied to the WES data set.  EXPANDS utilises 
VAFs and copy number data to estimate cell-frequency probabilities (305).  For this analysis, 
variants that were detected in at least 2 of the 3 replicates per group (control and RT) were 
included.  Figure 5.7A depicts the 10 predicted subpopulations found in control and irradiated 
NSC11 tumours with the largest subpopulation (blue) at the bottom of the graph; each black 
dot corresponds to a variant predicted to be in a subpopulation.  The lines indicate whether a 
specific variant in control tumours appeared in a subpopulation of the same ranking in the 
irradiated tumours or whether it had moved to another ranking.  Whereas the majority of 
variants are conserved between the largest subpopulations of control and irradiated tumours (as 
depicted by straight lines), there was also a considerable amount of shifting from control 
tumours to a subpopulation of a different prevalence in irradiated tumours, which is especially 
apparent in comparisons of the smaller subpopulations (top of figure).  Figure  5.7B shows 13 
predicted subpopulations for NSC20 tumours.  Again, the largest, most prevalent 
subpopulation (blue) is at the bottom of the graph.  Similar to NSC11, while the majority of 
variants are conserved within the largest subpopulations, there is still substantial subpopulation 
shifting for variants between control and irradiated tumours. 
 
 
Figure 5.7 Influence of radiation on subpopulation dynamics.  Orthotopic xenografts were 
treated and collected for WES as described in previous figures.  Overall variant shifts within 
defined subpopulations of control and irradiated A) NSC11 and B) NSC20 tumours.  The size 
of the subpopulations corresponds to its position on the y-axis, with the largest subpopulation 
at the bottom.  The black circles correspond to individual variants. 
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These analyses were extended to driver gene mutations previously associated with GB 
(50,74,307,308).  Initially, as shown in figures 5.8A-B, variants in driver genes were identified 
in each of 3 control and 3 irradiated GSC xenografts and classified as clonal (present in largest 
subpopulation), subclonal (present in smaller subpopulation), or both (multiple mutations for a 
given gene were individually found in both clonal and subclonal populations).  In NSC11 
tumours (Fig. 5.8A), multiple driver gene mutations were consistently lost in irradiated 
tumours, including AKAP9, FN1, SOX2, and SPTA1.  There were also mutations that sh ifted 
in clonal status from control to irradiated tumours such as MAP4K3.  Although there was more 
variability between individual tumours within control and irradiated groups, irradiation also 
resulted in changes in driver gene mutations detected in NSC20 tumours (Fig. 5.8B).  Lost 
consistently after irradiation of NSC20 tumours were mutations in PIK3CA and CARM1.  To 
further interrogate the observed GB driver gene mutation patterns, potential correlations 
between mutation changes after RT and survival and tumour growth were explored.  Of the 
tumours that underwent WES, NSC11 RT1 and NSC20 RT1 were found to have the shortest 
survival for their tumour types, while NSC20 RT3 had the longest survival (Fig. 5.9A).   NSC20 
RT1 also had a noticeably faster growth rate compared to the other two irradiated NSC20 
xenografts (Fig. 5.9B).  Loss of TP53 mutation after RT was observed for both the NSC11 
short survival tumour and the NSC20 long survival tumour and thus may not be correlated with 
survival (Fig. 5.9C).  However, the loss of MEN1 and PIK3R1 mutations were observed for 
the NSC20 short survival tumour only which may suggest that these mutations could be 
beneficial for prolonged tumour survival.  These data suggest that irradiation influenced the 
presence and clonality of GB driver mutations. 
The shifts of these GB driver gene mutations between the previously defined 
subpopulations were then assessed (only subpopulations containing a GB driver gene variant 
were included).  As in the overall WES data (Fig. 5.7A), the majority of NSC11 GB driver 
gene mutations were conserved within the largest subpopulations in control and irradiated 
samples (Fig. 5.8C).  However, there were several mutations that became less prevalent after 
irradiation (for example, lines from control subpopulation 1 to RT subpopulations 2 and 4).  
There was also one mutation that become more prevalent after irradiation (line from control 
subpopulation 5 to RT subpopulation 1), suggesting that this particular subclone may have had 
a better survival rate after radiotherapy.  Figure 5.8D displays similar subpopulation dynamics 
for NSC20 tumours, although more variant shifts between subpopulations were noted for 
NSC20 compared to NSC11, including at least 3 variants that increased in prevalence af ter 
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treatment.  Changes in the distribution of mutations as a function of subpopulation size between 
control and irradiated tumours are consistent with subclone expansion and contraction, i.e. 
subpopulation evolution.  Taken together, WES data support the radiation-driven evolution of 
orthotopic xenografts initiated from GSCs. 
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Figure 5.8 Influence of radiation on GB driver gene subpopulation dynamics.  GB driver 
mutations in control and irradiated A) NSC11 and B) NSC20 tumours.  Clonal variants were 
those in the sample’s largest subpopulation; subclonal variants were those in any of a sample’s 
smaller subpopulations.  Gray boxes represent mutations other than autosomal SNVs (indels, 
X or Y chromosome SNVs), which are not included in EXPANDS.  GB driver gene mutation 
shifts within the defined subpopulations of control and irradiated C) NSC11 and D) NSC20 
tumours. 
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Figure 5.9 Correlation of Mutation Changes with Survival and Tumour Growth.  A) 
Overall survival of mice bearing the irradiated NSC11 and NSC20 tumours which underwent 
WES.  B) Tumour growth defined by BLI ratio as a function of time after implant for sequenced 
NSC20 RT tumours. C) Description of the observed changes in GB driver gene mutations for 
NSC11 RT 1 (short survival), NSC20 RT 1 (short survival), and NSC20 RT3 (long survival).   
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5.3 Discussion 
 
The goal of this study was to test the hypothesis that radiation drives the evolution of 
orthotopic xenografts initiated from GSCs.  Given that ITH is a critical parameter mediating 
tumour evolution, VISA was used to assess the changes in clonal diversity existing in cell lines 
and tumour xenografts.  In these analyses, in the absence of any radiation exposure, comparison 
of the GSC lines grown in vitro and grown as brain tumours showed a significant reduction in 
the clonal diversity with intracerebral growth.  These results imply that, although isolated by 
CD133 expression, the GSC cultures are comprised of a heterogeneous population, which is 
consistent with previous reports (250,251,255,309) and that only selected subpopulations were 
capable of proliferation under orthotopic conditions.  As compared to untreated tumours, there 
was a dramatic additional reduction in clonal diversity in GSC-initiated tumours that had been 
irradiated.  These results are suggestive of radiation-induced selection of subpopulations within 
GSC xenografts with the ultimate consequence of a reduction in ITH.  The radiation-induced 
reduction in clonal diversity was also detected in orthotopic xenografts initiated from the long-
established GB cell line U251 indicating that the process is not unique to the GSC model and 
suggesting that radiation-driven evolution may be applicable to brain tumours in general. 
 Further analyses indicated that the reduction in ITH was dependent on the brain 
microenvironment.  No change was detected in clonal diversity when VISA was performed on 
NSC11 cells irradiated in vitro.  Moreover, comparison of U251 sc and ic xenografts showed 
that while there was a reduction in clonal diversity after irradiation of sc tumours, the effect 
was considerably more pronounced in ic U251 tumours, a reduction comparable to those 
detected in the GSC tumours.  The implication of this reduction in ITH is that the brain 
microenvironment imposes radioresistance on only certain subpopulations of the GSC and 
U251 cells.  Such a subpopulation selective effect could be attributed to  normal tissue influence 
dependent on intrinsic characteristics of the cells implanted (e.g., genotype) or localisation into 
a radioprotective niche independent of tumour cell type.  Whereas the mechanisms remain to 
be determined, the results presented emphasize the need to account for the brain 
microenvironment when investigating GB radioresponse. 
As an alternative approach to evaluating radiation-driven evolution, studies were 
extended to WES, which has been the standard approach to evaluating tumour evolution.  
Comparison of untreated GSC tumours and tumours that had regrown after irradiation revealed 
a consistently different set of mutations as well as mutational signatures.  There also appeared 
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to be a radiation induced shift in the genetic composition of the ranked sub-populations 
comprising the NSC11 and NSC20 xenografts.  In evaluating the driver genes associated with 
GB (50,74,307,308), there was a reduction in the number of mutations in irradiated NSC11 
tumours, which would be consistent with a reduction in ITH.  In NSC20 tumours, although 
there was also a reduction in the number of GB associated gene mutations, the number of losses 
as well as the specific genes affected were different as compared to NSC11.  The different 
mutation spectrums observed for NSC11 and NSC20 tumours with and without RT suggest 
that whereas radiation drives the evolutionary process, the specific events along with the 
functional consequences may be tumour dependent.  For example, a PIK3CA mutation was 
consistently lost after RT in NSC20 tumour samples which may indicate that the gene/mutation 
contributes to radiosensitivity and furthermore may suggest that NSC20 tumours could be 
sensitive to PI3K inhibition.  If future studies corroborate the sequencing findings through 
protein expression, then a PI3K inhibitor could be incorporated into in vivo studies.   Thus, 
whereas WES results are indicative of radiation-driven evolution and may suggest potential 
therapeutic targets on a tumour-dependent basis, they do not provide any clear, generalizable 
insight into the mechanisms involved or the characteristics of the surviving tumour cells.  Of 
note, the reduction in mutations detected in the irradiated xenografts is in contrast to the 
hypermutation reported for tumours treated with temozolomide (92,209,237,300).  Whether 
temozolomide, a component of GB standard of care, influences radiation -driven evolution 
remains to be determined. 
If radiation alters GB evolution, then the fundamental biology of the tumours that recur 
after an initially effective course of radiotherapy should be altered.  An example appears to be 
the morphology/histology of the NSC11 and NSC20 xenografts that regrow after the 
fractionated radiation protocol as compared to untreated tumours.  As shown, each tumour 
became less invasive with a more restricted growth pattern in response to irradiation.  Although 
in conflict with reports showing that radiation increases the invasion propensity of glioma cells 
in vitro (310,311), these results agree with clinical observations indicating that > 80% of GB 
recur in the initial radiation treatment volume (180,182).  The studies described here show that 
radiation alone drives the evolution of GSC orthotopic xenografts affecting their ITH, mutation 
profile and growth pattern.  If a similar process is operative in a clinical setting, then therapeutic 
targets in a primary, untreated GB may differ from those in the recurrent tumour, as previously 
suggested (312).  GSC xenograft tumours that regrow after an initial radiation exposure may 
thus provide a model system for testing therapies for recurrent GB.  This would include re -
irradiation alone as well as in combination with potential radiosensitisers. 
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Chapter 6.  Glioblastoma stem-like cell-initiated 
orthotopic xenografts provide a useful model for 
studying reirradiation 
 
 
 After primary diagnosis and first-line treatment, which includes surgery, radiation, and 
chemotherapy, glioblastoma inevitably recurs, typically within a year of treatment initiation 
(74,122).  The relatively rapid recurrence and progression of post-treatment GB demonstrates 
the ability of GB to evolve in response to harsh conditions (limited resources and therapeutic 
selective pressures) (24,31,35).  Alkylating chemotherapy has been implicated in therapy-
induced evolution by its ability to alter mutational profiles and lead to the emergence of 
temozolomide-resistant clones (235,300).  Because we have shown that radiation has the ability 
to drive evolution of GSC-initiated xenografts, it is possible that radiotherapy may also lead to 
the emergence of resistant clones.  The functional impact of radiation-induced reduction in 
clonal diversity and subpopulation selection must be interrogated due to its potential 
implications for recurrent GB treatment. 
 In particular, reirradiation protocols are a possible treatment option for recurrent 
glioblastoma.  There are several potential risks for re-exposure of the CNS to radiation, 
including the development of symptomatic radionecrosis and damage to sensitive brain areas 
such as the brain stem and optic nerves.  However, improved imaging to better define the 
tumour volume and advanced targeting techniques to more accurately provide radiation to the 
tumour while avoiding normal tissue are just a few of the methods used to mitigate the potential 
risks associated with re-exposure.  Initial studies indicate the potential for clinical benefit after 
various forms of reirradiation (195-197,313-315).  Shorter courses of radiation, which have 
been effectively employed in the elderly population (187,188), and pulse-reduced dose rate 
protocols may limit the additional radiation exposure for recurrent GB compared to standard 
fractionation techniques (198).  Larger clinical trials of reirradiation are currently underway 
(https://clinicaltrials.gov/ct2/results?cond=Recurrent+Glioblastoma&term=radiation&cntry=
&state=&city=&dist=), but the potential utility of reirradiation necessitates the investigation of 
GB models capable of studying retreatment protocols and their potential impact on and 
interaction with recurrent GB biology.  For example, if radiation leads to the emergence of 
resistant clones which repopulate a recurrent tumour, then reirradiation would be expected to 
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have no clinical survival benefit and would not be recommended for patients.  However, if 
radiation does not lead to the emergence of resistant clones, then patients may benefit from 
reirradiation and a more thorough understanding of radiation’s impact on GB evolution may 
eventually suggest targets which may sensitise both primary and recurrent GB to radiotherapy.     
To investigate the ability of radiation-induced evolution to positively select for 
radioresistant clones, potential functional implications of radiation on GSC-initiated orthotopic 
xenografts were examined through clonogenic survival analysis and in vivo reimplantation of 
xenograft-derived cell lines.  Furthermore, the utility of GSC-initiated orthotopic xenografts 
for studying recurrent GB biology and retreatment protocols was investigated.  Interestingly, 
tumour cells from control and irradiated tumours placed back into culture at morbidity did not 
demonstrate differences in radiosensitivity in vitro or in vivo.  Furthermore, after the addition 
of a reirradiation protocol to GSC-initiated xenografts, recurrent tumours experienced a 
significant increase in overall survival, suggesting retained sensitivity to radiation.  These 
results indicate that radiation-induced evolution of GSC xenografts does not lead to the 
emergence of radioresistant clones, which has positive treatment implications for GB patients.  
In particular, if this model is applicable to the clinical setting, then patients may experience 
further survival benefit with reirradiation protocols. Such reirradiation and recurrent GB 
treatment protocols and underlying recurrent GB biology and treatment response can be 
effectively studied with GSC-initiated xenograft models. 
 
 
6.1 Methods for studying reirradiation and recurrent GB 
radioresponse 
 
6.1.1 Clonogenic Survival Assay 
 
 Poly-L-lysine (PLL; Sigma) was added to each well of 6-well plates and allowed to 
stand 1 hour to overnight in 37oC incubator.  PLL was removed, wells were washed twice with 
sterile PBS, and wells were allowed to dry in 37oC incubator for several hours to overnight.  
GSCs, typically maintained as neurospheres, were spun down at 800 rpm for 3 minutes at room 
temperature.  Supernatant was aspirated and spheres were resuspended in 1 mL TryplE express.  
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After incubation for approximately 30 seconds at room temperature, 2 mL Defined Trypsin 
Inhibitor and 4 mL sterile PBS were added.  After pipetting up and down to disaggregate the 
neurospheres, cell suspension was filtered through a sterile 40 µm cell strainer to ensure a 
single cell suspension.  Cells were spun down at 1000 rpm for 5 minutes, supernatant was 
aspirated, and cells were resuspended in 5 mL sterile PBS.  Cells were then counted with a 
Coulter counter.  Cells were spun down a final time and resuspended in stem cell media at 
1x105 cells/ml in a 50 ml conical tube.  Serial 1:10 dilutions were performed in stem cell media 
until desire dilution was reached.  Appropriate number of cells were added to PLL-coated 
plates.  Cells were incubated overnight at 37oC, 5% CO2, and 5% O2 to allow cells to attach 
prior to radiation treatment.  After allowing time for cell attachment and recovery, plates were 
irradiated (0, 1, 2, or 3Gy) using a 320 kV Xray machine (Precision X-Ray Inc.). After 
irradiation, plates were returned to a 37oC, 5% CO2, and 5% O2 incubator and fresh stem cell 
media was added up to twice per week.  At approximately 21 days post-irradiation, wells were 
stained with 0.5% crystal violet for up to 5 minutes.  Plates were rinsed by immersion in a large 
bowl of water and crystal violet was properly disposed.  After drying, plates were counted for 
number of colonies per well with a stereomicroscope.  Colonies were defined as containing at 
least 25 cells (corresponding to 4-5 divisions).  To generate a radiation survival curve, 
surviving fraction (SF) for each dose of radiation was calculated by determining the plating 
efficiency (PE) (number of colonies divided by the number of cells seeded x 100), which was 
then divided by the PE determined for the untreated control sample.  Survival curves were 
constructed by plotting the surviving fraction versus radiation dose.  The control (0Gy) SF is 
set at 1.0 on the y-axis with the remaining SF data points plotted on a log scale (decreasing 
from 1.0); the x-axis corresponds to the radiation dose and is plotted on a linear scale (a semi-
log plot 
 
6.1.2 Flow cytometry 
 
A single cell suspension of GSCs was prepared as described above.  Cells were 
centrifuged and pellet resuspended in 800µL PBS and 200µL 10% Formalin for 10 minutes at 
room temperature.  Cells were centrifuged and resuspended in 500 µL of fixed cell staining 
buffer (PBS, 0.5% BSA, 0.1% Triton-X-100, 0.05% Tween20, 5% FBS).  Cells were aliquoted 
into Eppendorf tubes for appropriate samples and controls (unstained, Hoechst con trol, 
secondary control, CD133-1 and CD133-2).  To 100µL of cells, 20µL of pure CD133-1 and 
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CD133-2 (Miltenyi; PE-conjugated) were added.  Cells were incubated with antibody for 1-2 
hours at 4oC in the dark.  Stained cells were centrifuged and resuspended in PBS with Hoechst 
33258 (1:50,000).  Samples were filtered through a 40µm nylon mesh into flow tube.  Flow 
cytometry was performed on a BD LSRFortessa and analysis performed with FACSDiva 
software. 
 
6.1.3 Immunocytochemistry 
 
 Poly-L-Ornithine (PO; Sigma) was added to chamber slides and allowed to stand 
overnight in a 37oC incubator.  PO was removed, chambers were washed twice with sterile 
PBS, and PBS with Laminin (Sigma, 1:500) was added.  Chambers were incubated at 37 oC in 
Laminin for 4 hours to overnight.  A single cell suspension of GSCs was prepared and cells 
were counted with a Coulter counter as described above.  50,000 cells per chamber were added 
with 2mL stem cell media.  Cells were checked daily and were utilised for staining once cells 
reached approximately 70% confluency.  Media was removed and slides were washed twice 
with PBS.  Cells were fixed with 10% Formalin for 10 minutes at room temperature.  Formalin 
was removed and cells washed with PBS once prior to incubating in blocking buffer (PBS, 5% 
FBS, 0.5% BSA, 0.1% Triton-x-100) for one hour at room temperature.  Next, the primary 
antibody (CD133, Proteintech, 1:200) in antibody buffer (PBS, 5% FBS, 0.5% BSA, 0.1% 
Triton-X-100, 0.05% Tween20) was added and incubated overnight at 4oC with gentle shaking.  
Cells were washed three times with PBS and gentle shaking for 10 minutes prior to adding 
secondary antibody (Alexa Fluor 555, Invitrogen, 1:1000) in antibody buffer.  Cells were 
incubated for 1 hour at room temperature in the dark.  Cells were washed three times with PBS 
and gentle shaking for 10 minutes and chamber slides were removed.  Anti-fade with DAPI 
was added and slides covered with coverslips.  Slides were dried overnight and images taken 
with a fluorescent microscope (Zeiss).   
 
6.1.4 Xenograft Reirradiation Protocol 
 
 Orthotopic implantation of CD133+ GSCs into the right striatum of female athymic 
nude mice, initial bioluminescent imaging, randomisation, and treatment with fractionated 
radiation (3x5Gy) were completed as described in Chapter 3.  After the first course of treatment 
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(control or 3x5Gy), tumour growth was monitored weekly by BLI.  Once the average BLI ratio 
of irradiated tumours demonstrated an observable increase (approaching 10 on the logarithmic 
scale), the irradiated mice were re-randomised into two groups: control (previously received 
3x5Gy) and reirradiation (3x5Gy-3x5Gy).  Mice in the reirradiation group received three 
consecutive days of 5Gy.  After the second course of treatment, tumour growth was monitored 
by BLI out to morbidity.  Kaplan-Meir survival curves were generated in GraphPad Prism 7. 
 
 
6.2 Results 
 
6.2.1 Clonogenic survival analysis of in vivo tumour cultures 
 
 As an initial test of whether radiation-induced evolution leads to the emergence of 
radioresistant clones, xenograft-derived cell lines were established from in vivo NSC11 control 
and irradiated tumours.  For this experiment, once NSC11 tumour-bearing mice reached 
morbidity, mice were euthanised and GFP-expressing tumour tissue was dissected under a 
microscope.  Tumour tissue was immediately placed in Trypsin-EDTA and mechanically 
dissociated with sterile scalpels.  After inhibiting the trypsin, cells were washed with sterile 
PBS and spun down several times before adding stem cell media containing antibiotics.  Cells 
were monitored, washed, and given fresh media for several days until neurospheres began to 
form and proliferate.  After an antibiotic taper, xenograft-derived cell lines from both control 
and irradiated tumours were plated on PLL-coated plates for clonogenic survival assays to 
assess radioresponse.  Figure 6.1A demonstrates no difference in survival fraction as a function 
of dose between cell lines derived from control xenografts (NSC11ic Control) or irradiated 
xenografts (NSC11ic 3x5Gy).  While the colonies for NSC11 are typically small, there was no 
difference in colony size or morphology between the control and 3x5Gy cell lines (Fig. 6.1B) 
or between untreated cells (pictured) and irradiated cells.  Furthermore, flow cytometry 
analysis for CD133 positivity demonstrated similar levels of CD133 expression for both 
NSC11ic control xenografts and NSC11ic 3x5Gy xenografts (Figs. 6.1 C and D, respectively).  
Flow cytometry results were supported by immunocytochemistry demonstrating fairly uniform 
CD133 expression (green fluorescence) of cultured cells (Figs. 6.1E-F).  While the derivation 
protocol itself could perhaps be expected to generate a high percentage of CD133+ GSCs 
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regardless of xenograft characteristics, the GSCs composing each xenograft-derived cell line 
seem to display relatively similar radioresponses, regardless of treatment history (Fig. 6.1A).  
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Figure 6.1 Clonogenic survival assay and GSC proportion analysis .  A) Clonogenic 
survival curve comparing the survival fraction as a function of radiation dose between cell lines 
derived from control and irradiated (3x5Gy) xenografts. B) Representative images of NSC11ic 
Control and NSC11ic 3x5Gy clonogenic assay colonies (0 Gy).   Flow cytometry dot plot 
demonstrating the percentage of GFP+ (FITC+) tumour cells which express CD133 (PE+) from 
C) control or D) irradiated xenograft-derived cell lines.  Fluorescence images of attached E) 
control or F) irradiated xenograft-derived cells (blue=nuclear DAPI stain) which express 
CD133 (green) and Nestin (pink). 
 
 
6.2.2 Reimplantation Study 
 
 To ensure that the lack of difference in radiosensitivity between xenograft-derived cell 
lines with different treatment histories was not attributable to in vitro culturing, a 
reimplantation study was performed.  NSC11 cell lines were derived from xenograft tumour 
tissue as described for clonogenic assay experiments.  Once clonogenic neurosphere cultures 
were generated and antibiotics tapered, xenograft-derived cell lines from control (icCtrl) or 
irradiated (ic3x5) tumours were reimplanted into the right striatum of nude mice.  The tumour 
take rate for xenograft-derived cell lines was around 95%, similar to standard GSC 
implantation studies.  As in prior in vivo experiments, at day 21 post-implant, after visualisation 
of tumours with BLI, mice from both cohorts were randomised into control and fractionated 
radiotherapy (3x5Gy) groups.  After treatment, mice were followed out to morbidity with BLI 
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and overall survival was recorded.  As shown in figure 6.2A, a statistically significant 
difference in survival based on xenograft-derived cell line treatment history was not observed.  
While the median survival for the control tumour-derived cell line implants was higher than 
irradiated tumour-derived cell line implants (83 days vs. 72 days, respectively), Kaplan-Meir 
survival curve comparison demonstrates a clear lack of significant survival ad vantage 
(p=0.9889).  Similarities in survival between xenograft-derived cell lines were consistent with 
similarities in tumour growth delay for each reimplant type as assessed by BLI as a function of 
time after irradiation (Fig. 6.2B).  These data suggest that radiation-induced evolution does not 
select for radioresistant subclones. 
 
 
Figure 6.2 Radioresponse of reimplanted NSC11 xenograft-derived cell lines.  
Reimplanted xenografts were randomised and treated (3x5Gy) on day 21 post-implant as 
described in text.  A) Kaplan-Meier survival curves were generated for control tumour-derived 
reimplants (icCtrl) and irradiated tumour-derived reimplants (ic3x5) that received no treatment 
(Control) or fractionated radiation (3x5Gy) (n=8-9 mice per group).  B) Tumour growth 
defined by BLI ratio as a function of time after irradiation.  Day 21 represents initial, pre -
treatment BLI baseline imaging prior to randomisation and irradiation.   
 
 
6.2.3 Reirradiation of GSC-initiated orthotopic xenografts 
 
 Because our reimplantation study contained an intervening period of in vitro cell line 
derivation, it is possible that the in vitro environment led to a loss of potential differences in 
radiosensitivity that may have been gained by GSCs after treatment in the brain 
microenvironment.  Therefore, as a final, more clinically relevant assessment of radiation’s 
potential to induce the emergence of radioresistant subclones, we added a reirradiation protocol 
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to our GSC-initiated xenograft model.  Orthotopic implantation of CD133+ GFP+ GSCs, initial 
BLI, and first course of treatment (control or 3x5Gy) were completed as described previously.  
After completion of the initial course of treatment, tumour growth of control and irradiated 
tumours were followed weekly with BLI.  Once the irradiated tumours began to regrow, as 
determined by a consistent increase in BLI ratio as a function of time after irradiation, the mice 
were re-randomised into two groups: control and fractionated radiotherapy (3x5Gy).  After the 
second course of treatment, mice were followed out to morbidity with BLI and overall survival 
recorded.  Figure 6.3A shows that NSC11 tumour-bearing mice that underwent reirradiation 
experienced a significant increase in survival compared to mice that only received one course 
of fractionated irradiation.  Similar survival advantages from the reirradiation protocol were 
also observed in NSC20 and NSC23 tumour-bearing mice (figures 6.3B-C).  Consistent with 
increased survival, tumour growth delay was detected by BLI after both the initial and second 
courses of fractionated irradiation (figures 6.4A-C), suggesting that recurrent tumours that 
regrow after initial treatment remain sensitive to irradiation.  Finally, the fundamental change 
in recurrent GB biology, as evidenced by reduced invasive propensity, which was observed 
after one course of radiation (Fig. 5.2), was similarly observed in reirradiated NSC11 and 
NSC20 tumour-bearing brains at morbidity (figures 6.5A-B).  Taken together, these results 
suggest that radiation-induced evolution does not lead to the emergence of radioresistant clones 
and that GSC-initiated xenografts represent useful models for studying recurrent GB biology 
and retreatment protocols. 
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Figure 6.3 Survival of GSC-initiated xenografts after reirradiation.  After initial 
randomisation and treatment (3x5Gy), mice were followed by BLI weekly to monitor tumour 
growth.  Once the average BLI ratio of irradiated tumours demonstrated an observable increase 
(approaching 10 on the logarithmic scale), the irradiated mice were rerandomised and 
reirradiated (3x5Gy, 3x5Gy).   Kaplan-Meier survival curves were generated for A) NSC11, 
B) NSC20, and C) NSC23 tumour-bearing mice (n=6-10 mice per group).  Log-rank (Mantel-
Cox) test utilised for statistical analysis of survival benefit with GraphPad Prism 7 software.  
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Figure 6.4 Radioresponse of GSC-initiated xenografts after reirradiation. Tumour growth 
defined by BLI ratio as a function of time after irradiation for A) NSC11, B) NSC20, and C) 
NSC23 tumours. 
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Figure 6.5 Morphology and histology of NSC11 and NSC20 tumours . Right hemisphere 
sagittal sections at plane of injection site stained with A) SOX2 or B) H&E (magnification 20x) 
from A) NSC11 or B) NSC20 control, irradiated (3x5Gy), and reirradiated (3x5Gy-3x5Gy) 
tumour-bearing brains at morbidity. 
 
 
 
 
 
 
B) 
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6.3 Discussion 
 
 The aim of this study was to test the hypothesis that radiation-induced evolution leads 
to the emergence of radioresistant clones.  In vitro clonogenic survival and reimplantation 
studies of xenograft-derived cell lines were utilised as initial approaches for evaluating the 
functional implications of radiation-induced evolution.  By returning control and irradiated 
xenograft tumour cells back to culture, we were able to test the hypothesis that in vivo 
irradiation leads to the emergence of radioresistance.  The protocol we utilised for GB 
xenograft cell line derivation and subsequent in vitro maintenance potentially biased 
enrichment toward GSCs (241,267).  Utilising serum-containing media may have allowed the 
retention of more diverse and differentiated tumour cell types.  However, we ultimately 
required a population of clonogenic GSCs for successful reimplantation studies.  In addition, 
GSCs cultures have been shown to be heterogeneous by the ability to populate heterogeneous 
tumours (252).  Importantly, CSCs are considered to be an important cell type for mediating 
intrinsic radioresistance (245).  Therefore, if irradiation of GSC-initiated xenografts led to a 
recurrent tumour repopulated with radioresistant GSCs, then the derivation of GSC lines from 
irradiated xenografts would be expected to enrich for more radioresistant GSCs compared to 
control xenograft-derived GSCs.  If this is the case, then our results which showed no difference 
in in vitro clonogenic survival or in vivo survival after reimplantation suggest that radiation-
induced evolution of GSC-initiated orthotopic xenografts does not lead to the emergence of 
radioresistant clones in recurrent GB xenografts.  Instead of selecting for radioresistant clones, 
radiation may contribute to GB evolution by the selection of clones with different predilections 
for invasion versus proliferation and clones better able to benefit from microenvironmental 
interactions (migration to radioresistant niches, for example).   
 Despite aggressive first line treatment, glioblastoma inevitably recurs.  Even though 
progression is expected, a consensus on the best treatment approach for recurrent glioblastoma 
does not currently exist.  Many modalities have been employed with mostly palliative intent 
including re-resection, chemotherapy, and reirradiation.  Certainly, clinicians must weight 
clinical benefits with apparent risks and make decisions based on a given patient’s 
characteristics, but reirradiation seems to be a feasible retreatment strategy that may improve 
outcomes.  However, early studies with reirradiation demonstrated limited survival benefit and 
relatively high side effect profiles with conventional RT (314,316).  Fortunately, advances in 
imaging and radiation targeting, including conformal technology has improved tolerance and 
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survival (317).  Indeed, with new techniques, the incidence of necrosis does not seem to 
increase significantly until a combined dose of at least 100 Gy (317).  In a retrospective cohort 
study, Combs et al. demonstrated that fractionated stereotactic reirradiation with a median dose 
of 36Gy led to an 8-month median OS for reirradiated patients (5-month PFS) and was well 
tolerated with no major short- or long-term side effects (318).  Survival results comparable to 
systemic recurrent treatment strategies (e.g. bevacizumab) have been reported in single 
institution retrospective studies for hypofractionated (319) and pulsed reduced-dose-rate 
protocols (198).  Several retrospective studies have shown potential beneficial results for SRS 
with small volume recurrent tumours, but an increase in radionecrosis with larger volumes 
(320-322).  Many other retrospective series and systematic literature reviews have further 
suggested that reirradiation is well tolerated and seems to yield survival times comparable or 
better than other treatment modalities (195,196,313,315,323-328).  In addition to improved 
survival, studies have also observed the stabilisation and improvement of performance status 
(329,330).  As with other recurrent treatment strategies, patient stratification seems to be 
important, as patients with higher performance status (KPS>60) and smaller lesions (<40mm) 
(325), longer intervals between radiation courses, and gross total reresection prior to 
reirradiation tended to have better outcomes (323).  A few prognostic scoring mechanisms and 
expert survey data have been developed to delineate the patients who would best respond to 
reirradiation (197,331).  While many retrospective observation studies and a few prospective 
studies suggest that reirradiation is well tolerated and may provide comparable or perhaps even 
favorable clinical benefit for recurrent GB, there is clearly a need for more prospective trials 
and randomized control trials to fully establish efficacy, better define optimal patient selection, 
to guide dose/fractionation decisions, to confirm safe dose limits, and to support addition of 
systemic therapies.  While many reirradiation trials are currently ongoing, it seems likely that 
with continued improvements in radiation delivery and with the incorporation of targeted 
radiosensitisers to enhance radioresponse, reirradiation may eventually establish itself as a safe, 
effective recurrent GB treatment strategy.      
 Therefore, as an alternative approach to further assess the functional implications of 
radiation-induced evolution and to establish GSC-initiated xenografts as models for studying 
retreatment strategies, we added a reirradiation protocol to our previously described GSC-
initiated xenograft model which involves a single course of irradiation (266).  In the current 
study, after the initial course of irradiation, average tumour growth of irradiated tumours was 
monitored with bioluminescent imaging.  Once the average tumour size began to increase, as 
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assessed by BLI ratio when compared to pre-treatment BLI values, the mice were re-
randomised and half were reirradiated with the same fractionated radiation protocol (3x5Gy).  
The in vivo observations of initial response to treatment (delayed tumour growth assessed by 
differences in BLI), eventual progression of irradiated tumours (increase in BLI ratios above 
both pre-treatment and early post-treatment values), and response to a second course of 
irradiation (delayed tumour growth) seem to mimic standard GB clinical histories.  After an 
initial response to treatment and a period of progression free survival, GB inevitably recurs.  
Depending on the performance status of the individual, retreatment may be provided which 
often leads to another, shorter treatment response.  Unfortunately, the patient typically 
succumbs to the disease within 2 years of diagnosis.  Because the addition of a reirradiation 
protocol to GSC xenografts mirrors GB clinical histories, allows for the retreatment of 
recurrent tumours that regrow after treatment, and yields the ability to investigate changes in 
tumours at different intervals after one or more courses of treatment, this model represents a 
useful evolutionary tool.  This model of reirradiation and recurrent GB provides an opportunity 
to further interrogate the microenvironment-mediated mechanisms and implications of 
radiation-induced GB evolution, to more effectively study recurrent biology, and to test the 
preclinical efficacy of new retreatment protocols.  A more thorough understanding of 
treatment-induced evolution and possible sensitisation strategies could have potential 
implications toward improving treatment for recurrent glioblastoma. 
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Chapter 7. Discussion 
 
 
 This work was performed to examine the impact of radiation on glioblastoma evolution.  
The intrinsic intratumoral heterogeneity of glioblastoma coupled with selective pressures 
imposed by standard treatment regimens can lead to therapy-induced evolution.  This 
phenomenon has been demonstrated for chemotherapy (235,300).  However, the ability of 
radiation alone to induce glioblastoma evolution has not previously been described.  Therefore, 
this work presents novel findings on radiation-induced glioblastoma evolution and its potential 
implications for retreatment protocols and recurrent biology.  Furthermore, the study of 
radiosensitivity in the context of intratumoral heterogeneity may provide insight on the 
applicability of such findings.  Future work will seek to gain further understanding of the 
process of radiation-induced evolution in an effort to generate more effective treatment 
strategies for improving glioblastoma outcomes. 
 
 
7.1 Summary of Key Findings  
 
7.1.1 Impact of ITH on radiosensitivity 
 
 The hypothesis that there are differences in intrinsic radioresponse of glioblastoma cells 
isolated from spatially distinct regions of human tumours was tested by performing 
radiosensitivity studies and whole exome sequencing on patient-derived cell lines and 
corresponding tumour fragments.  Comparison of Pearson’s correlation coefficients and 
superFreq analysis of SNV and CNA data demonstrated that patient-derived cell lines were 
good models of their tumours of origin.  In addition, the J14 cell lines were also found to be 
good models of their specific corresponding tumour fragments.  SuperFreq-generated river 
plots allowed for the comparison of the presence and relative prevalence of defined clones 
between samples from a given tumour.  These plots revealed that while samples shared clones, 
they also harboured unique clones and combinations of clones which supported the use of cell 
lines derived from spatially distinct tumour fragments as models of intratumoral heterogeneity.  
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Cell lines underwent radiosensitivity testing with γH2AX foci analysis and limiting dilution 
assays.  The J7 cell lines displayed conflicting results in DSB foci induction (1-hour post RT) 
and repair (24 hours post RT).  All other cell lines showed no significant differences in foci 
analysis.  For limiting dilution assays, only the J14 cell lines displayed differences in 
proliferation capacity after irradiation.  Because no cell lines displayed consistent differences 
across radiosensitivity studies, it seems that cell lines derived from spatially distinct tumour 
regions exhibit similar levels of radiosensitivity in spite of observed ITH.  These results suggest 
that ITH does not produce dif ferences in intrinsic radiosensitivity and that GB radioresponse 
may be conserved across heterogeneous clones within a tumour.     
 
7.1.2 Radiation drives evolution of GSC-initiated orthotopic xenografts 
 
 Glioblastoma stem-like cell-initiated orthotopic xenografts were utilised to test whether 
radiation alone can drive the evolution of glioblastoma.  The fractionated radiotherapy protocol 
(3x5Gy) provided a significant survival advantage and caused a tumour growth delay for 
irradiated mice, which mimics the clinical course of treated GB.  Histological analysis revealed 
that control tumour-bearing brains demonstrated different growth patterns when compared to 
irradiated tumour-bearing brains.  In particular, GB cells in control tumours were more 
diffusely scattered throughout the right hemisphere both anteriorly and posteriorly from the 
injection site in the striatum.  In contrast, irradiated tumours demonstrated a clearly demarcated 
tumour border anterior to the right striatum.  Such clear differences in growth patterns point 
towards a fundamental change in recurrent biology after irradiation.   
We investigated the potential role of clonal selection in this process by performing Viral 
integration site analysis.  VISA demonstrated a significant reduction in the number of unique 
integration sites when transitioning from an in vitro to an in vivo environment.  Clonal diversity 
was even further reduced when implanted tumours were irradiated.  This reduction in clonal 
diversity was detected in two different GSC lines, suggesting that radiation has the ability to 
drive evolution.  To test whether radiation alone was sufficient to promote clonal selection, we 
irradiated NSC11 cells in vitro.  However, there was no difference in the number of integration 
sites between control and irradiated cells in vitro.  Furthermore, VISA of U251 xenografts 
demonstrated that while irradiation of subcutaneous xenografts did lead to a reduction in clonal 
diversity, the largest reduction in diversity occurred after irradiation of intracerebral xenografts.  
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This suggests that radiation-induced GB evolution is not specific to GSCs and that the brain 
microenvironment plays an important role in mediating the evolutionary process.   
Whole exome sequencing of morbid control and irradiated tumours further supported 
the observed impact of radiation on GB evolution.  COSMIC mutational signature profiles 
were found to be different between control and irradiated NSC11 and NSC20 tumours.  
Additionally, EXPANDS analysis demonstrated extensive subpopulation dynamics as many 
variants shifted into more or less prevalent subpopulations following irradiation.  Similarly, 
patterns of GB driver genes differed between control and irradiated tumours and GB driver 
gene variants were also found to shift between defined subpopulations after irradiation.  The 
WES results coupled with VISA, histology, and survival support the radiation-driven evolution 
of GSC-initiated orthotopic xenografts.   
 
7.1.3 Glioblastoma reirradiation model 
 
 To test the hypothesis that radiation-driven evolution leads to the emergence of resistant 
clones, clonogenic assays of xenograft-derived cell lines as well as reimplantation studies were 
performed.  Cells from control and irradiated NSC11 morbid tumours were put back into 
culture to establish xenograft-derived cell lines grown as neurospheres.  These lines were 
subjected to clonogenic survival analysis which demonstrated no difference in radiosensitivity 
between the lines.  Next, control and irradiated NSC11 xenograft-derived cell lines were 
reimplanted into the right striatum of nude mice and treated with fractionated irradiation.  No 
differences in survival after irradiation were noted regardless of the prior treatment received 
by the xenograft-derived cell lines.   
An alternative approach for testing the effects of radiation-driven evolution was the 
addition of a reirradiation protocol to the previously described GSC-initiated orthotopic 
xenograft model.  Tumour bearing mice that received fractionated irradiation (3x5Gy) were 
followed by serial BLI imaging to monitor for tumour regrowth.  Once an increase in BLI 
suggested regrowth (recurrence), an additional fractionated irradiation protocol (3x5Gy) was 
applied to half of the mice.  Similar to a single course of irradiation, the second course of 
irradiation led to an observed tumour growth delay by BLI and mice that were reirradiated 
experienced a significant increase in median survival compared to mice that only received one 
course of irradiation.  Because the GSC xenograft reirradiation protocol better mirrors the 
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clinical course of GB by retreating recurrent tumours, this model represents a useful method 
for studying recurrent GB biology and retreatment strategies.  Furthermore, these reirradiation 
results coupled with clonogenic survival analysis and reimplantation results  indicate that 
radiation-induced evolution does not lead to the emergence of radioresistant clones in GSC-
initiated orthotopic xenografts.   
 
 
7.2 Limitations 
 
 When comparing patient-derived cell lines to their tumours of origin, the cell lines were 
found to be good models of their parent tumours.  However, in some cases the cell lines were 
good models of the originating tumour as a whole, but they were more similar to other cell 
lines from the same tumour than they were to their specific corresponding tumour fragments.  
Logistical and biological challenges could have contributed to this result.  Care was taken in 
the operating room to cut a single, small tumour fragment in half to  send one half for tissue 
processing and storage in the Tumour Bank and the other half for cell line derivation.  While 
labelling was done in the operating room in an attempt to numerically define each tumour 
fragment, tissue frozen by the Tumour Bank was processed separately from tissue utilised for 
line derivation, which could have introduced unknown discrepancies in labelling.  This could 
be rectified in the future by having both tasks performed in the same facility by the same 
personnel.  Furthermore, as has been demonstrated with single cell analysis (281), even two 
halves of a small tumour fragment could possibly demonstrate ITH.  While manual 
homogenisation of the entire tissue fragment prior to splitting for separate purposes would 
potentially lessen the amount of ITH present, homogenisation would also diminish tissue 
integrity which could have negative consequences for freezing, thawing, and eventual DNA 
extraction from tissue fragments.  In this case, immediate DNA extraction from homogenized 
tissue would potentially be better than tissue bank storage and later extraction.   In addition to 
improving derivation techniques to improve the accuracy of the models, in vivo radiosensitivity 
studies would provide further information on the impact of ITH on intrinsic radiosensitivity 
(discussed further in section 7.3). 
 As this study represents the first observation of the impact of radiation on glioblastoma 
evolution, WES was employed to examine differences in variant patterns, mutational 
7. Discussion 
  135 
signatures, and subpopulation dynamics between untreated and irradiated tumours.  WES of 
DNA extracted from bulk tumour samples has been a standard approach for studying cancer 
evolution and ITH.  Despite its extensive use in studying cancer genomics, WES has been 
shown to be susceptible to sequencing artifacts particularly at low coverage and in low-
mappability regions (332).  In our analyses, we sought to improve likelihood of more accurate 
variant calling by only analyzing variants that were detected in 2 out of 3 replicates.  While our 
sequencing had a depth >180x, ultra-deep sequencing could improve reliability of results (333).  
Also, single cell techniques could provide more detailed analysis of ITH and 
genomic/transcriptomic evolution (34,281).  In addition, WGS would provide a more 
comprehensive picture of radiation-induced effects on the genome.  Beyond just examining 
variants in protein-coding genes, WGS would describe the potential effects of radiation on 
genomic instability and the role that such instability may play in the evolutionary process (334-
336).  While many other genomic approaches could potentially be utilised in the future to more 
deeply investigate the impact of radiation on GB genomic evolution, WES is a reasonable first 
approach for studying and describing therapy-induced evolution.           
 The finding that in vitro irradiation of GSCs did not lead to a reduction in clonal 
diversity while irradiation of in vivo brain tumours led to a significant reduction in clonal 
diversity suggests a contributory role for the brain tumour microenvironment in radiation-
induced glioblastoma evolution.  As such, it seems likely that future studies on radiation-
induced GB evolution will also need to be performed in vivo.  Nude mice represent a commonly 
utilised immunocompromised mouse strain for studying glioblastoma orthotopic xenografts.  
Nude mice harbour a few functioning types of immune cells, unlike NOD-SCIDs which are 
even more immunocompromised.  The use of nude mice is necessary when performing 
radioresponse studies due to SCID mice having a Prkdc mutation and deficiency in DNA-PK 
activity resulting in hypersensitivity to ionizing radiation (337).  However, the lack of a 
functioning immune system may limit the ability to fully understand the interactions of the 
microenvironment and glioblastoma cells that result in treatment-induced evolution.  For 
example, radiation-induced cell death is thought to release tumour neoantigens which in turn 
can be taken up by antigen presenting cells (dendritic cells) to generate and activate tumour-
specific T cells.  Radiation also has complex effects on the tumour microenvironment that can 
contribute to immune responses, such as increasing the production of cell adhesion molecules 
in irradiated vascular endothelium resulting in T cell recruitment (338).  Therefore, various 
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trials are underway to enhance anti-tumour immunity by the complementary and potentially 
synergistic actions of targeted immunotherapies and radiation.   
 
 
7.3 Future Work 
 
 To further confirm that ITH does not have a significant impact on radiosensitivity, a 
next step would be to compare in vivo growth patterns and in vivo radiosensitivities of patient-
derived cell lines derived from spatially distinct tumour fragments.  The brain 
microenvironment has been previously shown to influence radioresponse of GSCs and has even 
revealed differences in radiosensitivities of CD133+ and CD133- cell populations in vivo that 
were not found in vitro (254,266).  Therefore, comparison of in vivo tumour growth and 
radiation treatment of multiple cell lines from the same tumour would be expected to provide 
a more clinically relevant picture of ITH.  To date, J3 and J7 cells transduced to express 
GFP/Luciferase have been intracerebrally implanted into athymic nude mice.  While these cells 
do produce tumours, untreated mice survive upwards of 100 days, making their utility for 
radiation-related studies difficult.  The cell lines utilised in Appendix A, A25M and A25C, 
represent an attractive pair of lines to study due to observed differences in tumour growth 
patterns; A25M grows as a nodular tumour whereas A25C grows as a diffuse tumour.  A25M 
has been successfully transduced and has already been incorporated into ongoing reirradiation 
studies.  Unfortunately, while transduced A25C cells do generate tumours, the cells in culture 
and tumours in vivo seem to be growing more slowly than previously observed.  Future studies 
will attempt to boost in vivo growth rates so that the two lines can be compared.  However, 
many patient-derived cell lines are still available for future tumourigenicity studies.  
Ultimately, by generating a few workable models of in vivo ITH, the potential of ITH to yield 
differences in in vivo radiosensitivity could be assessed.  In addition to the study of in vivo 
radiosensitivity, paired cell lines from the same tumour would provide the opportunity to study 
the impact of radiation and other treatments on clonal evolution of mixed cell populations in 
vivo.       
 As our results suggest, the microenvironment may play an important role in radiation-
induced glioblastoma evolution.  Therefore, future studies will seek to better delineate the role 
of the brain microenvironment, a unique and complex system, in guiding the evolutionary 
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process (339,340).  Initial assessments could involve staining histological time course slides 
with various makers expressed in the brain microenvironment such as VEGF (angiogenesis), 
Tenascin C (ECM), and CD11b/CD68 (microglia) to assess potential differences in these 
microenvironmental components after irradiation.  Future in vivo work could examine the 
potential role of protective niches in mediating cell survival and evolution after radiation.  
Additionally, examining the role of resident non-tumour brain cells in radioresponse could 
provide further insights on the ability of the microenvironment to guide evolution.  For 
instance, astrocytes have been shown to both enhance the invasion of GSCs and to reduce their 
in vitro radiosensitivity (reduce DSBs and enhance foci dispersal) (229,230).  Therefore, co-
implantation of human GSCs with human astrocytes could potentially demonstrate the ability 
of an important resident brain cell to affect in vivo radioresponse.  While utilizing in vivo 
methods arguably provide the most physiologically relevant microenvironmental model, such 
models can be difficult to manipulate.  Therefore, new in vitro methods of 3D cell culturing 
including hyaluronic acid and hydrogel-based ECM 3D scaffolds, microfluidic systems, and 
brain and tumour organoids represent potential ways to mimic some of the features of the brain 
microenvironment while assessing the ability of radiation to impact the relationship of GB cells 
to those specific microenvironmental features (341).          
  The studied reirradiation protocol led to an increase in survival suggesting that 
radiation-driven evolution does not select for radioresistant clones.   To further assess the 
functional implications of reirradiation and to study recurrent tumour biology and evolution 
(first recurrence to second recurrence), the studies described in this thesis (VISA, WES) could 
be extended to tumours that were reirradiated.  Sequencing of recurrent tumours could provide 
valuable information on potential genomic divergence of tumours after reirradiation or other 
treatment exposures compared to primary tumours or earlier recurrent tumours.  Many targeted 
therapies are selected based on GB driver mutations, so sequencing of recurrent tumours can 
assess the status of such driver mutations in order to inform whether previously utilized 
targeted therapies should be continued or stopped and whether new targeted therapies may be 
effective.  While clinical tissue specimens are useful for sequencing if re-resection is completed 
as part of recurrent GB treatment regimens, liquid biopsies provide an important alternative 
when resection is not recommended to periodically (and less invasively) assess treatment 
effectiveness and to inform treatment decisions.  In addition to sequencing recurrent tumours, 
histological time course studies could be done after reirradiation to examine differences in 
underlying phenotypes between control, once irradiated, and twice irradiated tumour-bearing 
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brains.  To achieve a more comprehensive understanding of treatment-induced GB evolution, 
other treatment regimens should be assessed to compare to radiation-induced evolution.  While 
it was necessary to study radiation-driven evolution and the subsequent reirradiation protocol 
by treating tumour-bearing mice with fractionated irradiation only, such treatment regimens do 
not mirror those typically utilised in clinic.  First line treatment for most newly diagnosed and 
resected GB patients is the Stupp protocol consisting of radiotherapy with concomitant and 
adjuvant temozolomide (122).  As such, future studies will interrogate the impact of 
combinatorial therapeutics on GSC-initiated xenograft evolution.  In particular, it would be 
interesting to determine whether the addition of TMZ or a potent radiosensitiser to fractionated 
irradiation has any effect on the emergence of radioresistant clones.  Such studies would pair 
well with additional retreatment protocols so that the treatment responses of recurrent tumours 
could be directly tested with various single modality retreatments in an effort to better 
understand resistance mechanisms and recurrent biology. 
  
  
7.4 Conclusion 
 
 Glioblastoma is a heterogeneous, malignant brain tumour.  Despite aggressive 
treatment with surgery, radiotherapy, and chemotherapy, patients have a median survival time 
from diagnosis of 15 months.  Intratumoral heterogeneity and the ability of glioblastoma to 
rapidly evolve in response to selective pressures contribute to inevitable treatment failure and 
disease recurrence.  Radiation is an integral component of most first line treatment regimens 
for glioblastoma.  The results presented in this thesis demonstrate that radiation has the ability 
to drive glioblastoma evolution.  In particular, radiation produced a reduction in clonal 
diversity.  While the selection of subpopulations demonstrated in irradiated tumours may not 
lead to the emergence of radioresistant clones, as demonstrated by reirradiation protocols, the 
results do suggest changes in fundamental biology at tumour recurrence and an important role 
for the microenvironment in guiding the evolutionary process.  Because intratumoral 
heterogeneity was not shown to yield differential radiosensitivities, future insights on radiation-
induced glioblastoma evolution may contribute to improved therapies that enhance 
radioresponse for the entire tumour at both primary and recurrent stages.  
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List of Abbreviations 
  
2-HG 2-hydroxy glutarate 
5-ALA 5-Aminolevulinic acid 
ALT Alternative lengthening of telomeres 
ATRX Alpha thalassemia/mental retardation syndrome X-linked  
BBB Blood brain barrier 
BCNU Bis-chloroethylnitrosourea (carmustine) 
BLI Bioluminescent imaging 
CCBR Cancer Research Collaborative Bioinformatics Resource 
CNA/CNV Copy number alteration/Copy number variation 
COSMIC Catalogue of Somatic Mutations in Cancer 
CSC Cancer stem cell 
DC Dendritic cell 
DCTD Division of Cancer Treatment and Diagnosis Tumour Repository 
DSB Double strand break 
ECM Extracellular matrix 
EGFR Epidermal growth factor receptor 
EMT Epithelial-mesenchymal transition 
EORTC European Organisation for Research and Treatment of Cancer 
GATK Genome Analysis Toolkit 
GB Glioblastoma 
G-CIMP Glioma-CpG island methylator phenotype 
GEM Genetically engineered mouse model 
GFP Green fluorescent protein 
GLASS Glioma Longitudinal Analysis Consortium 
GSC Glioblastoma stem-like cells 
IC Intracranial/intracerebral 
IDH Isocitrate dehydrogenase 
ITH Intratumoral heterogeneity 
LDA Limiting dilution assay 
LOH Loss of heterozygosity 
MGMT Methylguanine DNA methyltransferase 
   165 
NCI National Cancer Institute 
OS Overall survival 
PBS Phosphate-buffered saline 
PE Plating efficiency 
PFS Progression free survival 
PI3K Phosphatidylinositol 3-kinase 
PLL Poly-L-lysine 
PO Poly-L-ornithine 
PTEN Tyrosine phosphatase/tensin homolog protein 
RAGE Receptor for advanced glycation end product 
Rb Retinoblastoma 
RT  Radiotherapy 
RTK Receptor Tyrosine Kinase 
RTOG Radiation Therapy Oncology Group 
SC Subcutaneous 
SF Surviving fraction 
SFM Serum-free media 
SNV Single nucleotide variant 
SRS Stereotactic radiosurgery 
TAM Tumour-associated macrophages 
TCGA The Cancer Genome Atlas 
TERT Telomerase reverse transcriptase  
TET Ten-eleven translocation methylcytosine dioxygenase 
TME Tumour microenvironment 
TMZ Temozolomide 
TP53/P53 Tumour suppressor protein 53 
VAF Variant allele frequency 
VEGF Vascular endothelial growth factor 
VISA Viral integration site analysis 
WES/WGS Whole exome sequencing/Whole genome sequencing 
WHO World Health Organisation 
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